Document:

exv10w69

 

Exhibit 10.69

SOLEXA, INC.

SECURITIES PURCHASE AGREEMENT

November 18, 2005

 

 

SOLEXA, INC.

SECURITIES PURCHASE AGREEMENT

     This Securities Purchase Agreement (this “Agreement”) is made as of November 18,
2005, by and among Solexa, Inc., a Delaware corporation (the “Company”) with its principal
office at 25861 Industrial Boulevard, Hayward, California 94545, and the individuals and entities
identified on the signature pages hereto (the “Purchasers”).

RECITALS

     Whereas, the Company has authorized the sale and issuance of the Common Shares and
the Warrants (each as defined herein);

     Whereas, the Company and the Purchasers are executing and delivering this Agreement
in reliance upon the exemption from securities registration afforded by the provisions of
Regulation D, as promulgated by the SEC (as defined herein) under the Securities Act (as defined
herein);

     Whereas, at the First Closing (as defined herein), the Company desires to sell, and
each Purchaser desires severally, and not jointly, to purchase, the Shares and the Warrants, each
as indicated below such Purchaser’s name on the applicable signature page of this Agreement upon
the terms and conditions stated in this Agreement and at the Second Closing (as defined herein), if
Stockholder Approval (as defined herein) is obtained, each Purchaser hereto desires severally, and
not jointly, to purchase, the Shares and the Warrants, each as indicated below such Purchaser’s
name on the applicable signature page of this Agreement upon the terms and conditions stated in
this Agreement;

     Whereas, concurrent with the execution and delivery of this Agreement, as a material
inducement to the Purchasers to enter into this Agreement, certain principal stockholders of the
Company are entering into a Voting Agreement, in the form attached hereto as Exhibit F; and

     Now, Therefore, in consideration of the foregoing recitals and the mutual promises,
representations, warranties and covenants hereinafter set forth and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto
agree as follows:

ARTICLE 1

Authorization and Sale of Common Shares and Warrants

     1.1 Authorization. The Company has authorized (a) the sale and issuance of up to ten million
(10,000,000) shares (the “Common Shares”) of Company’s common stock, par value $0.01 per share (the
“Common Stock”) at a price per shares of six dollars and fifty cents ($6.50) and (b) the sale and
issuance of warrants, in the form attached hereto as Exhibit A, (the “Warrants”), to purchase up to
three million five hundred thousand (3,500,000) shares of the Common Stock, at a price per share of
seven dollars and fifty cents ($7.50) (the “Warrant

 1.

 

Price”) pursuant to this Agreement. The shares of Common Stock issuable upon exercise of or
otherwise pursuant to the Warrants are referred to herein as the “Warrant Shares.” The Common
Shares and the Warrant Shares are collectively referred to herein as the “Shares.” The Shares and
the Warrants are collectively referred to herein as the “Securities.”

          (a) First Closing. Subject to the terms and conditions of this Agreement, including without
limitation, the conditions set forth in Article 5 and Article 6 of this Agreement (excluding
Stockholder Approval in Section 7.8), there shall be a closing at which the Company shall issue and
sell, and each Purchaser, shall severally, and not jointly, purchase, the number of shares of
Common Stock and the number of Warrants, in each case, in the respective amounts indicated below
such Purchaser’s name on the applicable signature page of this Agreement, in exchange for the cash
consideration set forth as the “First Closing Purchase Price” indicated below such Purchaser’s name
on the signature page of this Agreement (the “First Closing”).

          (b) Second Closing. Subject to the terms and conditions of this Agreement, including without
limitation, the conditions set forth in Article 5 and Article 6 of this Agreement (including
Stockholder Approval in Section 7.8), at the Second Closing, there shall be a closing at which the
Company shall issue and sell, and each Purchaser, shall severally, and not jointly, purchase, the
number of shares of Common Stock and the number of Warrants, in each case, in the respective
amounts indicated below such Purchaser’s name on the signature page of this Agreement, in exchange
for the cash consideration set forth as the “Second Closing Purchase Price” indicated below such
Purchaser’s name on the applicable signature page of this Agreement (the “Second Closing”).

ARTICLE 2

Closing Dates; Delivery

2.1 Closing Dates. Delivery.

          (a) Location. The First Closing and Second Closing of the purchase and sale of the Common
Shares and Warrants hereunder (together, the “Closings”) shall be held at the offices of Cooley
Godward llp (“Cooley Godward”), 3175 Hanover Street, Palo Alto, California 94304, or at
such other location upon which the Company and the Purchasers purchasing a majority of the Common
Shares at the applicable Closing shall agree, on the applicable Closing Date.

          (b) First Closing. Subject to the satisfaction (or waiver) of the conditions thereto set
forth in Article 5 and Article 6 of this Agreement, on the date hereof or at such other time and
place upon which the Company and the Purchasers purchasing a majority of the Common Shares at the
First Closing shall agree, the Company will deliver or cause to be delivered to each Purchaser, a
duly executed Warrant and a certificate representing the number of Common Shares purchased by such
Purchaser, registered in the Purchaser’s name as indicated on the Stock Certificate Questionnaire
in the form attached hereto as Exhibit B-1. Such delivery shall be against payment of the purchase
price therefor by each such Purchaser as set forth as the “First Closing Purchase Price” below
their respective names on the signature page attached hereto by wire transfer of immediately
available funds to the Company in accordance with the

 2.

 

Company’s written wiring instructions. The date of the First Closing is hereinafter referred
to as the “First Closing Date.”

     (c) Second Closing. Subject to the satisfaction (or waiver) of the conditions thereto set
forth in Article 5 and Article 6 of this Agreement, on the date one (1) business day following the
Company’s receipt of the Stockholder Approval (as defined herein), or at such other time and place
upon which the Company and the Purchasers purchasing a majority of the Common Shares at the Second
Closing shall agree, the Company will deliver or cause to be delivered to each Purchaser, a duly
executed Warrant and a certificate representing the number of Common Shares purchased by such
Purchaser, registered in the Purchaser’s name as indicated on the Stock Certificate Questionnaire
in the form attached hereto as Exhibit B-1. Such delivery shall be against payment of the purchase
price therefor by each such Purchaser as set forth as the “Second Closing Purchase Price” below
their names on the signature page attached hereto by wire transfer of immediately available funds
to the Company in accordance with the Company’s written wiring instructions. The date of the Second
Closing is hereinafter referred to as the “Second Closing Date.”

ARTICLE 3

Representations and Warranties of the Company

     Except as set forth on the Disclosure Schedule delivered by the Company to the Purchasers
herewith, the Company represents and warrants to the Purchasers on and as of the date hereof and on
the applicable Closing Date:

     3.1 Organization and Standing. The Company is a corporation duly organized and validly
existing under, and by virtue of, the laws of the State of Delaware and is in good standing as a
domestic corporation under the laws of said state. The Company does not own or control any equity
security or other interest of any corporation, limited partnership or other business entity.

     3.2 Corporate Power; Authorization. The Company has all requisite legal and corporate power
and has taken all requisite corporate action to execute and deliver this Agreement, to sell and
issue the Common Shares and Warrants, to issue the Warrant Shares upon exercise of the Warrants in
accordance with the terms of such Warrants, and to carry out and perform all of its obligations
under this Agreement. This Agreement constitutes, and upon execution and delivery by the Company of
the Warrants, the Warrants will constitute, legal, valid and binding obligations of the Company,
enforceable in accordance with their respective terms, except (a) as limited by applicable
bankruptcy, insolvency, reorganization or similar laws relating to or affecting the enforcement of
creditors’ rights generally and (b) as limited by equitable principles generally. The execution and
delivery of this Agreement does not, and the performance of this Agreement and the compliance with
the provisions hereof, the issuance, sale and delivery of the Common Shares and the Warrants by the
Company will not materially conflict with, or result in a material breach or violation of the
terms, conditions or provisions of, or constitute a material default under, or result in the
creation or imposition of any material lien pursuant to the terms of, the Amended and Restated
Certificate of Incorporation, as amended (the “Restated Certificate”) or Bylaws of the Company or
any statute, law, rule or regulation or any

 3.

 

state or federal order, judgment or decree or any indenture, mortgage, lease or other material
agreement or instrument to which the Company or any of its properties is subject.

     3.3 Issuance and Delivery of the Shares. When issued in compliance with the provisions of
this Agreement and the Restated Certificate, the Common Shares will be validly issued, fully paid
and nonassessable. Upon exercise of the Warrants in accordance with the terms thereof, the Warrant
Shares will be validly issued, fully paid and nonassessable. The issuance and delivery of the
Common Shares and the Warrants is not subject to preemptive or any other similar rights of the
stockholders of the Company or any liens or encumbrances.

     3.4 SEC Documents; Financial Statements. The Company has filed in a timely manner all
documents that the Company was required to file with the Securities and Exchange Commission (the
“SEC”) under Sections 13, 14(a) and 15(d) of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), during the twelve (12) months preceding the date of this Agreement. As of their
respective filing dates, all such documents filed by the Company with the SEC (the “SEC Documents”)
complied in all material respects with the requirements of the Exchange Act or the Securities Act
of 1933, as amended (the “Securities Act”), as applicable. None of the SEC Documents as of their
respective dates contained any untrue statement of material fact or omitted to state a material
fact required to be stated therein or necessary to make the statements made therein, in light of
the circumstances under which they were made, not misleading. The financial statements of the
Company included in the SEC Documents (the “Financial Statements”) comply as to form in all
material respects with applicable accounting requirements and with the published rules and
regulations of the SEC with respect thereto. The Financial Statements have been prepared in
accordance with generally accepted accounting principles consistently applied and fairly present
the consolidated financial position of the Company and any subsidiaries at the dates thereof and
the consolidated results of their operations and consolidated cash flows for the periods then ended
(subject, in the case of unaudited statements, to normal, recurring adjustments or to the extent
that such unaudited statements do not include footnotes).

     3.5 Governmental Consents. No consent, approval, order or authorization of, or registration,
qualification, designation, declaration or filing with, any federal, state, or local governmental
authority on the part of the Company is required in connection with the consummation of the
transactions contemplated by this Agreement except for (a) compliance with the securities and blue
sky laws in the states in which the Common Shares and Warrants are offered and/or sold, which
compliance will be effected in accordance with such laws, (b) the filing of the Registration
Statement (as defined herein) and all amendments thereto with the SEC as contemplated by Section
7.2 of this Agreement and (c) the filing of a Form D pursuant to Securities and Exchange Commission
Regulation D.

     3.6 No Material Adverse Change. Except as otherwise disclosed herein or in the SEC Documents,
since December 31, 2004, there have not been any changes in the assets, liabilities, financial
condition, business prospects or operations of the Company from that reflected in the Financial
Statements except changes in the ordinary course of business which have not been, either
individually or in the aggregate, materially adverse.

 4.

 

     3.7 Authorized Capital Stock. The authorized capital stock of the Company consists of (a)
sixty million (60,000,0000) shares of Common Stock, $0.01 par value, of which, as of November 18,
2005, twenty-six million one hundred eight thousand two hundred eighty six (26,108,286) shares were
outstanding, and (b) two million (2,000,000) shares of Preferred Stock, $0.01 par value, none of
which shares is currently outstanding. Except as described on Schedule 3.7 of the
Disclosure Schedule, there are no outstanding warrants, options, convertible securities or other
rights, agreements or arrangements of any character under which the Company is or may be obligated
to issue any equity securities of any kind and except as contemplated by this Agreement.

     3.8 Litigation. Except as disclosed in the SEC Documents, there are no actions, suits
proceedings or investigations pending or, to the best of the Company’s knowledge, threatened
against the Company or any of its properties before or by any court or arbitrator or any
governmental body, agency or official in which there is a reasonable likelihood (in the judgment of
the Company) of an adverse decision that (a) could have a material adverse effect on the Company’s
properties or assets or the business of the Company as currently conducted or (b) could impair the
ability of the Company to perform in any material respect its obligations under this Agreement.

     3.9 Eligibility to Use Form S-3. The Company is eligible to use Form S-3 for the registration
of its securities under the Securities Act which are offered in transactions involving secondary
offerings.

     3.10 Company not an “Investment Company.” The Company has been advised of the rules and
requirements under the Investment Company Act of 1940, as amended
(the “Investment Company Act”).
The Company is not, and immediately after receipt of payment for the Shares will not be, an
“investment company” or an entity “controlled” by an “investment company” within the meaning of the
Investment Company Act and shall conduct its business in a manner so that it will not become
subject to the Investment Company Act.

     3.11 NASDAQ Compliance. The Common Stock is registered pursuant to Section 12(g) of the
Exchange Act and is listed on The Nasdaq Stock Market, Inc. Capital Market (the “Nasdaq Capital
Market”), and the Company has taken no action designed to, or likely to have the effect of,
terminating the registration of the Common Stock under the Exchange Act or de-listing the Common
Stock from the Nasdaq Capital Market, nor has the Company received any notification that the SEC or
the National Association of Securities Dealers, Inc. (the “NASD”) is contemplating terminating such
registration or listing.

     3.12 Use of Proceeds. The proceeds of the sale of the Common Shares and the Warrants
hereunder shall be used by the Company for working capital and general corporate purposes.

     3.13 Brokers and Finders. No person or entity will have, as a result of the transactions
contemplated by this Agreement, any valid right, interest or claim against or upon the Company or a
Purchaser for any commission, fee or other compensation pursuant to any agreement, arrangement or
understanding entered into by or on behalf of the Company, other

 5.

 

than SG Cowen & Co., LLC as lead placement agent and Leerink, Swann & Company as co-placement
agent.

     3.14 No Directed Selling Efforts or General Solicitation. Neither the Company nor any person
or entity acting on its behalf has conducted any general solicitation or general advertising (as
those terms are used in Regulation D) in connection with the offer or sale of any of the
Securities.

     3.15 No Integrated Offering. Neither the Company nor any of its Affiliates, nor any person or
entity acting on its or their behalf has, directly or indirectly, made any offers or sales of any
Company security or solicited any offers to buy any security, under circumstances that would
adversely affect reliance by the Company on Section 4(2) for the exemption from registration for
the transactions contemplated hereby or would require registration of the Securities under the
Securities Act.

     3.16 Private Placement. The offer and sale of the Securities to the Purchasers as
contemplated hereby is exempt from the registration requirements of the Securities Act.

     3.17 Internal Accounting Controls. Except as described in the SEC Document, the Company
maintains a system of internal accounting controls sufficient to provide reasonable assurance that
(i) transactions are executed in accordance with management’s general or specific authorizations,
(ii) transactions are recorded as necessary to permit preparation of financial statements in
conformity with generally accepted accounting principles, (iii) access to assets is permitted only
in accordance with management’s general or specific authorization, and (iv) the recorded
accountability for assets is compared with the existing assets at reasonable intervals and
appropriate action is taken with respect to any differences.

     3.18 Sarbanes-Oxley; Disclosure Controls and Procedures. To its knowledge, the Company is in
compliance in all material respects with all of the provisions of the Sarbanes-Oxley Act of 2002
that are applicable to it or any of its subsidiaries. Except as disclosed in the SEC Documents,
the Company has established and maintains disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) that are effective in all material respects to ensure
that material information relating to the Company, including any of its subsidiaries, is made known
to its chief executive officer and chief financial officer by others within those entities. The
Company’s certifying officers have evaluated the effectiveness of the Company’s controls and
procedures as of the end of the period covered by the most recently filed quarterly or annual
periodic report under the Exchange Act (such date, the “Evaluation Date”). The Company presented
in its most recently filed quarterly or annual periodic report under the Exchange Act the
conclusions of the certifying officers about the effectiveness of the disclosure controls and
procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there
have been no significant changes in the Company’s internal controls over financial reporting (as
defined in Item 307(b) of Regulation S-K under the Exchange Act) or, to the Company’s knowledge, in
other factors that could significantly affect the Company’s internal controls over financial
reporting.

 6.

 

     3.19 Intellectual Property.

          (a) “Intellectual Property” shall mean patents, trademarks, service marks, trade names,
copyrights, trade secrets, licenses, information and other proprietary rights and processes.

          (b) Except as disclosed in the SEC Documents and to the knowledge of the Company, the Company
owns or has the valid right to use all of the Intellectual Property that is necessary for the
conduct of the Company’s business as currently conducted or as currently proposed to be conducted
as described in the SEC Documents, free and clear of all material liens and encumbrances.

          (c) Except as disclosed in the SEC Documents, the conduct of the Company’s business as
currently conducted does not infringe or otherwise conflict with (collectively, “Infringe”) any
Intellectual Property rights of any third party or any confidentiality obligation owed by the
Company to a third party, and, to the knowledge of the Company, the Intellectual Property and
confidential information of the Company are not being Infringed by any third party.

          (d) Each employee, consultant and contractor of the Company who has had access to confidential
information of the Company that is necessary for the conduct of Company’s business as currently
conducted or as currently proposed to be conducted has executed an agreement to maintain the
confidentiality of such confidential information and has executed appropriate agreements that are
substantially consistent with the Company’s standard forms thereof.

     3.20 Questionable Payments. Neither the Company nor, to the knowledge of the Company, any of
its current or former stockholders, directors, officers, employees, agents or other persons acting
on behalf of the Company, has on behalf of the Company or in connection with its business: (a) used
any corporate funds for unlawful contributions, gifts, entertainment or other unlawful expenses
relating to political activity; (b) made any direct or indirect unlawful payments to any
governmental officials or employees from corporate funds; (c) established or maintained any
unlawful or unrecorded fund of corporate monies or other assets; (d) made any false or fictitious
entries on the books and records of the Company; or (e) made any unlawful bribe, rebate, payoff,
influence payment, kickback or other unlawful payment of any nature.

     3.21 Transactions with Affiliates. Except as disclosed in the SEC Documents and as
contemplated pursuant to this Agreement, none of the officers or directors of the Company and, to
the knowledge of the Company, none of the employees of the Company is presently a party to any
transaction with the Company or to a presently contemplated transaction (other than for services as
employees, officers and directors) that would be required to be disclosed pursuant to Item 404 of
Regulation S-K promulgated under the Securities Act.

     3.22 Disclosure. Except as disclosed on Schedule 3.21 of the Disclosure Schedule, the
information contained in the Exchange Act Documents as of the date hereof and as of the applicable
Closing Date, did not and shall not contain an untrue statement of a material fact or omit to state
a material fact required to be stated therein or necessary to make the statements therein, in light
of the circumstances under which they were made, not misleading. For purposes

 7.

 

herein, “Exchange Act Documents” are the documents filed by the Company under the Exchange
Act, since the end of its most recently completed fiscal year through the date hereof, including,
without limitation, its most recent report on Form 10-K. The Company confirms that neither the
Company nor, to the Company’s knowledge, any other person acting on its behalf has provided any of
the Purchasers or their agents or counsel with any information that constitutes or would reasonably
be expected to constitute material, non-public information other than those Purchasers listed on
Schedule 5.5 or Purchasers who have executed a written agreement regarding the confidentiality and
use of such information. The Company acknowledges and agrees that no Purchaser makes or has made
any representations or warranties with respect to the transactions contemplated hereby other than
those specifically set forth in Article IV hereof.

     3.23 Dilution; Sales By Purchasers. The Company acknowledges that the issuance of the
Securities may result in dilution of the outstanding shares of Common Stock, which dilution may be
substantial under certain market conditions. The Company further acknowledges that its obligations
under this Agreement and the Warrant, including without limitation its obligation to issue the
Warrant, are unconditional and absolute and not subject to any right of set off, counterclaim,
delay or reduction, regardless of the effect of any such dilution or any claim the Company may have
against any Purchaser and regardless of the dilutive effect that such issuance may have on the
ownership of the other stockholders of the Company. Anything in this Agreement or elsewhere herein
to the contrary notwithstanding (except for Section 4.5 hereof and pursuant to those certain
Amended and Restated Support Agreements, dated as of the date hereof), it is understood and agreed
by the Company (i) that none of the Purchasers have been asked by the Company to agree, nor has any
Purchaser agreed, to desist from purchasing or selling, long and/or short, securities of the
Company, or “derivative” securities based on securities issued by the Company or to hold the
Securities for any specified term; (ii) that future open market or other transactions by any
Purchaser, including short sales, and specifically including, without limitation, short sales or
“derivative” transactions, before or after the closing of this or future private placement
transactions, may negatively impact the market price of the Company’s publicly-traded securities;
(iii) that any Purchaser, and counter parties in “derivative” transactions to which any such
Investor is a party, directly or indirectly, presently may have a “short” position in the Common
Stock, and (iv) that each Purchaser shall not be deemed to have any affiliation with or control
over any arm’s length counter-party in any “derivative” transaction.

ARTICLE 4

Representations, Warranties and Covenants of the Purchasers

     Each Purchaser hereby severally, and not jointly, represents and warrants to the Company on
and as of the date hereof and on the applicable Closing Date:

     4.1 Authorization. Purchaser represents and warrants to the Company that: (a) Purchaser has
all requisite legal and corporate or other power and capacity and has taken all requisite corporate
or other action to execute and deliver this Agreement, to purchase the Common Shares and the
Warrants to be purchased by it and to carry out and perform all of its

 8.

 

obligations under this Agreement; and (b) this Agreement constitutes the legal, valid and
binding obligation of such Purchaser, enforceable in accordance with its terms, except (i) as
limited by applicable bankruptcy, insolvency, reorganization or similar laws relating to or
affecting the enforcement of creditors’ rights generally and (ii) as limited by equitable
principles generally.

     4.2 Investment Experience. Purchaser is an “accredited investor” as defined in Rule 501(a)
under the Securities Act. Purchaser is aware of the Company’s business affairs and financial
condition and has had access to and has acquired sufficient information about the Company to reach
an informed and knowledgeable decision to acquire the Common Shares and the Warrants. Purchaser has
such business and financial experience as is required to give it the capacity to protect its own
interests in connection with the purchase of the Common Shares and Warrants.

     4.3 Investment Intent. Purchaser is purchasing the Common Shares and the Warrants for its own
account as principal, for investment purposes only, and not with a present view to, or for, resale,
distribution or fractionalization thereof, in whole or in part, within the meaning of the
Securities Act, other than as contemplated by Article 7. Purchaser understands that its acquisition
of the Common Shares and the Warrants has not been registered under the Securities Act or
registered or qualified under any state securities law in reliance on specific exemptions
therefrom, which exemptions may depend upon, among other things, the bona fide nature of
Purchaser’s investment intent as expressed herein. Purchaser has completed or caused to be
completed the Purchaser Questionnaire attached hereto as Exhibit B-2 (or has provided the
information requested thereon in the form otherwise acceptable to the Company) for use in
preparation of the Registration Statement, and the responses provided therein shall be true and
correct as of the applicable Closing Date and will be true and correct as of the effective date of
the Registration Statement. Purchaser, in connection with its decision to purchase the Common
Shares and the Warrants, has relied solely upon the SEC Documents and the representations and
warranties of the Company contained herein. Purchaser will not, directly or indirectly, offer,
sell, pledge, transfer or otherwise dispose of (or solicit any offers to buy, purchase or otherwise
acquire or take a pledge of) any of the Securities except in compliance with the Securities Act,
and the rules and regulations promulgated thereunder.

     4.4 Registration or Exemption Requirements. Purchaser further acknowledges and understands
that the Securities may not be resold or otherwise transferred except in a transaction registered
under the Securities Act or unless an exemption from such registration is available.

     4.5 Dispositions.

          (a) Purchaser will not, prior to the effectiveness of the Registration Statement (as defined
below), if then prohibited by law or regulation: (a) sell, offer to sell, solicit offers to buy,
dispose of, loan, pledge or grant any right with respect to (collectively, a “Disposition”) the
Securities; or (b) engage in any hedging or other transaction which is designed or could reasonably
be expected to lead to or result in a Disposition of the Securities by such Purchaser or an
affiliate. In addition, Purchaser agrees that for so long as it owns any Common Shares, it will
not enter into any short sale of Shares executed at a time when the Purchaser has no equivalent
offsetting long position in the Common Shares. For purposes of determining whether the Purchaser
has an equivalent offsetting long position in the Common Shares, shares that the

 9.

 

Purchaser is entitled to receive within sixty (60) days (whether pursuant to contract or upon
conversion or exercise of convertible securities) will be included as if held long by the
Purchaser.

          (b) Purchaser has not directly or indirectly, nor has any Person acting on behalf of or
pursuant to any understanding with such Purchaser, engaged in any transactions in the Company’s
securities (including, without limitation, any Short Sales involving the Company’s securities)
since the time that such Purchaser was first contacted by the Company, SG Cowen & Co., LLC,
Leerink, Swann & Company, or any other Person regarding the transactions contemplated hereby. Such
Purchaser covenants that neither it nor any Person acting on its behalf or pursuant to any
understanding with it will engage in any transactions in the Company’s securities (including,
without limitation, any Short Sales involving the Company’s securities) prior to the time that the
transactions contemplated by this Agreement are publicly disclosed.

     For purposes of this Section 4.5(b), (i) “Person” shall include, without limitation, any
individual or corporation, partnership, trust, incorporated or unincorporated association, joint
venture, limited liability company or joint stock company and (ii) “Short Sales” shall include,
without limitation, all “short sales” as defined in Rule 200 promulgated under Regulation SHO under
the Exchange Act and all types of direct and indirect stock pledges, forward sale contracts,
options, puts, calls, short sales, swaps and similar arrangements (including on a total return
basis), and sales and other transactions through non-U.S. broker-dealers or foreign regulated
brokers.

     4.6 No Legal, Tax or Investment Advice. Purchaser understands that nothing in this Agreement
or any other materials presented to Purchaser in connection with the purchase and sale of the
Common Shares and the Warrants constitutes legal, tax or investment advice. Purchaser has
consulted such legal, tax and investment advisors as it, in its sole discretion, has deemed
necessary or appropriate in connection with its purchase of the Common Shares and the Warrants.

     4.7 Confidentiality. Purchaser will hold in confidence all information concerning this
Agreement and the placement of the Securities hereunder until the earlier of such time as (a) the
Company has made a public announcement concerning the Agreement and the placement of the Securities
hereunder, which announcement shall be made in a press release pursuant to Section 7.9, or (b) this
Agreement is terminated.

     4.8 Residency. Purchaser’s principal executive offices are in the jurisdiction set forth
immediately below Purchaser’s name on the applicable signature page attached hereto.

     4.9 Governmental Review. Purchaser understands that no United States federal or state agency
or any other government or governmental agency has passed upon or made any recommendation or
endorsement of the Shares or the Warrants.

     4.10 Legend. Purchaser understands that, until such time as the Registration Statement has
been declared effective or the Securities may be sold pursuant to Rule 144 under the Securities Act
without any restriction as to the number of securities as of a particular date that can then be
immediately sold, the Securities may bear a restrictive legend in substantially the

 10.

 

following form (and a stop transfer order may be placed against transfer of the certificates
for the Shares):

“THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES
LAWS OF ANY STATE OF THE UNITED STATES OR IN ANY OTHER JURISDICTION. THE
SECURITIES REPRESENTED HEREBY MAY NOT BE OFFERED, SOLD OR TRANSFERRED IN THE
ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER
APPLICABLE SECURITIES LAWS UNLESS OFFERED, SOLD OR TRANSFERRED PURSUANT TO
AN AVAILABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THOSE LAWS.”

          (a) The Company agrees that following the effectiveness of the Registration Statement or at
such time as such legend is no longer required under this Section 4.10, it will, no later than
three business days following the delivery by a Purchaser to the Company or the Company’s transfer
agent of a certificate representing Common Shares or Warrant Shares, as applicable, issued with a
restrictive legend and a signed and completed notice of sale in substantially the form of Exhibit E
attached hereto (such third Trading Day, the “Legend
Removal Date”), deliver or cause to be
delivered to such Purchaser a certificate representing such shares that is free from any legend
referring to the Securities Act. The Company may not make any notation on its records or give
instructions to any transfer agent of the Company that enlarge the restrictions on transfer set
forth in this Section. Certificates for Securities subject to legend removal hereunder shall be
transmitted by the transfer agent of the Company to the Purchasers by crediting the account of the
Purchaser’s prime broker with the Depository Trust Company System. All costs and expenses related
to the removal of the legends and the reissuance of any Securities shall be borne by the Company.

               (b) Each Purchaser, severally and not jointly with the other Purchasers, agrees that the
removal of the restrictive legend from certificates representing Securities as set forth in this
Section 4.10 is predicated upon the Company’s reliance that the Purchaser will sell any Securities
pursuant to either (i) the registration requirements of the Securities Act, and such Purchaser
shall have delivered a current prospectus in connection with such sale; unless constructive
delivery is permitted at the time pursuant to Rule 172 under the Securities Act (“Rule 172”) is
then in effect, such Purchaser shall have confirmed that a current prospectus is deemed to be
delivered in connection with such sale, or (ii) an exemption therefrom.

     4.11 Foreign Investors. If Purchaser is not a United States person (as defined by Section
7701(a)(30) of the Internal Revenue Code of 1986, as amended), Purchaser hereby represents that it
has satisfied itself as to the full observance of the laws of its jurisdiction in connection with
any invitation to subscribe for the Common Shares and the Warrants or any use of this Agreement,
including (a) the legal requirements within its jurisdiction for the purchase of the Common Shares
and the Warrants, (b) any foreign exchange restrictions applicable to such purchase or acquisition,
(c) any government or other consents that may need to be obtained, and

 11.

 

(d) the income tax and other tax consequences, if any, that may be relevant to the purchase,
holding, redemption, sale or transfer of the Securities. Purchaser’s subscription and payment for
and continued beneficial ownership of the Securities will not violate any applicable securities or
other laws of Purchaser’s jurisdiction.

ARTICLE 5

Conditions to Closing Obligations of Purchasers

     Each Purchaser’s obligation to purchase the Common Shares and the Warrants at the relevant
Closing is, at the option of such Purchaser, subject to the fulfillment or waiver as of the
relevant Closing Date of the following conditions:

     5.1 Representations and Warranties. The representations and warranties made by the Company in
Article 3 hereof qualified as to materiality shall be true and correct at all times prior to and on
the applicable Closing Date, except to the extent any such representation or warranty expressly
speaks as of an earlier date, in which case such representation or warranty shall be true and
correct as of such earlier date, and the representations and warranties made by the Company in
Article 3 hereof not qualified as to materiality shall be true and correct in all material respects
at all times prior to and on the applicable Closing Date, except to the extent any such
representation or warranty expressly speaks as of an earlier date, in which case such
representation or warranty shall be true and correct in all material respects as of such earlier
date.

     5.2 Covenants. All covenants, agreements and conditions contained in this Agreement to be
performed by the Company on or prior to the applicable Closing Date shall have been performed or
complied with in all material respects.

     5.3 Certificates. The Company shall deliver or cause to be delivered to the Purchasers duly
executed certificates for the Common Shares and the Warrants (in such denominations as set forth
below each Purchaser’s name on the applicable signature page attached hereto.)

     5.4 Legal Opinion. The Purchasers shall have received on the applicable Closing Date an
opinion of Cooley Godward, counsel for the Company, dated the applicable Closing Date, in
substantially the form of Exhibit C.

     5.5 Voting Agreement. A Voting Agreement, in the form of Exhibit F shall have been executed
by each of the entities set forth on Schedule 5.5.

     5.6 Listing. The Company shall have complied with all requirements with respect to the
listing of the Shares on the Nasdaq Capital Market, except for such requirements not required until
after the issuance of the Shares, such requirements to be complied with promptly after the
applicable Closing.

     5.7 Officer’s Certificate. The Company shall have delivered a Certificate, executed on behalf
of the Company by its Chief Executive Officer or its Chief Financial Officer, dated as of the
applicable Closing Date, certifying to the fulfillment of the conditions specified in Sections 5.1
and 5.2.

 12.

 

     5.8 Judgments. No judgment, writ, order, injunction, award or decree of or by any court, or
judge, justice or magistrate, including any bankruptcy court or judge, or any order of or by any
governmental authority, shall have been issued, and no action or proceeding shall have been
instituted by any governmental authority, enjoining or preventing the consummation of the
transactions contemplated hereby.

     5.9 Secretary’s Certificate. The Company shall have delivered a Certificate, executed on
behalf of the Company by its Secretary or Chief Financial Officer, dated as of the applicable
Closing Date, certifying the resolutions adopted by the Board of Directors of the Company approving
the transactions contemplated by this Agreement and the issuance of the Securities, certifying the
current versions of the Restated Certificate and Bylaws of the Company and certifying as to the
signatures and authority of persons signing this Agreement and related documents on behalf of the
Company.

     5.10 Stop Orders. No stop order or suspension of trading shall have been imposed by the
Nasdaq Capital Market, the SEC or any other governmental regulatory body with respect to public
trading in the Common Stock.

     5.11 Stockholder Approval. In the case of the Second Closing, the Company shall have obtained
Stockholder Consent prior to the 120th day following the date hereof.

ARTICLE 6

Conditions to Closing Obligations of Company

     The Company’s obligation to sell and issue the Common Shares and the Warrants at the relevant
Closing is, at the option of the Company, subject to the fulfillment or waiver of the following
conditions:

     6.1 Receipt of Payment. The Purchasers shall have delivered payment of the purchase price to
the Company for the Common Shares and the Warrants being issued at the applicable Closing.

     6.2 Representations and Warranties. The representations and warranties made by the Purchasers
in Article 4 hereof qualified as to materiality shall be true and correct at all times prior to and
on the applicable Closing Date, except to the extent any such representation or warranty expressly
speaks as of an earlier date, in which case such representation or warranty shall be true and
correct as of such earlier date, and, the representations and warranties made by the Purchasers in
Article 4 hereof not qualified as to materiality shall be true and correct in all material respects
at all times prior to and on the applicable Closing Date, except to the extent any such
representation or warranty expressly speaks as of an earlier date, in which case such
representation or warranty shall be true and correct in all material respects as of such earlier
date.

     6.3 Covenants. All covenants, agreements and conditions contained in this Agreement to be
performed by the Purchasers on or prior to the applicable Closing Date shall have been performed or
complied with in all material respects.

 13.

 

     6.4 Delivery of Purchaser Questionnaire. The Company shall have received from each Purchaser
a fully completed Purchaser Questionnaire in the form attached hereto as Exhibit B (or shall have
received the information requested thereon in the form otherwise acceptable to the Company) prior
to the Second Closing for the Company’s use in preparing the Registration Statement pursuant to
Article 7 below; provided, however, in the event that the Second Closing does not take place, such
Purchaser Questionnaire (or the information requested thereon in the form otherwise acceptable to
the Company) shall have been received from each Purchaser within ten (10) days following
notification by the Company of the filing of such Registration Statement.

ARTICLE 7

Covenants

     7.1 Definitions. For the purpose of this Article 7:

          (a) the term “Registration Statement” shall mean any registration statement required to be
filed by Section 7.2 below, and shall include any preliminary prospectus, final prospectus, exhibit
or amendment included in or relating to such registration statements; and

          (b) the term “Registrable Shares” shall mean all of the Common Shares issued pursuant to this
Agreement and the Warrant Shares issuable upon exercise of the Warrants issued pursuant to this
Agreement.

     7.2 Registration Procedures and Expenses. The Company shall:

          (a) use its best efforts to file a Registration Statement with the SEC within ten (10) days
following the Second Closing Date, but in no event after the date that is eighty (80) days after
the First Closing Date (the “Filing Date”), to register the Registrable Shares and shares of the
Common Stock listed on Schedule 7.2 attached hereto on Form S-3 under the Securities Act
(providing for shelf registration of such Registrable Shares and shares of the Common Stock listed
on Schedule 7.2 under SEC Rule 415) or on such other form which is appropriate to register
such Registrable Shares for resale from time to time by the Purchasers; provided, however, if a
Registration Statement covering the Registrable Shares is not filed with the SEC on or prior to the
Filing Date, the Company will make payments to each Holder, as liquidated damages and not as a
penalty, in an amount equal to one percent (1%) of the aggregate purchase price paid by such Holder
for the Common Shares purchased hereunder for each 30 day period (or a portion thereof) following
the date by which such Registration Statement should have been filed for which no Registration
Statement is filed with respect to the Registrable Securities;

          (b) use its best efforts, subject to receipt of necessary information from the Purchasers, to
cause any such Registration Statement filed pursuant to Section 7.2(a) above to become effective as
promptly after filing of such Registration Statement as practicable but in any event by the date
that is one hundred (100) days following the First Closing Date; provided, however, that in the
event that a Registration Statement is reviewed by the SEC, then such date shall be the date that
is one hundred fifty (150) days following the First Closing Date; If (i) the

 14.

 

Company fails to file with the SEC a request for acceleration in accordance with Rule 461
promulgated under the Securities Act, within five business days of the date that the Company is
notified (orally or in writing, whichever is earlier) by the SEC that a Registration Statement will
not be “reviewed,” or is not subject to further review, or (ii) the Registration Statement has not
been declared effective by the appropriate date in the preceding sentence, then the Company will
make payments to each Holder, as liquidated damages and not as a penalty, in an amount equal to one
percent (1%) of the aggregate purchase price paid by such Holder for the Common Shares purchased
hereunder for each thirty (30) day period (or a portion thereof) following the date by which such
Registration Statement should have been effective as described above had the Company used its best
efforts to have the Registration Statement declared effective;

          (c) prepare and file with the SEC such amendments and supplements to such Registration
Statement and the prospectus used in connection therewith as may be necessary to keep such
Registration Statement continuously effective until termination of such obligation as provided in
Section 7.5 below, subject to the Company’s right to suspend pursuant to Section 7.4;

          (d) furnish to each Purchaser (and to each underwriter, if any, of such Registrable Shares)
such number of copies of prospectuses in conformity with the requirements of the Securities Act and
such other documents as the Purchasers may reasonably request, in order to facilitate the public
sale or other disposition of all or any of the Registrable Shares by the Purchasers, including a
copy of the prospectus to be furnished to each Purchaser pursuant to Section 7.2(g);

          (e) file such documents as may be required of the Company for normal securities law clearance
for the resale of the Registrable Shares in such states of the United States as may be reasonably
requested by each Purchaser; provided, however, that the Company shall not be required in
connection with this paragraph (e) to qualify as a foreign corporation or execute a general consent
to service of process in any jurisdiction;

          (f) upon notification by the SEC that that the Registration Statement will not be reviewed or
is no longer subject to further review and comments by the SEC, the Company shall within five
business days request acceleration of such Registration Statement such that it becomes effective at
5:00 p.m. New York Time on the date that effectiveness is requested
(the “Effective Date”);

          (g) deliver to each Purchaser, by 9:00 a.m. New York time on the day following the Effective
Date, without charge, an electronic copy of each prospectus or prospectuses (including each form of
prospectus) and each amendment or supplement thereto. The Company hereby consents to the use of
such prospectus and each amendment or supplement thereto by each of the selling Holders in
connection with the offering and sale of the Registrable Securities covered by such prospectus and
any amendment or supplement thereto;

          (h) advise each Purchaser promptly:

               (i) of the effectiveness of the Registration Statement or any post-effective amendments
thereto;

 15.

 

               (ii) of any request by the SEC for amendments to the Registration Statement or amendments to
the prospectus or for additional information relating thereto;

               (iii) of the issuance by the SEC of any stop order suspending the effectiveness of the
Registration Statement under the Securities Act or of the suspension by any state securities
commission of the qualification of the Registrable Shares for offering or sale in any jurisdiction,
or the initiation of any proceeding for any of the preceding purposes; and

               (iv) of the existence of any fact and the happening of any event that makes any statement of a
material fact made in the Registration Statement, the prospectus and amendment or supplement
thereto, or any document incorporated by reference therein, untrue, or that requires the making of
any additions to or changes in the Registration Statement or the prospectus in order to make the
statements therein not misleading;

          (i) use its best efforts to cause all Registrable Shares to be listed on each securities
exchange, if any, on which equity securities by the Company are then listed;

          (j) bear all expenses in connection with the procedures in paragraphs (a) through (I) of this
Section 7.2 and the registration of the Registrable Shares on such Registration Statement and the
satisfaction of the blue sky laws of such states; and

          (k) otherwise use commercially reasonable efforts to make available to its security holders no
later than the Availability Date (as defined below), an earnings statement covering a period of at
least twelve (12) months, beginning after the effective date of each Registration Statement, which
earnings statement shall satisfy the provisions of Section 11(a) of the Securities Act, including
Rule 158 promulgated thereunder (for the purpose of this subsection 7.2(k), “Availability Date”
means the 45th day following the end of the fourth fiscal quarter after the fiscal quarter that
includes the effective date of such Registration Statement, except that, if such fourth fiscal
quarter is the last quarter of the Company’s fiscal year, “Availability Date” means the 90th day
after the end of such fourth fiscal quarter).

     7.3 Indemnification.

          (a) The Company agrees to indemnify and hold harmless each Purchaser, the partners, members,
officers and directors of each Purchaser and each person, if any, who controls such Purchaser
within the meaning of the Securities Act or the Exchange Act, from and against any losses, claims,
damages or liabilities to which they may become subject (under the Securities Act or otherwise)
insofar as such losses, claims, damages or liabilities (or actions or proceedings in respect
thereof) arise out of, or are based upon, any untrue statement or alleged untrue statement of a
material fact contained in the Registration Statement or any omission or alleged omission to state
therein a material fact required to be stated therein or necessary to make the statements therein,
in light of the circumstances under which they were made, not misleading or arise out of any
failure by the Company to fulfill any undertaking included in the Registration Statement and the
Company will, as incurred, reimburse such Purchaser, partner, member, officer, director or
controlling person for any legal or other expenses reasonably incurred in investigating, defending
or preparing to defend any such action, proceeding or claim; provided, however, that the Company
shall not be liable in any such case to the extent that such loss, claim,

 16.

 

damage or liability (collectively, “Loss”) arises out of, or is based upon, an untrue
statement or omission or alleged untrue statement or omission made in such Registration Statement
in reliance upon and in conformity with written information furnished to the Company by or on
behalf of such Purchaser, partner, member, officer, director or controlling person specifically for
use in preparation of the Registration Statement or any breach of this Agreement by such Purchaser;
and provided further, however, that the Company shall not be liable to any Purchaser of Registrable
Shares (or any partner, member, officer, director or controlling person of such Purchaser) to the
extent that any such Loss is caused by an untrue statement or omission or alleged untrue statement
or omission made in any preliminary prospectus if either (i)(A) such Purchaser failed to send or
deliver a copy of the final prospectus with or prior to, or, if Rule 172 is then in effect, such
Purchaser failed to confirm that a final prospectus was deemed to be delivered prior to, the
delivery of written confirmation of the sale by such Purchaser to the person asserting the claim
from which such Loss resulted and (B) the final prospectus corrected such untrue statement or
omission, (ii) (X) such untrue statement or omission is corrected in an amendment or supplement to
the prospectus and (Y) having previously been furnished by or on behalf of the Company with copies
of the prospectus as so amended or supplemented, or if Rule 172 is then in effect, notified by the
Company that such amended or supplemented prospectus has been filed with the SEC, such Purchaser
thereafter fails to deliver such prospectus as so amended or supplemented, with or prior to, or, if
Rule 172 is then in effect, such Purchaser fails to confirm that the prospectus so amended or
supplemented was deemed to be delivered prior to, the delivery of written confirmation of the sale
of a Registrable Share to the person asserting the claim from which such Loss resulted or (iii)
such Purchaser sold Registrable Shares in violation of such Purchaser’s covenant contained in
Section 7.4 of this Agreement.

          (b) Each Purchaser, severally and not jointly, agrees to indemnify and hold harmless the
Company (and each person, if any, who controls the Company within the meaning of Section 15 of the
Securities Act or Section 20 of the Exchange Act, each officer of the Company who signs the
Registration Statement and each director of the Company), from and against any losses, claims,
damages or liabilities to which the Company (or any such officer, director or controlling person)
may become subject (under the Securities Act or otherwise), insofar as such losses, claims, damages
or liabilities (or actions or proceedings in respect thereof) arise out of, or are based upon, any
breach of this Agreement by such Purchaser or any untrue statement or alleged untrue statement of a
material fact contained in the Registration Statement or any omission or alleged omission to state
therein a material fact required to be stated therein or necessary to make the statements therein,
in light of the circumstances under which they were made, not misleading in each case, on the
effective date thereof, if, and to the extent, such untrue statement or omission or alleged untrue
statement or omission was made in reliance upon and in conformity with written information
furnished by or on behalf of such Purchaser specifically for use in preparation of the Registration
Statement, and such Purchaser will reimburse the Company (and each of its officers, directors or
controlling persons) for any legal or other expenses reasonably incurred in investigating,
defending or preparing to defend any such action, proceeding or claim; provided, however, that in
no event shall any indemnity under this Section 7.3(b) be greater in amount than the dollar amount
of the proceeds (net of the amount of any damages such Purchaser has otherwise been required to pay
by reason of such untrue statement or omission or alleged untrue statement or omission) received by
such Purchaser upon the sale of the Registrable Securities included in the Registration Statement
giving rise to such indemnification obligation.

 17.

 

          (c) Promptly after receipt by any indemnified person of a notice of a claim or the beginning
of any action in respect of which indemnity is to be sought against an indemnifying person pursuant
to this Section 7.3, such indemnified person shall notify the indemnifying person in writing of
such claim or of the commencement of such action, and, subject to the provisions hereinafter
stated, in case any such action shall be brought against an indemnified person and such
indemnifying person shall have been notified thereof, such indemnifying person shall be entitled to
participate therein, and, to the extent that it shall wish, to assume the defense thereof, with
counsel reasonably satisfactory to such indemnified person. After notice from the indemnifying
person to such indemnified person of its election to assume the defense thereof, such indemnifying
person shall not be liable to such indemnified person for any legal expenses subsequently incurred
by such indemnified person in connection with the defense thereof; provided, however, that if there
exists or shall exist a conflict of interest that would make it inappropriate in the reasonable
judgment of the indemnified person for the same counsel to represent both the indemnified person
and such indemnifying person or any affiliate or associate thereof, the indemnified person shall be
entitled to retain its own counsel at the expense of such indemnifying person; provided, further,
that no indemnifying person shall be responsible for the fees and expense of more than one separate
counsel for all indemnified parties. The indemnifying party shall not settle an action without the
consent of the indemnified party, which consent shall not be unreasonably withheld.

          (d) If after proper notice of a claim or the commencement of any action against the
indemnified party, the indemnifying party does not choose to participate, then the indemnified
party shall assume the defense thereof and upon written notice by the indemnified party requesting
advance payment of a stated amount for its reasonable defense costs and expenses, the indemnifying
party shall advance payment for such reasonable defense costs and expenses (the “Advance
Indemnification Payment”) to the indemnified party. In the event that the indemnified party’s
actual defense costs and expenses exceed the amount of the Advance Indemnification Payment, then
upon written request by the indemnified party, the indemnifying party shall reimburse the
indemnified party for such difference; in the event that the Advance Indemnification Payment
exceeds the indemnified party’s actual costs and expenses, the indemnified party shall promptly
remit payment of such difference to the indemnifying party.

          (e) If the indemnification provided for in this Section 7.3 is held by a court of competent
jurisdiction to be unavailable to an indemnified party with respect to any losses, claims, damages
or liabilities referred to herein, the indemnifying party, in lieu of indemnifying such indemnified
party thereunder, shall to the extent permitted by applicable law contribute to the amount paid or
payable by such indemnified party as a result of such loss, claim, damage or liability in such
proportion as is appropriate to reflect the relative fault of the indemnifying party on the one
hand and of the indemnified party on the other, as well as any other relevant equitable
considerations; provided, that in no event shall any contribution by an indemnifying party
hereunder be greater in amount than the dollar amount of the proceeds (net of the amount of any
damages such indemnifying party has otherwise been required to pay by reason of such untrue
statement or omission or alleged untrue statement or omission) received by such indemnifying party
upon the sale of the Registrable Securities included in the Registration Statement giving rise to
such indemnification obligation.

 18.

 

     7.4 Prospectus Delivery. Each Purchaser hereby covenants with the Company not to make any
sale of the Registrable Shares without complying with Section 8.3. The Purchaser acknowledges that
there may be times when the Company must suspend the use of the prospectus forming a part of the
Registration Statement until such time as an amendment to the Registration Statement has been filed
by the Company and declared effective by the SEC, or until such time as the Company has filed an
appropriate report with the SEC pursuant to the Exchange Act. The Purchaser hereby covenants that
it will not sell any Registrable Shares pursuant to said prospectus during the period commencing at
the time at which the Company gives the Purchaser written notice of the suspension of the use of
said prospectus and ending at the time the Company gives the Purchaser written notice that the
Purchaser may thereafter effect sales pursuant to said prospectus; provided that such suspension
periods shall in no event exceed thirty (30) days in any twelve (12) month period and that, in the
good faith judgment of the Company’s Board of Directors, the Company would, in the absence of such
delay or suspension hereunder, be required under state or federal securities laws to disclose any
corporate development, a potentially significant transaction or event involving the Company, or any
negotiations, discussions, or proposals directly relating thereto, in either case the disclosure of
which would reasonably be expected to have a material adverse effect upon the Company or its
stockholders; provided further, that the Company may suspend the use of the prospectus forming a
part of the Registration Statement to the extent necessary to file any post-effective amendment to
the Registration Statement in order to amend the table of selling stockholders within the
Registration Statement to reflect transfers of the Securities pursuant to Sections 8.3(a) and
8.3(b). If, after the Registration Statement has been declared effective by the SEC, sales cannot
be made pursuant to such Registration Statement, except as excused pursuant to this Section 7.4,
then the Company will make pro rata payments to each Holder, as liquidated damages and not as a
penalty, in an amount equal to one percent (1%) of the aggregate purchase price paid by such Holder
for the Common Shares purchased hereunder for each thirty (30) day period following the date sales
cannot be made pursuant to such Registration Statement after it has been declared effective.

     7.5 Termination of Obligations. The obligations of the Company pursuant to Section 7.2 hereof
shall cease and terminate upon the earlier to occur of (a) such time as all of the Registrable
Shares have been resold, (b) such time as all of the Registrable Shares may be resold in a
three-month period pursuant to Rule 144(k), or (c) the fifth anniversary of the Second Closing Date
or, if the Second Closing does not occur, the First Closing Date.

     7.6 Reporting Requirements.

          (a) With a view to making available the benefits of certain rules and regulations of the SEC
that may at any time permit the sale of the Securities to the public without registration or
pursuant to a registration statement on Form S-3, the Company agrees to use its best efforts to:

               (i) make and keep public information available, as those terms are understood and defined in
Rule 144 under the Securities Act;

               (ii) file with the SEC in a timely manner all reports and other documents required of the
Company under the Securities Act and the Exchange Act; and

 19.

 

               (iii) so long as any of the Purchasers own Registrable Shares, to furnish to such Purchaser
upon request (A) a written statement by the Company as to whether it is in compliance with the
reporting requirements of Rule 144, the Securities Act and the Exchange Act, or whether it is
qualified as a registrant whose securities may be resold pursuant to SEC Form S-3, and (B) a copy
of the most recent annual or quarterly report of the Company and such other reports and documents
so filed by the Company.

     7.7 Blue Sky. The Company shall obtain and maintain all necessary blue sky law permits and
qualifications, or secured exemptions therefrom, required by any state for the offer and sale of
Securities.

     7.8 Stockholder Approval. Promptly following the First Closing Date, the Company shall take
all action necessary to call a special meeting of its stockholders
(the “Special Stockholders
Meeting”) and seek the approval of the Company’s stockholders for, among other matters, the
authorization and issuance of the Common Shares and Warrants at the Second Closing and the issuance
of the Warrant Shares upon exercise of such Warrants in compliance with Rule 4350(i) of the
Marketplace Rules of the NASD (the “Stockholder
Approval”), to the extent required by The Nasdaq
Stock Market, Inc. In connection therewith, the Company will promptly prepare and file with the
SEC proxy materials (including a proxy statement and form of proxy) for use at the Special
Stockholders Meeting and, promptly after receiving clearance from the SEC, shall promptly mail such
proxy materials to the stockholders of the Company.

     7.9 Publicity. The Company shall, on or before 9:30 a.m. New York City time on the first
business day following the date hereof, issue a press release disclosing the material terms of the
transactions contemplated hereby. Except with respect to the press release contemplated by this
section, the Company agrees that it will not use in advertising or publicity the names of Fidelity
Securities Fund: Fidelity OTC Portfolio
(“Fidelity”), any of its partners or employees, any of the
funds or accounts managed by it or any of its affiliates, or any trade name, trademark, trade
device, service mark, symbol or any abbreviation, contraction or simulation thereof, in any case
without the prior written consent of Fidelity.

     7.10 Limitation of Liability. A copy of the Agreement and Declaration of Trust of Fidelity is
on file with the Secretary of State of the Commonwealth of Massachusetts, and notice is hereby
given that this Agreement is executed on behalf of the Trustees of Fidelity as Trustees and not
individually and that the obligations of this Agreement are not binding upon any of the Trustees,
officers or stockholders of Fidelity individually but are binding only upon the assets and property
of Fidelity. The Company is expressly put on notice that the rights and obligations of each series
of shares of each affiliate of Fidelity under its Declaration of Trust are separate and distinct
from those of any and all other entities.

ARTICLE 8

Restrictions on Transferability of Securities;

Compliance with Securities Act

     8.1 Restrictions on Transferability. The Securities shall not be transferable in the absence
of a registration under the Securities Act or an exemption therefrom. The Company shall

 20.

 

be entitled to give stop transfer instructions to its transfer agent with respect to the
Securities in order to enforce the foregoing restrictions.

     8.2 Instruction Sheet. Each certificate representing Registrable Shares shall bear the
Instruction Sheet attached hereto as Exhibit D (in addition to any legends required under
applicable securities laws).

8.3 Transfer of Securities.

          (a) Each Purchaser hereby covenants with the Company not to make any sale of the Securities
except:

               (i) in accordance with the Registration Statement, in which case such Purchaser shall have
delivered a current prospectus in connection with such sale; provided, however, that if Rule 172 is
then in effect, such Purchaser shall have confirmed that a current prospectus is deemed to be
delivered in connection with such sale; or

               (ii) in accordance with Rule 144, in which case Purchaser covenants to comply with Rule 144;
or

               (iii) (A) If the transferee has agreed in writing to be bound by the terms of this Agreement,
(B) such Purchaser shall have notified the Company of the proposed disposition and shall have
furnished the Company with a reasonably detailed statement of the circumstances surrounding the
proposed disposition and (C) if reasonably requested by the Company, such Purchaser shall have
furnished the Company with an opinion of counsel, reasonably satisfactory to the Company, that such
disposition will not require registration of such shares under the Securities Act.

          (b) Notwithstanding the provisions of subsection (a) above, no such restriction shall apply to
a transfer by a Purchaser that is (i) a partnership transferring to its partners or former partners
in accordance with partnership interests, (ii) a corporation transferring to a wholly-owned
subsidiary or a parent corporation that owns all of the capital stock of the Purchaser, (iii) a
limited liability company transferring to its members or former members in accordance with their
interest in the limited liability company or (iv) an individual transferring to the Purchaser’s
family member or trust for the benefit of an individual Purchaser; provided that in each case the
transferee will agree in writing to be subject to the terms of this Agreement to the same extent as
if he were an original Purchaser hereunder.

          (c) Purchaser further acknowledges and agrees that, if a Purchaser is selling the Securities
using the prospectus forming a part of the Registration Statement, such Securities are not
transferable on the books of the Company unless the certificate evidencing such Securities is
submitted to the Company’s transfer agent and a separate certificate executed by an officer of, or
other person duly authorized by, the Purchaser in the form attached hereto as Exhibit E is
submitted to Cooley Godward or the Company’s transfer agent.

     8.4 Purchaser Information. Each Purchaser covenants that it will promptly notify the Company
of any changes in the information set forth in the Registration Statement regarding such Purchaser
or such Purchaser’s “Plan of Distribution.”

 21.

 

     8.5 Material Non-Public Information. Except with respect to those Purchasers listed on
Schedule 5.5 hereof, the Company covenants and agrees that neither it nor any other person
acting on its behalf will provide any Purchaser or its agents or counsel with any information that
the Company believes constitutes material non-public information, unless either prior thereto such
Purchaser shall have executed a written agreement regarding the confidentiality and use of such
information. The Company understands and confirms that each Purchaser shall be relying on the
foregoing representations in effecting transactions in securities of the Company.

ARTICLE 9

Miscellaneous

     9.1 Termination.

          (a) This Agreement may be terminated and the sale and purchase of the Common Shares and the
Warrants abandoned at any time prior to the First Closing, by written notice of any individual
Purchaser if the First Closing has not occurred within five (5) business days of the date hereof
(other than as a result of the failure on the part of the party giving such notice of termination
to perform its covenants and obligations under this Agreement in all material respects); provided,
however, that the abandonment of the sale and purchase of the Common Shares and the Warrants shall
be applicable only to such Purchaser providing such written notice.

          (b) If this Agreement is terminated pursuant to this Section 9.1 all further obligations of
the Company to such Purchaser and of such Purchaser to the Company shall terminate and the Company
shall notify the Purchasers in writing of such notice and termination; provided, however, that (i)
no party shall be relieved of any liability arising from any breach by such party of any provision
of this Agreement and (ii) the parties shall, in all events, remain bound by and continue to be
subject to the provisions set forth in this Article 9.

          (c) The sale and purchase of the Common Shares and the Warrants at the Second Closing may be
abandoned, and the obligations of any individual Purchaser with respect to the Second Closing may
be terminated by written notice of such Purchaser if the Second Closing has not occurred within
120 days of the date of this Agreement (other than as a result of the failure on the part of the
party giving such notice to perform its covenants and obligations under this Agreement in all
material respects). The Company shall notify the remaining Purchasers in writing of any such
notice.

     9.2 Waivers and Amendments. With the exception of Article 7 hereof, the terms of this
Agreement may be waived or amended with the written consent of the Company and the holders of a
majority in interest of the Shares issued or issuable hereunder. With respect to Article 7 hereof,
with the written consent of the Company and the record holders of a majority in interest of the
Registrable Shares issued or issuable hereunder, the terms of this Agreement may be waived or
amended and any such amendment or waiver shall be binding upon the Company and all holders of
Registrable Shares.

 22.

 

     9.3 Broker’s Fee. Each Purchaser acknowledges that the Company intends to pay a fee in
respect of the sale of the Securities to SG Cowen & Co., LLC as lead agent, to Leerkink, Swann &
Company and to the entities listed on Schedule 3.13 of the Disclosure Schedule. Each of
the parties to this Agreement represents that, on the basis of any actions and agreements by it,
there are no other brokers or finders entitled to compensation in connection with the sale of
Securities to the Purchasers.

     9.4 Governing Law. This Agreement shall be governed in all respects by and construed in
accordance with the laws of the State of California without any regard to conflicts of laws
principles.

     9.5 Survival. The representations, warranties, covenants and agreements made in this
Agreement shall survive any investigation made by the Company or the Purchasers and the Closing.

     9.6 Successors and Assigns. The provisions hereof shall inure to the benefit of, and be
binding upon, the successors, assigns, heirs, executors and administrators of the parties to this
Agreement. Upon a permitted transfer of a Purchaser’s Securities on the books of the Company in
accordance with the terms of Sections 8.3(a)(iii) or 8.3(b), the Purchaser may assign this
Agreement to the permitted transferee upon prior written notice to the Company. Except as set
forth in the previous sentence, no Purchaser shall assign this Agreement without the prior written
consent of the Company.

     9.7 Entire Agreement. This Agreement constitutes the full and entire understanding and
agreement between the parties with regard to the subjects thereof.

     9.8 Notices, etc. All notices and other communications required or permitted under this
Agreement shall be in writing and may be delivered in person, by telecopy, overnight delivery
service or registered or certified United States mail, addressed to the Company or the Purchasers,
as the case may be, at their respective addresses set forth on the applicable signature pages
hereto, or at such other address as the Company or the Purchasers shall have furnished to the other
party in writing. All notices and other communications shall be effective upon the earlier of
actual receipt thereof by the person to whom notice is directed or (a) in the case of notices and
communications sent by personal delivery or telecopy, one business day after such notice or
communication arrives at the applicable address or was successfully sent to the applicable telecopy
number, (b) in the case of notices and communications sent by overnight delivery service, at noon
(local time) on the second business day following the day such notice or communication was sent,
and (c) in the case of notices and communications sent by United States mail, seven days after such
notice or communication shall have been deposited in the United States mail.

     9.9 Severability of this Agreement. If any provision of this Agreement shall be judicially
determined to be invalid, illegal or unenforceable, the validity, legality and enforceability of
the remaining provisions shall not in any way be affected or impaired thereby.

     9.10 Counterparts. This Agreement may be executed in any number of counterparts, each of
which shall be an original, but all of which together shall constitute one instrument.

 23.

 

     9.11 Further Assurances. Each party to this Agreement shall do and perform or cause to be
done and performed all such further acts and things and shall execute and deliver all such other
agreements, certificates, instruments and documents as the other party hereto may reasonably
request in order to carry out the intent and accomplish the purposes of this Agreement and the
consummation of the transactions contemplated hereby.

     9.12 Currency. All references to “dollars” or “$” in this Agreement shall be deemed to refer
to United States dollars.

     9.13 Waiver of Conflicts. Each party to this Agreement acknowledges that legal counsel for
the Company, Cooley Godward, has in the past and may continue in the future to perform legal
services for one or more of the Purchasers or their affiliates in matters unrelated to the
transactions contemplated by this Agreement, including, but not limited to, the representation of
the Purchasers in matters of a similar nature to the transactions contemplated herein. Each party
to this Agreement hereby: (a) acknowledges that they have had an opportunity to ask for and have
obtained information relevant to such representation, including disclosure of the reasonably
foreseeable adverse consequences of such representation; (b) acknowledges that with respect to the
transactions contemplated herein, Cooley Godward has represented the Company and not any individual
Purchaser or any individual stockholder, director or employee of the Company; and (c) gives its
informed consent to Cooley Godward’s representation of the Company in the transactions contemplated
by this Agreement.

 24.

 

The foregoing agreement is hereby executed as of the date first above written.

	 	 	 	 	 
	Solexa, Inc., a Delaware corporation
	 
	 	 	 	 
	By:	 	/s/ John West
	 	 	 
	 
	 	 	 	 
	Name:	 	John West
	 
	 	 	 	 
	Title:	 	CEO

 

 

     IN WITNESS WHEREOF, the undersigned has executed this Purchase Agreement or caused its
duly authorized officers to execute this Purchase Agreement as of the date first above written.

	 	 	 	 	 	 	 
	IF AN INDIVIDUAL:	 	IF A CORPORATION, PARTNERSHIP,
	 	 	  TRUST, ESTATE OR OTHER ENTITY:
	 
 

	 	 	 	 	 	 
	(Signature)	 	Signed by
	 	 	for and on behalf of
	 	 	AMADEUS CAPITAL PARTNERS LIMITED
	 	 	in its capacity as manager of
	 	 	AMADEUS II ‘A’
	 	 	 
	 	 	Print name of entity
	 
 

	 	 	 	 	 	 
	(Printed Name)	 	By:	 	/s/ Hermann Hauser
	 	 	 	 	 
	 

	 	 	 	Name:
	 	Hermann Hauser
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	 
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	 
	 	 	Print jurisdiction of organization of entity
	 
	 	 	 	 	 	 

	 	 	 
	Address:

	 	Address:
	 
	 	 
	 
 

	 	Mount Pleasant House, 2 Mount Pleasant 
	 
 

	 	Huntingdon Road 
	 
 

	 	Cambridge CB3 0RN 
	 

	 	United Kingdom

Aggregate dollar amount of Common Shares and Warrants committed to be purchased pursuant to the
terms of the Agreement:

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Common Shares	 	 	Warrant Shares	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	First Closing Purchase Price
	 	$	0	 	 	 	0	 	 	 	0	 
	Second Closing Purchase Price
	 	$	1,125,000.50	 	 	 	173,077	 	 	 	60,577	 

 2.

 

     IN WITNESS WHEREOF, the undersigned has executed this Purchase Agreement or caused its duly
authorized officers to execute this Purchase Agreement as of the date first above written.

	 	 	 	 	 	 	 
	IF AN INDIVIDUAL:	 	IF A CORPORATION, PARTNERSHIP,
	 	 	  TRUST, ESTATE OR OTHER ENTITY:
	 
 

	 	 	 	 	 	 
	(Signature)	 	Signed by
	 	 	for and on behalf of
	 	 	AMADEUS CAPITAL PARTNERS LIMITED
	 	 	in its capacity as manager of
	 	 	AMADEUS II ‘B’
	 	 	 
	 	 	Print name of entity
	 
 

	 	 	 	 	 	 
	(Printed Name)	 	By:	 	/s/ Hermann Hauser
	 	 	 	 	 
	 

	 	 	 	Name:
	 	Hermann Hauser
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	 
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	 
	 	 	Print jurisdiction of organization of entity

	 	 	 
	Address:

	 	Address:
	 
	 	 
	 
 

	 	Mount Pleasant House, 2 Mount Pleasant 
	 
 

	 	Huntingdon Road 
	 
 

	 	Cambridge CB3 0RN 
	 

	 	United Kingdom

Aggregate dollar amount of Common Shares and Warrants committed to be purchased pursuant to the
terms of the Agreement:

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Common Shares	 	 	Warrant Shares	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	First Closing Purchase Price
	 	$	0	 	 	 	0	 	 	 	0	 
	Second Closing Purchase Price
	 	$	750,002.50	 	 	 	115,385	 	 	 	40,385	 

 3.

 

     IN WITNESS WHEREOF, the undersigned has executed this Purchase Agreement or caused its duly
authorized officers to execute this Purchase Agreement as of the date first above written.

	 	 	 	 	 	 	 
	IF AN INDIVIDUAL:	 	IF A CORPORATION, PARTNERSHIP,
	 	 	  TRUST, ESTATE OR OTHER ENTITY:
	 
 

	 	 	 	 	 	 
	(Signature)	 	Signed by
	 	 	for and on behalf of
	 	 	AMADEUS CAPITAL PARTNERS LIMITED
	 	 	in its capacity as manager of
	 	 	AMADEUS II ‘C’
	 	 	 
	 	 	Print name of entity
	 
 

	 	 	 	 	 	 
	(Printed Name)	 	By:	 	/s/ Hermann Hauser
	 	 	 	 	 
	 

	 	 	 	Name:
	 	Hermann Hauser
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	 
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	 
	 	 	Print jurisdiction of organization of entity

	 	 	 
	Address:

	 	Address:
	 
	 	 
	 

	 	Mount Pleasant House, 2 Mount Pleasant
	 

	 	 
	 

	 	Huntingdon Road
	 

	 	 
	 

	 	Cambridge CB3 0RN
	 

	 	 
	 

	 	United Kingdom
	 

	 	 

Aggregate dollar amount of Common Shares and Warrants committed to be purchased pursuant to the
terms of the Agreement:

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Common Shares	 	 	Warrant Shares	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	First Closing Purchase Price
	 	$	0	 	 	 	0	 	 	 	0	 
	Second Closing Purchase Price
	 	$	524,998.50	 	 	 	80,769	 	 	 	28,269	 

 4.

 

     IN WITNESS WHEREOF, the undersigned has executed this Purchase Agreement or caused its duly
authorized officers to execute this Purchase Agreement as of the date first above written.

	 	 	 	 	 	 	 
	IF AN INDIVIDUAL:	 	IF A CORPORATION, PARTNERSHIP,
	 	 	  TRUST, ESTATE OR OTHER ENTITY:
	 
 

	 	 	 	 	 	 
	(Signature)	 	Signed by
	 	 	for and on behalf of
	 	 	AMADEUS CAPITAL PARTNERS LIMITED
	 	 	in its capacity as manager of
	 	 	AMADEUS II ‘D’ GMBH & CO KG
	 	 	 
	 	 	Print name of entity
	 
 

	 	 	 	 	 	 
	(Printed Name)	 	By:	 	/s/ Hermann Hauser
	 	 	 	 	 
	 

	 	 	 	Name:
	 	Hermann Hauser
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	 
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	 
	 	 	Print jurisdiction of organization of entity

	 	 	 
	Address:

	 	Address:
	 
	 	 
	 

	 	VCM Venture Capital Management and
	 

	 	 
	 

	 	Beteiligungsgesellschaft mbH,
	 

	 	 
	 

	 	Max-Joseph Strasse 7, Munich, Germany
	 

	 	 

Aggregate dollar amount of Common Shares and Warrants committed to be purchased pursuant to the
terms of the Agreement:

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Common Shares	 	 	Warrant Shares	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	First Closing Purchase Price
	 	$	0	 	 	 	0	 	 	 	0	 
	Second Closing Purchase Price
	 	$	24,999	 	 	 	3,846	 	 	 	1,346	 

 5.

 

     IN WITNESS WHEREOF, the undersigned has executed this Purchase Agreement or caused its duly
authorized officers to execute this Purchase Agreement as of the date first above written.

	 	 	 	 	 	 	 
	IF AN INDIVIDUAL:	 	IF A CORPORATION, PARTNERSHIP,
	 	 	  TRUST, ESTATE OR OTHER ENTITY:
	 
 

	 	 	 	 	 	 
	(Signature)	 	Signed by
	 	 	for and on behalf of
	 	 	AMADEUS CAPITAL PARTNERS LIMITED
	 	 	in its capacity as manager of
	 	 	AMADEUS II AFFILIATES FUND LP
	 	 	 
	 	 	Print name of entity
	 
 

	 	 	 	 	 	 
	(Printed Name)	 	By:	 	/s/ Hermann Hauser
	 	 	 	 	 
	 

	 	 	 	Name:
	 	Hermann Hauser
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	 
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	 
	 	 	Print jurisdiction of organization of entity

	 	 	 
	Address:

	 	Address:
	 
	 	 
	 

	 	The Corporation Trust Company, 1209
	 

	 	 
	 

	 	Orange Street, Wilmington, New Castle
	 

	 	 
	 

	 	County, Delaware, USA 19801
	 

	 	 

Aggregate dollar amount of Common Shares and Warrants committed to be purchased pursuant to the
terms of the Agreement:

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Common Shares	 	 	Warrant Shares	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	First Closing Purchase Price
	 	$	0	 	 	 	0	 	 	 	0	 
	Second Closing Purchase Price
	 	$	74,997	 	 	 	11,538	 	 	 	4,038	 

 6.

 

     IN WITNESS WHEREOF, the undersigned has executed this Purchase Agreement or caused its duly
authorized officers to execute this Purchase Agreement as of the date first above written.

	 	 	 	 	 	 	 
	IF AN INDIVIDUAL:	 	IF A CORPORATION, PARTNERSHIP,
	 	 	  TRUST, ESTATE OR OTHER ENTITY:
	 
 

	 	 	 	 	 	 
	(Signature)	 	Signed by
	 	 	for and on behalf of
	 	 	Prothro Family Limited Partnership, Ltd.
	 	 	 
	 	 	Print name of entity
	 
 

	 	 	 	 	 	 
	(Printed Name)	 	By:	 	/s/ J.H. Cullum Clark
	 	 	 	 	 
	 

	 	 	 	Name:
	 	J.H. Cullum Clark
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	Managing General Partner
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	  State of Texas Limited Partnership
	 	 	 
	 	 	Print jurisdiction of organization of entity

	 	 	 
	Address:

	 	Address:
	 
	 	 
	 

	 	2626 Cole Avenue, Suite 400
	 

	 	 
	 

	 	Dallas, Texas 75204
	 

	 	 
	 
 

	 	 

Aggregate dollar amount of Common Shares and Warrants committed to be purchased pursuant to the
terms of the Agreement:

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Common Shares	 	 	Warrant Shares	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	First Closing Purchase Price
	 	$	6.50	 	 	 	14,178	 	 	 	4,962	 
	Second Closing Purchase Price
	 	$	6.50	 	 	 	18,099	 	 	 	6,335	 
	 
	 	 	 	 	 	 	32,277	 	 	 	11,297	 
	 
	 	 	 	 	 	 	 	 	 	 

 7.

 

     IN WITNESS WHEREOF, the undersigned has executed this Purchase Agreement or caused its duly
authorized officers to execute this Purchase Agreement as of the date first above written.

	 	 	 	 	 	 	 
	IF AN INDIVIDUAL:	 	IF A CORPORATION, PARTNERSHIP,
	 	 	  TRUST, ESTATE OR OTHER ENTITY:
	 
 

	 	 	 	 	 	 
	(Signature)	 	Signed by
	 	 	for and on behalf of
	 	 	Cimarron Biomedical Equity Master Fund, LP
	 	 	 
	 	 	Print name of entity
	 
 

	 	 	 	 	 	 
	(Printed Name)	 	By:	 	/s/ J.H. Cullum Clark
	 	 	 	 	 
	 

	 	 	 	Name:
	 	J.H. Cullum Clark
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	Manager for General Partner
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	  Cayman Islands Limited Partnership
	 	 	 
	 	 	Print jurisdiction of organization of entity

	 	 	 
	Address:

	 	Address:
	 
	 	 
	 

	 	c/o Cimarron Biomedical Investors
	 

	 	 
	 

	 	2626 Cole Avenue, Suite 400
	 

	 	 
	 

	 	Dallas, Texas 75204
	 

	 	 

Aggregate dollar amount of Common Shares and Warrants committed to be purchased pursuant to the
terms of the Agreement: $432,250

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Common Shares	 	 	Warrant Shares	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	First Closing Purchase Price
	 	$	6.50	 	 	 	29,210	 	 	 	10,224	 
	Second Closing Purchase Price
	 	$	6.50	 	 	 	37,290	 	 	 	13,051	 
	 
	 	 	 	 	 	 	66,500	 	 	 	23,275	 
	 
	 	 	 	 	 	 	 	 	 	 

 8.

 

     IN WITNESS WHEREOF, the undersigned has executed this Purchase Agreement or caused its duly
authorized officers to execute this Purchase Agreement as of the date first above written.

	 	 	 	 	 	 	 
	IF AN INDIVIDUAL:	 	IF A CORPORATION, PARTNERSHIP,
	 	 	  TRUST, ESTATE OR OTHER ENTITY:
	 
 

	 	 	 	 	 	 
	(Signature)	 	Signed by
	 	 	for and on behalf of
	 	 	Topwater Exclusive Fund II LLC
	 	 	 
	 	 	Print name of entity
	 
 

	 	 	 	 	 	 
	(Printed Name)	 	By:	 	/s/ J.H. Cullum Clark
	 	 	 	 	 
	 

	 	 	 	Name:
	 	J.H. Cullum Clark
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	Manager/Cimarron GLOBAL Management dba Cimarron Biomedical Investors
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	  Delaware Limited Liability Company
	 	 	 
	 	 	Print jurisdiction of organization of entity

	 	 	 
	Address:

	 	Address:
	 
	 	 
	 

	 	c/o Cimarron Biomedical Investors
	 

	 	 
	 

	 	2626 Cole Avenue, Suite 400
	 

	 	 
	 

	 	Dallas, Texas 75204
	 

	 	 

Aggregate dollar amount of Common Shares and Warrants committed to be purchased pursuant to the
terms of the Agreement: $157,950

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Common Shares	 	 	Warrant Shares	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	First Closing Purchase Price
	 	$	6.50	 	 	 	10,673	 	 	 	3,736	 
	Second Closing Purchase Price
	 	$	6.50	 	 	 	13,627	 	 	 	4,769	 
	 
	 	 	 	 	 	 	24,300	 	 	 	8,505	 
	 
	 	 	 	 	 	 	 	 	 	 

 9.

 

     IN WITNESS WHEREOF, the undersigned has executed this Purchase Agreement or caused its duly
authorized officers to execute this Purchase Agreement as of the date first above written.

	 	 	 	 	 	 	 
	IF AN INDIVIDUAL:	 	IF A CORPORATION, PARTNERSHIP,
	 	 	  TRUST, ESTATE OR OTHER ENTITY:
	 
 

	 	 	 	 	 	 
	(Signature)	 	Signed by
	 	 	for and on behalf of
	 	 	D3 LifeScience Ltd.
	 	 	 
	 	 	Print name of entity
	 
 

	 	 	 	 	 	 
	(Printed Name)	 	By:	 	/s/ Nathan Fischel
	 	 	 	 	 
	 

	 	 	 	Name:
	 	Nathan Fischel, MD, CFA
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	Managing Member of the Investment Manager, D3 Capital Management, LLC on behalf of D3 LifeScience Ltd.
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	  Cayman Islands
	 	 	 
	 	 	Print jurisdiction of organization of entity

	 	 	 
	Address:

	 	Address:
	 
	 	 
	 

	 	D3 LifeScience Ltd.
	 

	 	 
	 

	 	c/o D3 Capital Management, LLC
	 

	 	 
	 

	 	10990 Wilshire Blvd., Suite 1400
	 

	 	 
	 

	 	Los Angeles, California 90024
	 

	 	 

Aggregate dollar amount of Common Shares and Warrants committed to be purchased pursuant to the
terms of the Agreement: $249,996.50

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Common Shares	 	 	Warrant Shares	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	First Closing Purchase Price
	 	$	6.50	 	 	 	16,894	 	 	 	5,913	 
	Second Closing Purchase Price
	 	$	6.50	 	 	 	21,569	 	 	 	7,549	 
	For Total Commitment of:
	 	$	249,996.50	 	 	 	 	 	 	 	 	 

 10.

 

     IN WITNESS WHEREOF, the undersigned has executed this Purchase Agreement or caused its duly
authorized officers to execute this Purchase Agreement as of the date first above written.

	 	 	 	 	 	 	 
	IF AN INDIVIDUAL:	 	IF A CORPORATION, PARTNERSHIP,
	 	 	  TRUST, ESTATE OR OTHER ENTITY:
	 
 

	 	 	 	 	 	 
	(Signature)	 	Signed by
	 	 	for and on behalf of
	 	 	D3 LifeScience Select Ltd.
	 	 	 
	 	 	Print name of entity
	 
 

	 	 	 	 	 	 
	(Printed Name)	 	By:	 	/s/ Nathan Fischel
	 	 	 	 	 
	 

	 	 	 	Name:
	 	Nathan Fischel, MD, CFA
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	Managing Member of the Investment Manager, D3 Capital Management, LLC on behalf of D3 LifeScience Select Ltd.
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	  Cayman Islands
	 	 	 
	 	 	Print jurisdiction of organization of entity

	 	 	 
	Address:

	 	Address:
	 
	 	 
	 

	 	D3 LifeScience Select Ltd.
	 

	 	 
	 

	 	c/o D3 Capital Management, LLC
	 

	 	 
	 

	 	10990 Wilshire Blvd., Suite 1400
	 

	 	 
	 

	 	Los Angeles, California 90024
	 

	 	 

Aggregate dollar amount of Common Shares and Warrants committed to be purchased pursuant to the
terms of the Agreement: $250,009.50

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Common Shares	 	 	Warrant Shares	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	First Closing Purchase Price
	 	$	6.50	 	 	 	16,894	 	 	 	5,913	 
	Second Closing Purchase Price
	 	$	6.50	 	 	 	21,567	 	 	 	7,548	 
	For Total Commitment of:
	 	$	250,009.50	 	 	 	 	 	 	 	 	 

 11.

 

     IN WITNESS WHEREOF, the undersigned has executed this Purchase Agreement or caused its duly
authorized officers to execute this Purchase Agreement as of the date first above written.

	 	 	 	 	 	 	 
	IF AN INDIVIDUAL:	 	IF A CORPORATION, PARTNERSHIP,
	 	 	  TRUST, ESTATE OR OTHER ENTITY:
	 
 

	 	 	 	 	 	 
	(Signature)	 	Enable Growth Partners LP
	 	 	 
	 	 	Print name of entity
	 
 

	 	 	 	 	 	 
	(Printed Name)	 	By:	 	/s/ Brendan O’Neil
	 	 	 	 	 
	 

	 	 	 	Name:
	 	Brendan O’Neil
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	Principal & Portfolio Manager
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	 
	 	 	Print jurisdiction of organization of entity

	 	 	 
	Address:

	 	Address:
	 
	 	 
	 

	 	 
	 

	 	 
	 

	 	 
	 

	 	 
	 

	 	 
	 

	 	 

Aggregate dollar amount of Common Shares and Warrants committed to be purchased pursuant to the
terms of the Agreement: $975,000

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Common Shares	 	 	Warrant Shares	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	First Closing Purchase Price
	 	$	6.50	 	 	 	65,887	 	 	 	23,060	 
	Second Closing Purchase Price
	 	$	6.50	 	 	 	84,113	 	 	 	29,440	 

 12.

 

     IN WITNESS WHEREOF, the undersigned has executed this Purchase Agreement or caused its duly
authorized officers to execute this Purchase Agreement as of the date first above written.

	 	 	 	 	 	 	 
	IF AN INDIVIDUAL:	 	IF A CORPORATION, PARTNERSHIP,
	 	 	  TRUST, ESTATE OR OTHER ENTITY:
	 
 

	 	 	 	 	 	 
	(Signature)	 	Enable Opportunity Partners L.P.
	 	 	 
	 	 	Print name of entity
	 
 

	 	 	 	 	 	 
	(Printed Name)	 	By:	 	/s/ Brendan O’Neil
	 	 	 	 	 
	 

	 	 	 	Name:
	 	Brendan O’Neil
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	Principal & Portfolio Manager
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	 
	 	 	Print jurisdiction of organization of entity

	 	 	 
	Address:

	 	Address:
	 
	 	 
	 

	 	 
	 

	 	 
	 

	 	 
	 

	 	 
	 

	 	 
	 

	 	 

Aggregate dollar amount of Common Shares and Warrants committed to be purchased pursuant to the
terms of the Agreement: $274,995.50

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Common Shares	 	 	Warrant Shares	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	First Closing Purchase Price
	 	$	6.50	 	 	 	18,583	 	 	 	6,504	 
	Second Closing Purchase Price
	 	$	6.50	 	 	 	23,724	 	 	 	8,303	 

 13.

 

     IN WITNESS WHEREOF, the undersigned has executed this Purchase Agreement or caused its duly
authorized officers to execute this Purchase Agreement as of the date first above written.

	 	 	 	 	 	 	 
	IF AN INDIVIDUAL:	 	IF A CORPORATION, PARTNERSHIP,
	 	 	  TRUST, ESTATE OR OTHER ENTITY:
	 
 

	 	 	 	 	 	 
	(Signature)	 	Caduceus Capital Master Fund Limited
	 	 	 
	 	 	Print name of entity
	 
 

	 	 	 	 	 	 
	(Printed Name)	 	By:	 	/s/ Samuel D. Isaly
	 	 	 	 	 
	 

	 	 	 	Name:
	 	Samuel D. Isaly
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	Investment Advisor
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	  Bermuda
	 	 	 
	 	 	Print jurisdiction of organization of entity

	 	 	 
	Address:

	 	Address:
	 
	 	 
	 

	 	c/o OrbiMed Advisors LLC
	 

	 	 
	 

	 	767 Third Avenue, 30th Floor
	 

	 	 
	 

	 	New York, New York 10017
	 

	 	 

Aggregate dollar amount of Common Shares and Warrants committed to be purchased pursuant to the
terms of the Agreement: $2,047,500.00

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Common Shares	 	 	Warrant Shares	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	First Closing Purchase Price
	 	$	6.50	 	 	 	138,362	 	 	 	48,427	 
	Second Closing Purchase Price
	 	$	6.50	 	 	 	176,638	 	 	 	61,823	 

 14.

 

     IN WITNESS WHEREOF, the undersigned has executed this Purchase Agreement or caused its duly
authorized officers to execute this Purchase Agreement as of the date first above written.

	 	 	 	 	 	 	 
	IF AN INDIVIDUAL:	 	IF A CORPORATION, PARTNERSHIP,
	 	 	  TRUST, ESTATE OR OTHER ENTITY:
	 
 

	 	 	 	 	 	 
	(Signature)	 	Caduceus Capital II, L.P.
	 	 	 
	 	 	Print name of entity
	 
 

	 	 	 	 	 	 
	(Printed Name)	 	By:	 	/s/ Samuel D. Isaly
	 	 	 	 	 
	 

	 	 	 	Name:
	 	Samuel D. Isaly
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	General Partner
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	Delaware
	 	 	 
	 	 	Print jurisdiction of organization of entity

	 	 	 
	Address:

	 	Address:
	 
	 	 
	 

	 	c/o OrbiMed Advisors LLC
	 

	 	 
	 

	 	767 Third Avenue, 30th Floor
	 

	 	 
	 

	 	New York, New York 10017
	 

	 	 

Aggregate dollar amount of Common Shares and Warrants committed to be purchased pursuant to the
terms of the Agreement: $975,000.00

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Common Shares	 	 	Warrant Shares	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	First Closing Purchase Price
	 	$	6.50	 	 	 	65,888	 	 	 	23,061	 
	Second Closing Purchase Price
	 	$	6.50	 	 	 	84,112	 	 	 	29,439	 

 15.

 

     IN WITNESS WHEREOF, the undersigned has executed this Purchase Agreement or caused its duly
authorized officers to execute this Purchase Agreement as of the date first above written.

	 	 	 	 	 	 	 
	IF AN INDIVIDUAL:	 	IF A CORPORATION, PARTNERSHIP,
	 	 	  TRUST, ESTATE OR OTHER ENTITY:
	 
 

	 	 	 	 	 	 
	(Signature)	 	UBS Eucalyptus Fund, L.L.C.
	 	 	 
	 	 	Print name of entity
	 
 

	 	 	 	 	 	 
	(Printed Name)	 	By:	 	/s/ Samuel D. Isaly
	 	 	 	 	 
	 

	 	 	 	Name:
	 	Samuel D. Isaly
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	JV Partner
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	  Delaware
	 	 	 
	 	 	Print jurisdiction of organization of entity

	 	 	 
	Address:

	 	Address:
	 
	 	 
	 

	 	c/o OrbiMed Advisors LLC
	 

	 	 
	 

	 	767 Third Avenue, 30th Floor
	 

	 	 
	 

	 	New York, New York 10017
	 

	 	 

Aggregate dollar amount of Common Shares and Warrants committed to be purchased pursuant to the
terms of the Agreement: $1,475,500

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Common Shares	 	 	Warrant Shares	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	First Closing Purchase Price
	 	$	6.50	 	 	 	99,709	 	 	 	34,898	 
	Second Closing Purchase Price
	 	$	6.50	 	 	 	127,291	 	 	 	44,552	 

 16.

 

     IN WITNESS WHEREOF, the undersigned has executed this Purchase Agreement or caused its duly
authorized officers to execute this Purchase Agreement as of the date first above written.

	 	 	 	 	 	 	 
	IF AN INDIVIDUAL:	 	IF A CORPORATION, PARTNERSHIP,
	 	 	  TRUST, ESTATE OR OTHER ENTITY:
	 
 

	 	 	 	 	 	 
	(Signature)	 	PW Eucalyptus Fund, Ltd.
	 	 	 
	 	 	Print name of entity
	 
 

	 	 	 	 	 	 
	(Printed Name)	 	By:	 	/s/ Samuel D. Isaly
	 	 	 	 	 
	 

	 	 	 	Name:
	 	Samuel D. Isaly
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	JV Partner
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	Cayman Islands
	 	 	 
	 	 	Print jurisdiction of organization of entity

	 	 	 
	Address:

	 	Address:
	 
	 	 
	 

	 	c/o OrbiMed Advisors LLC
	 

	 	 
	 

	 	767 Third Avenue, 30th Floor
	 

	 	 
	 

	 	New York, New York 10017
	 

	 	 

Aggregate dollar amount of Common Shares and Warrants committed to be purchased pursuant to the
terms of the Agreement: $162,500

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Common Shares	 	 	Warrant Shares	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	First Closing Purchase Price
	 	$	6.50	 	 	 	10,981	 	 	 	3,843	 
	Second Closing Purchase Price
	 	$	6.50	 	 	 	14,019	 	 	 	4,907	 

 17.

 

     IN WITNESS WHEREOF, the undersigned has executed this Purchase Agreement or caused its duly
authorized officers to execute this Purchase Agreement as of the date first above written.

	 	 	 	 	 	 	 
	IF AN INDIVIDUAL:	 	IF A CORPORATION, PARTNERSHIP,
	 	 	  TRUST, ESTATE OR OTHER ENTITY:
	 
 

	 	 	 	 	 	 
	(Signature)	 	HFR SHC Aggressive Master Trust Fund
	 	 	 
	 	 	Print name of entity
	 
 

	 	 	 	 	 	 
	(Printed Name)	 	By:	 	/s/ Dora Hines
	 	 	 	 	 
	 

	 	 	 	Name:
	 	Dora Hines
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	 
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	Bermuda
	 	 	 
	 	 	Print jurisdiction of organization of entity

	 	 	 
	Address:

	 	Address:
	 
	 	 
	 

	 	c/o OrbiMed Advisors LLC
	 

	 	 
	 

	 	767 Third Avenue, 30th Floor
	 

	 	 
	 

	 	New York, New York 10017
	 

	 	 

Aggregate dollar amount of Common Shares and Warrants committed to be purchased pursuant to the
terms of the Agreement: $338,000

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Common Shares	 	 	Warrant Shares	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	First Closing Purchase Price
	 	$	6.50	 	 	 	22,840	 	 	 	7,994	 
	Second Closing Purchase Price
	 	$	6.50	 	 	 	29,160	 	 	 	10,206	 

 18.

 

     IN WITNESS WHEREOF, the undersigned has executed this Purchase Agreement or caused its duly
authorized officers to execute this Purchase Agreement as of the date first above written.

	 	 	 	 	 	 	 
	IF AN INDIVIDUAL:	 	IF A CORPORATION, PARTNERSHIP,
	 	 	  TRUST, ESTATE OR OTHER ENTITY:
	 
 

	 	 	 	 	 	 
	(Signature)	 	Signed by
	 	 	for and on behalf of
	 
 

	 	MRNA Fund II L.P.
	(Printed Name)	 	By: OBP Management IV L.P.
	 	 	Its General Partner
	 	 	 
	 	 	Print name of entity
	 
	 	 	 	 	 	 
	 	 	By:	 	/s/ Michael Lytton
	 	 	 	 	 
	 

	 	 	 	Name:
	 	Michael Lytton
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	General Partner
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	  Delaware
	 	 	 
	 	 	Print jurisdiction of organization of entity

	 	 	 
	Address:

	 	Address:
	 
	 	 
	 

	 	Oxford Bioscience Partners
	 

	 	 
	 

	 	222 Berkeley Street, Suite 1650
	 

	 	 
	 

	 	Boston, Massachusetts 02116
	 

	 	 

Aggregate dollar amount of Common Shares and Warrants committed to be purchased pursuant to the
terms of the Agreement: $19,870.50

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Common Shares	 	 	Warrant Shares	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	First Closing Purchase Price
	 	$	0	 	 	 	0	 	 	 	0	 
	Second Closing Purchase Price
	 	$	6.50	 	 	 	3,057	 	 	 	1,070	 

 19.

 

     IN WITNESS WHEREOF, the undersigned has executed this Purchase Agreement or caused its duly
authorized officers to execute this Purchase Agreement as of the date first above written.

	 	 	 	 	 	 	 
	IF AN INDIVIDUAL:	 	IF A CORPORATION, PARTNERSHIP,
	 	 	  TRUST, ESTATE OR OTHER ENTITY:
	  

	 	 	 	 	 	 
	(Signature)	 	Oxford Bioscience Partners IV L.P.
	 	 	By: OBP Management IV L.P.
	 	 	Its General Partner
	 	 	 
	 	 	Print name of entity
	  

	 	 	 	 	 	 
	(Printed Name)	 	By:	 	/s/ Michael Lytton
	 	 	 	 	 
	 

	 	 	 	Name:
	 	Michael Lytton
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	General Partner
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	Delaware
	 	 	 
	 	 	Print jurisdiction of organization of entity

	 	 	 
	Address:

	 	Address:
	 
	 	 
	 

	 	Oxford Bioscience Partners
	 

	 	 
	 

	 	222 Berkeley Street, Suite 1650
	 

	 	 
	 

	 	Boston, Massachusetts 02116
	 

	 	 

Aggregate dollar amount of Common Shares and Warrants committed to be purchased pursuant to the
terms of the Agreement: $1,980,134

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Common Shares	 	 	Warrant Shares	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	First Closing Purchase Price
	 	$	0	 	 	 	0	 	 	 	0	 
	Second Closing Purchase Price
	 	$	6.50	 	 	 	304,636	 	 	 	106,623	 

 20.

 

     IN WITNESS WHEREOF, the undersigned has executed this Purchase Agreement or caused its duly
authorized officers to execute this Purchase Agreement as of the date first above written.

	 	 	 	 	 	 	 
	IF AN INDIVIDUAL:	 	IF A CORPORATION, PARTNERSHIP,
	 	 	  TRUST, ESTATE OR OTHER ENTITY:
	 
 

	 	 	 	 	 	 
	(Signature)	 	Special Situations Fund III, L.P.
	 	 	 
	 	 	Print name of entity
	 
 

	 	 	 	 	 	 
	(Printed Name)	 	By:	 	/s/ David Greenhouse
	 	 	 	 	 
	 

	 	 	 	Name:
	 	David Greenhouse
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	Managing Director
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	 
	 	 	Print jurisdiction of organization of entity

	 	 	 
	Address:

	 	Address:
	 
	 	 
	 

	 	153 East 53rd Street, 55th Floor
	 

	 	 
	 

	 	New York, New York 10022
	 

	 	 
	 
 

	 	 

Aggregate dollar amount of Common Shares and Warrants committed to be purchased pursuant to the
terms of the Agreement:

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Common Shares	 	 	Warrant Shares	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	First Closing Purchase Price
	 	$	6.50	 	 	 	216,244	 	 	 	75,685	 
	Second Closing Purchase Price
	 	$	6.50	 	 	 	276,063	 	 	 	96,623	 
	 
	 	 	 	 	 	 	 	 	 	 
	Purchase Price
	 	$	6.50	 	 	 	492,307	 	 	 	172,308	 
	Total
	 	$	3,199,995.50	 	 	 	 	 	 	 	 	 

 21.

 

     IN WITNESS WHEREOF, the undersigned has executed this Purchase Agreement or caused its duly
authorized officers to execute this Purchase Agreement as of the date first above written.

	 	 	 	 	 	 	 
	IF AN INDIVIDUAL:	 	IF A CORPORATION, PARTNERSHIP,
	 	 	  TRUST, ESTATE OR OTHER ENTITY:
	 
 

	 	 	 	 	 	 
	(Signature)	 	Special Situations Cayman Fund, L.P.
	 	 	 
	 	 	Print name of entity
	 
 

	 	 	 	 	 	 
	(Printed Name)	 	By:	 	/s/ David Greenhouse
	 	 	 	 	 
	 

	 	 	 	Name:
	 	David Greenhouse
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	Managing Director
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	 
	 	 	Print jurisdiction of organization of entity

	 	 	 
	Address:

	 	Address:
	 
	 	 
	 

	 	153 East 53rd Street, 55th Floor
	 

	 	 
	 

	 	New York, New York 10022
	 

	 	 
	 
 

	 	 

Aggregate dollar amount of Common Shares and Warrants committed to be purchased pursuant to the
terms of the Agreement:

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Common Shares	 	 	Warrant Shares	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	First Closing Purchase Price
	 	$	6.50	 	 	 	54,061	 	 	 	18,921	 
	Second Closing Purchase Price
	 	$	6.50	 	 	 	69,016	 	 	 	24,156	 
	 
	 	 	 	 	 	 	 	 	 	 
	Purchase Price
	 	$	6.50	 	 	 	123,077	 	 	 	43,077	 
	Total
	 	$	800,000.50	 	 	 	 	 	 	 	 	 

 22.

 

     IN WITNESS WHEREOF, the undersigned has executed this Purchase Agreement or caused its duly
authorized officers to execute this Purchase Agreement as of the date first above written.

	 	 	 	 	 	 	 
	IF AN INDIVIDUAL:	 	IF A CORPORATION, PARTNERSHIP,
	 	 	  TRUST, ESTATE OR OTHER ENTITY:
	 
 

	 	 	 	 	 	 
	(Signature)	 	Special Situations Private Equity Fund, L.P.
	 	 	 
	 	 	Print name of entity
	 
 

	 	 	 	 	 	 
	(Printed Name)	 	By:	 	/s/ David Greenhouse
	 	 	 	 	 
	 

	 	 	 	Name:
	 	David Greenhouse
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	Managing Director
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	 
	 	 	Print jurisdiction of organization of entity

	 	 	 
	Address:

	 	Address:
	 
	 	 
	 

	 	153 East 53rd Street, 55th Floor
	 

	 	 
	 

	 	New York, New York 10022
	 

	 	 
	 
 

	 	 

Aggregate dollar amount of Common Shares and Warrants committed to be purchased pursuant to the
terms of the Agreement:

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Common Shares	 	 	Warrant Shares	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	First Closing Purchase Price
	 	$	6.50	 	 	 	33,788	 	 	 	11,826	 
	Second Closing Purchase Price
	 	$	6.50	 	 	 	43,135	 	 	 	15,097	 
	Purchase Price
	 	$	6.50	 	 	 	76,923	 	 	 	26,923	 
	Total
	 	$	499,999.50	 	 	 	 	 	 	 	 	 

 23.

 

     IN WITNESS WHEREOF, the undersigned has executed this Purchase Agreement or caused its duly
authorized officers to execute this Purchase Agreement as of the date first above written.

	 	 	 	 	 	 	 
	IF AN INDIVIDUAL:	 	IF A CORPORATION, PARTNERSHIP,
	 	 	  TRUST, ESTATE OR OTHER ENTITY:
	 
 

	 	 	 	 	 	 
	(Signature)	 	Special Situations Life Sciences Fund, L.P.
	 	 	 
	 	 	Print name of entity
	 
 

	 	 	 	 	 	 
	(Printed Name)	 	By:	 	/s/ David Greenhouse
	 	 	 	 	 
	 

	 	 	 	Name:
	 	David Greenhouse
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	Managing Director
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	 
	 	 	Print jurisdiction of organization of entity

	 	 	 
	Address:

	 	Address:
	 
	 	 
	 

	 	153 East 53rd Street, 55th Floor
	 

	 	 
	 

	 	New York, New York 10022
	 

	 	 
	 
 

	 	 

Aggregate dollar amount of Common Shares and Warrants committed to be purchased pursuant to the
terms of the Agreement:

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Common Shares	 	 	Warrant Shares	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	First Closing Purchase Price
	 	$	6.50	 	 	 	33,788	 	 	 	11,826	 
	Second Closing Purchase Price
	 	$	6.50	 	 	 	43,135	 	 	 	15,097	 
	Purchase Price
	 	$	6.50	 	 	 	76,923	 	 	 	26,923	 
	Total
	 	$	499,999.50	 	 	 	 	 	 	 	 	 

 24.

 

     IN WITNESS WHEREOF, the undersigned has executed this Purchase Agreement or caused its duly
authorized officers to execute this Purchase Agreement as of the date first above written.

	 	 	 	 	 	 	 
	IF AN INDIVIDUAL:	 	IF A CORPORATION, PARTNERSHIP,
	 	 	  TRUST, ESTATE OR OTHER ENTITY:
	 
 

	 	 	 	 	 	 
	(Signature)	 	The Aries Master Fund II
	 	 	 
	 	 	Print name of entity
	 
 

	 	 	 	 	 	 
	(Printed Name)	 	By:	 	/s/ Lindsay A. Rosenwald
	 	 	 	 	 
	 

	 	 	 	Name:
	 	Lindsay A. Rosenwald, M.D.
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	Chairman and CEO of Paramount BioCapital Asset Management, Inc., its Investment Manager
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	 
	 	 	Print jurisdiction of organization of entity

	 	 	 
	Address:

	 	Address:
	 
	 	 
	 
	 	c/o Paramount BioCapital Assets Management, Inc. 
	 

	 	 
	 

	 	787 Seventh Avenue, 48th Floor
	 

	 	 
	 

	 	New York, New York 10019
	 

	 	 

Aggregate dollar amount of Common Shares and Warrants committed to be purchased pursuant to the
terms of the Agreement: $82,498.00

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Common Shares	 	 	Warrant Shares	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	First Closing Purchase Price
	 	$	6.50	 	 	 	11,156	 	 	 	3,902	 
	Second Closing Purchase Price
	 	$	6.50	 	 	 	1,542	 	 	 	540	 

 25.

 

     IN WITNESS WHEREOF, the undersigned has executed this Purchase Agreement or caused its duly
authorized officers to execute this Purchase Agreement as of the date first above written.

	 	 	 	 	 	 	 
	IF AN INDIVIDUAL:	 	IF A CORPORATION, PARTNERSHIP,
	 	 	  TRUST, ESTATE OR OTHER ENTITY:
	 
 

	 	 	 	 	 	 
	(Signature)	 	RAQ, LLC
	 	 	 
	 	 	Print name of entity
	 
 

	 	 	 	 	 	 
	(Printed Name)	 	By:	 	/s/ Lindsay A. Rosenwald
	 	 	 	 	 
	 

	 	 	 	Name:
	 	Lindsay A. Rosenwald, M.D.
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	Managing Member
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	 
	 	 	Print jurisdiction of organization of entity

	 	 	 
	Address:

	 	Address:
	 
	 	 
	 

	 	c/o Paramount BioCapital Investment, LLC
	 

	 	 
	 

	 	787 Seventh Avenue, 48th Floor
	 

	 	 
	 

	 	New York, New York 10019
	 

	 	 

Aggregate dollar amount of Common Shares and Warrants committed to be purchased pursuant to the
terms of the Agreement: $250,003

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Common Shares	 	 	Warrant Shares	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	First Closing Purchase Price
	 	$	6.50	 	 	 	0	 	 	 	0	 
	Second Closing Purchase Price
	 	$	6.50	 	 	 	38,462	 	 	 	13,462	 

 26.

 

     IN WITNESS WHEREOF, the undersigned has executed this Purchase Agreement or caused its duly
authorized officers to execute this Purchase Agreement as of the date first above written.

	 	 	 	 	 	 	 
	IF AN INDIVIDUAL:	 	IF A CORPORATION, PARTNERSHIP,
	 	 	  TRUST, ESTATE OR OTHER ENTITY:
	 
 

	 	 	 	 	 	 
	(Signature)	 	Aries Domestic Fund, L.P.
	 	 	 
	 	 	Print name of entity
	 
 

	 	 	 	 	 	 
	(Printed Name)	 	By:	 	/s/ Lindsay A. Rosenwald
	 	 	 	 	 
	 

	 	 	 	Name:
	 	Lindsay A. Rosenwald, M.D.
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	Chairman and CEO of Paramount BioCapital Asset Management, Inc., its General Partner
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	 
	 	 	Print jurisdiction of organization of entity

	 	 	 
	Address:

	 	Address:
	 
	 	 
	 

	 	c/o Paramount BioCapital Assets Management, Inc.
	 

	 	 
	 

	 	787 Seventh Avenue, 48th Floor
	 

	 	 
	 

	 	New York, New York 10019
	 

	 	 

Aggregate dollar amount of Common Shares and Warrants committed to be purchased pursuant to the
terms of the Agreement: $142,499.50

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Common Shares	 	 	Warrant Shares	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	First Closing Purchase Price
	 	$	6.50	 	 	 	19,259	 	 	 	6,741	 
	Second Closing Purchase Price
	 	$	6.50	 	 	 	2,664	 	 	 	932	 

 27.

 

     IN WITNESS WHEREOF, the undersigned has executed this Purchase Agreement or caused its duly
authorized officers to execute this Purchase Agreement as of the date first above written.

	 	 	 	 	 	 	 
	IF AN INDIVIDUAL:	 	IF A CORPORATION, PARTNERSHIP,
	 	 	  TRUST, ESTATE OR OTHER ENTITY:
	 
 

	 	 	 	 	 	 
	(Signature)	 	Aries Domestic Fund II, L.P.
	 	 	 
	 	 	Print name of entity
	 
 

	 	 	 	 	 	 
	(Printed Name)	 	By:	 	/s/ Lindsay A. Rosenwald
	 	 	 	 	 
	 

	 	 	 	Name:
	 	Lindsay A. Rosenwald, M.D.
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	Chairman and CEO of Paramount BioCapital Asset Management, Inc., its General Partner
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	 
	 	 	Print jurisdiction of organization of entity

	 	 	 
	Address:

	 	Address:
	 
	 	 
	 

	 	c/o Paramount BioCapital Assets
	 

	 	 
	 

	 	Management, Inc.
	 

	 	 
	 

	 	787 Seventh Avenue, 48th Floor
	 

	 	 
	 

	 	New York, New York 10019
	 

	 	 

Aggregate dollar amount of Common Shares and Warrants committed to be purchased pursuant to the
terms of the Agreement: $25,005.50

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Common Shares	 	 	Warrant Shares	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	First Closing Purchase Price
	 	$	6.50	 	 	 	3,379	 	 	 	1,183	 
	Second Closing Purchase Price
	 	$	6.50	 	 	 	468	 	 	 	163	 

 28.

 

     IN WITNESS WHEREOF, the undersigned has executed this Purchase Agreement or caused its duly
authorized officers to execute this Purchase Agreement as of the date first above written.

	 	 	 	 	 	 	 
	IF AN INDIVIDUAL:	 	IF A CORPORATION, PARTNERSHIP,
	 	 	  TRUST, ESTATE OR OTHER ENTITY:
	 
 

	 	 	 	 	 	 
	(Signature)	 	SDS Capital International, Ltd.
	 	 	 
	 	 	Print name of entity
	 
 

	 	 	 	 	 	 
	(Printed Name)	 	By:	 	/s/ Steve Derby
	 	 	 	 	 
	 

	 	 	 	Name:
	 	Steve Derby
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	Director
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	British Virgin Islands
	 	 	 
	 	 	Print jurisdiction of organization of entity

	 	 	 
	Address:

	 	Address:
	 
	 	 
	 

	 	c/o SDS Management, LLC
	 

	 	 
	 

	 	53 Forest Avenue, 2nd Floor
	 

	 	 
	 

	 	Old Greenwich, Connecticut 06870
	 

	 	 

Aggregate dollar amount of Common Shares and Warrants committed to be purchased pursuant to the
terms of the Agreement: $2,000,004.50

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Common Shares	 	 	Warrant Shares	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	First Closing Purchase Price
	 	$	6.50	 	 	 	135,153	 	 	 	47,304	 
	Second Closing Purchase Price
	 	$	6.50	 	 	 	172,540	 	 	 	60,389	 
	Total Closing Purchase Price
	 	 	 	 	 	 	307,693	 	 	 	107,693	 

 29.

 

     IN WITNESS WHEREOF, the undersigned has executed this Purchase Agreement or caused its duly
authorized officers to execute this Purchase Agreement as of the date first above written.

	 	 	 	 	 	 	 
	IF AN INDIVIDUAL:	 	IF A CORPORATION, PARTNERSHIP,
	 	 	  TRUST, ESTATE OR OTHER ENTITY:
	 
 

	 	 	 	 	 	 
	(Signature)	 	SF Capital Partners Ltd.
	 	 	 
	 	 	Print name of entity
	 
 

	 	 	 	 	 	 
	(Printed Name)	 	By:	 	/s/ Brian H. Davidson
	 	 	 	 	 
	 

	 	 	 	Name:
	 	Brian H. Davidson
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	Authorized Signatory
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	  British Virgin Islands
	 	 	 
	 	 	Print jurisdiction of organization of entity

	 	 	 
	Address:

	 	Address:
	 
	 	 
	 

	 	c/o Stark Offshore Management, LLC
	 

	 	 
	 

	 	3600 South Lake Drive
	 

	 	 
	 

	 	St. Francis, Wisconsin 53235
	 

	 	 

Aggregate dollar amount of Common Shares and Warrants committed to be purchased pursuant to the
terms of the Agreement: $1,299,993.50

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Common Shares	 	 	Warrant Shares	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	First Closing Purchase Price
	 	$	6.50	 	 	 	87,848	 	 	 	30,747	 
	Second Closing Purchase Price
	 	$	6.50	 	 	 	112,151	 	 	 	39,252	 

 30.

 

     IN WITNESS WHEREOF, the undersigned has executed this Purchase Agreement or caused its duly
authorized officers to execute this Purchase Agreement as of the date first above written.

	 	 	 	 	 	 	 
	IF AN INDIVIDUAL:	 	IF A CORPORATION, PARTNERSHIP,
	 	 	  TRUST, ESTATE OR OTHER ENTITY:
	 
 

	 	 	 	 	 	 
	(Signature)	 	Shea Ventures, LLC as Nominee 2005-2
	 	 	 
	 	 	Print name of entity
	 
 

	 	 	 	 	 	 
	(Printed Name)	 	By:	 	/s/ Ronald L. Lakey
	 	 	 	 	 
	 

	 	 	 	Name:
	 	Ronald L. Lakey
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	Manager
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	California
	 	 	 
	 	 	Print jurisdiction of organization of entity

	 	 	 
	Address:

	 	Address:
	 
	 	 
	 

	 	655 Brea Canyon Road
	 

	 	 
	 

	 	Walnut, California 91789
	 

	 	 
	 
	 

	 	 

Aggregate dollar amount of Common Shares and Warrants committed to be purchased pursuant to the
terms of the Agreement: $800,501

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Common Shares	 	 	Warrant Shares	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	First Closing Purchase Price:
	 	$	6.50	 	 	 	54,094	 	 	 	18,933	 
	Second Closing Purchase Price
	 	$	6.50	 	 	 	69,060	 	 	 	24,171	 

 31.

 

     IN WITNESS WHEREOF, the undersigned has executed this Purchase Agreement or caused its duly
authorized officers to execute this Purchase Agreement as of the date first above written.

	 	 	 	 	 	 	 
	IF AN INDIVIDUAL:	 	IF A CORPORATION, PARTNERSHIP,
	 	 	  TRUST, ESTATE OR OTHER ENTITY:
	 
 

	 	 	 	 	 	 
	(Signature)	 	Tang Capital Partners, LP
	 	 	 
	 	 	Print name of entity
	 
 

	 	 	 	 	 	 
	(Printed Name)	 	By:	 	/s/ Kevin C. Tang
	 	 	 	 	 
	 

	 	 	 	Name:
	 	Kevin C. Tang
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	Managing Member
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	 
	 	 	Print jurisdiction of organization of entity

	 	 	 
	Address:

	 	Address:
	 
	 	 
	 

	 	4401 Eastgate Mall
	 

	 	 
	 

	 	San Diego, California 92121
	 

	 	 
	 
 

	 	 

Aggregate dollar amount of Common Shares and Warrants committed to be purchased pursuant to the
terms of the Agreement: $2,550,002

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	Common Shares	 	 	Warrant Shares	 
	First Closing Purchase Price
	 	$	6.50	 	 	 	 	 	 	 	172,319	 	 	 	60,312	 
	Second Closing Purchase Price
	 	$	6.50	 	 	 	 	 	 	 	219,989	 	 	 	76,996	 

 32.

 

     IN WITNESS WHEREOF, the undersigned has executed this Purchase Agreement or caused its duly
authorized officers to execute this Purchase Agreement as of the date first above written.

	 	 	 	 	 	 	 
	IF AN INDIVIDUAL:	 	IF A CORPORATION, PARTNERSHIP,
	 	 	  TRUST, ESTATE OR OTHER ENTITY:
	 
 

	 	 	 	 	 	 
	(Signature)	 	UBS O’Conner LLC FBO O’Connor
PIPES Corporate Strategies Master Ltd.
	 	 	 
	 	 	Print name of entity
	 
 

	 	 	 	 	 	 
	(Printed Name)	 	By:	 	/s/ George Locasto
	 	 	 	 	 
	 

	 	 	 	Name:
	 	George Locasto
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	Managing Director
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	 
	 	 	Print jurisdiction of organization of entity

	 	 	 
	Address:

	 	Address:
	 
	 	 
	 

	 	 
	 
	 	 
	 

	 	 
	 
 

	 	 

Aggregate dollar amount of Common Shares and Warrants committed to be purchased pursuant to the
terms of the Agreement: $1,300,000

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	Common Shares	 	 	Warrant Shares	 
	First Closing Purchase Price
	 	$	6.50	 	 	 	 	 	 	 	87,849	 	 	 	30,747	 
	Second Closing Purchase Price
	 	$	6.50	 	 	 	 	 	 	 	112,151	 	 	 	39,253	 

 33.

 

     IN WITNESS WHEREOF, the undersigned has executed this Purchase Agreement or caused its duly
authorized officers to execute this Purchase Agreement as of the date first above written.

	 	 	 	 	 	 	 
	IF AN INDIVIDUAL:	 	IF A CORPORATION, PARTNERSHIP,
	 	 	  TRUST, ESTATE OR OTHER ENTITY:
	 
 

	 	 	 	 	 	 
	(Signature)	 	ValueAct Capital Master Fund, L.P.,
	 	 	 
	 	 	Print name of entity
	 
 

	 	 	 	 	 	 
	(Printed Name)	 	By:	 	/s/ G. Mason Morfit
	 	 	 	 	 
	 

	 	 	 	Name:
	 	G. Mason Morfit
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	Member of General Partner, VA Partners LLC
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	British Virgin Islands
	 	 	 
	 	 	Print jurisdiction of organization of entity

	 	 	 
	Address:

	 	Address:
	 
	 	 
	 

	 	435 Pacific Avenue, 4th Floor
	 

	 	 
	 

	 	San Francisco, California 94133
	 

	 	 
	 
	 	 
	 

	 	 

Aggregate dollar amount of Common Shares and Warrants committed to be purchased pursuant to the
terms of the Agreement: $1,500,000.05

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	Common Shares	 	 	Warrant Shares	 
	First Closing Purchase Price
	 	$	6.50	 	 	 	 	 	 	 	0	 	 	 	0	 
	Second Closing Purchase Price
	 	$	6.50	 	 	 	 	 	 	 	230,770	 	 	 	80,770	 

 34.

 

     IN WITNESS WHEREOF, the undersigned has executed this Purchase Agreement or caused its duly
authorized officers to execute this Purchase Agreement as of the date first above written.

	 	 	 	 	 	 	 
	IF AN INDIVIDUAL:	 	IF A CORPORATION, PARTNERSHIP,
	 	 	  TRUST, ESTATE OR OTHER ENTITY:
	 
 

	 	 	 	 	 	 
	(Signature)	 	Steeple Capital Fund I L.P.
	 	 	 
	 	 	Print name of entity
	 
 

	 	 	 	 	 	 
	(Printed Name)	 	By:	 	/s/ John Regan
	 	 	 	 	 
	 

	 	 	 	Name:
	 	John Regan
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	CEO
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	Delaware
	 	 	 
	 	 	Print jurisdiction of organization of entity

	 	 	 
	Address:

	 	Address:
	 
	 	 
	 

	 	655 Montgomery St.
	 

	 	 
	 

	 	Suite 1438
	 

	 	 
	 

	 	San Francisco, California 94111
	 

	 	 

Aggregate dollar amount of Common Shares and Warrants committed to be purchased pursuant to the
terms of the Agreement: $48,100

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	Common Shares	 	 	Warrant Shares	 
	First Closing Purchase Price
	 	$	6.50	 	 	 	 	 	 	 	3,251	 	 	 	1,137	 
	Second Closing Purchase Price
	 	$	6.50	 	 	 	 	 	 	 	4,149	 	 	 	1,453	 

 35.

 

     IN WITNESS WHEREOF, the undersigned has executed this Purchase Agreement or caused its duly
authorized officers to execute this Purchase Agreement as of the date first above written.

	 	 	 	 	 	 	 
	IF AN INDIVIDUAL:	 	IF A CORPORATION, PARTNERSHIP,
	 	 	  TRUST, ESTATE OR OTHER ENTITY:
	 
 

	 	 	 	 	 	 
	(Signature)	 	Steeple Capital Fund II L.P.
	 	 	 
	 	 	Print name of entity
	 
 

	 	 	 	 	 	 
	(Printed Name)	 	By:	 	/s/ John Regan
	 	 	 	 	 
	 

	 	 	 	Name:
	 	John Regan
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	CEO
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	Delaware
	 	 	 
	 	 	Print jurisdiction of organization of entity

	 	 	 
	Address:

	 	Address:
	 
	 	 
	 

	 	655 Montgomery St.
	 

	 	 
	 

	 	Suite 1438
	 

	 	 
	 

	 	San Francisco, California 94111
	 

	 	 

Aggregate dollar amount of Common Shares and Warrants committed to be purchased pursuant to the
terms of the Agreement: $459,810

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	Common Shares	 	 	Warrant Shares	 
	First Closing Purchase Price
	 	$	6.50	 	 	 	 	 	 	 	31,073	 	 	 	10,876	 
	Second Closing Purchase Price
	 	$	6.50	 	 	 	 	 	 	 	39,667	 	 	 	13,883	 

 36.

 

     IN WITNESS WHEREOF, the undersigned has executed this Purchase Agreement or caused its duly
authorized officers to execute this Purchase Agreement as of the date first above written.

	 	 	 	 	 	 	 
	IF AN INDIVIDUAL:	 	IF A CORPORATION, PARTNERSHIP,
	 	 	  TRUST, ESTATE OR OTHER ENTITY:
	 
 

	 	 	 	 	 	 
	(Signature)	 	Steeple Capital Fund III L.P.
	 	 	 
	 	 	Print name of entity
	 
 

	 	 	 	 	 	 
	(Printed Name)	 	By:	 	/s/ John Regan
	 	 	 	 	 
	 

	 	 	 	Name:
	 	John Regan
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	CEO
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	Delaware
	 	 	 
	 	 	Print jurisdiction of organization of entity

	 	 	 
	Address:

	 	Address:
	 
	 	 
	 

	 	655 Montgomery St.
	 

	 	 
	 

	 	Suite 1438
	 

	 	 
	 

	 	San Fransisco, California 94111
	 

	 	 

Aggregate dollar amount of Common Shares and Warrants committed to be purchased pursuant to the
terms of the Agreement: $109,850

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	Common Shares	 	 	Warrant Shares	 
	First Closing Purchase Price
	 	$	6.50	 	 	 	 	 	 	 	7,423	 	 	 	2,598	 
	Second Closing Purchase Price
	 	$	6.50	 	 	 	 	 	 	 	9,477	 	 	 	3,317	 

 37.

 

     IN WITNESS WHEREOF, the undersigned has executed this Purchase Agreement or caused its duly
authorized officers to execute this Purchase Agreement as of the date first above written.

	 	 	 	 	 	 	 
	IF AN INDIVIDUAL:	 	IF A CORPORATION, PARTNERSHIP,
	 	 	  TRUST, ESTATE OR OTHER ENTITY:
	 
 

	 	 	 	 	 	 
	(Signature)	 	Steeple Capital Offshore Fund, Ltd.
	 	 	 
	 	 	Print name of entity
	 
 

	 	 	 	 	 	 
	(Printed Name)	 	By:	 	/s/ John Regan
	 	 	 	 	 
	 

	 	 	 	Name:
	 	John Regan
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	CEO
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	Delaware
	 	 	 
	 	 	Print jurisdiction of organization of entity

	 	 	 
	Address:

	 	Address:
	 
	 	 
	 

	 	655 Montgomery St.
	 

	 	 
	 

	 	Suite 1438
	 

	 	 
	 

	 	San Fransisco, California 94111
	 

	 	 

Aggregate dollar amount of Common Shares and Warrants committed to be purchased pursuant to the
terms of the Agreement: $776,750

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	Common Shares	 	 	Warrant Shares	 
	First Closing Purchase Price
	 	$	6.50	 	 	 	 	 	 	 	52,489	 	 	 	18,371	 
	Second Closing Purchase Price
	 	$	6.50	 	 	 	 	 	 	 	67,011	 	 	 	23,454	 

 38.

 

     IN WITNESS WHEREOF, the undersigned has executed this Purchase Agreement or caused its duly
authorized officers to execute this Purchase Agreement as of the date first above written.

	 	 	 	 	 	 	 
	IF AN INDIVIDUAL:	 	IF A CORPORATION, PARTNERSHIP,
	 	 	  TRUST, ESTATE OR OTHER ENTITY:
	 
 

	 	 	 	 	 	 
	(Signature)	 	Steeple Capital Offshore Fund III, Ltd.
	 	 	 
	 	 	Print name of entity
	 
 

	 	 	 	 	 	 
	(Printed Name)	 	By:	 	/s/ John Regan
	 	 	 	 	 
	 

	 	 	 	Name:
	 	John Regan
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	CEO
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	Delaware
	 	 	 
	 	 	Print jurisdiction of organization of entity

	 	 	 
	Address:

	 	Address:
	 
	 	 
	 

	 	655 Montgomery St.
	 

	 	 
	 

	 	Suite 1438
	 

	 	 
	 

	 	San Fransisco, California 94111
	 

	 	 

Aggregate dollar amount of Common Shares and Warrants committed to be purchased pursuant to the
terms of the Agreement: $105,950

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	Common Shares	 	 	Warrant Shares	 
	First Closing Purchase Price
	 	$	6.50	 	 	 	 	 	 	 	7,159	 	 	 	2,506	 
	Second Closing Purchase Price
	 	$	6.50	 	 	 	 	 	 	 	9,141	 	 	 	3,199	 

 39.

 

     IN WITNESS WHEREOF, the undersigned has executed this Purchase Agreement or caused its duly
authorized officers to execute this Purchase Agreement as of the date first above written.

	 	 	 	 	 	 	 
	IF AN INDIVIDUAL:	 	IF A CORPORATION, PARTNERSHIP,
	 	 	  TRUST, ESTATE OR OTHER ENTITY:
	 
 

	 	 	 	 	 	 
	(Signature)	 	ORPHAN FUND, L.P.
	 	 	 
	 	 	Print name of entity
	 
 

	 	 	 	 	 	 
	(Printed Name)	 	By:	 	/s/ W. Bradford Stephens
	 	 	 	 	 
	 

	 	 	 	Name:
	 	W. Bradford Stephens
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	Managing Member
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	 
	 	 	Print jurisdiction of organization of entity

	 	 	 
	Address:

	 	Address:
	 
	 	 
	 

	 	c/o Stephens Investment Managment
	 

	 	 
	 

	 	One Sansome Street, Suite 2900
	 

	 	 
	 

	 	San Francisco, CA 94104
	 

	 	 

Aggregate dollar amount of Common Shares and Warrants committed to be purchased pursuant to the
terms of the Agreement:

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	Common Shares	 	 	Warrant Shares	 
	First Closing Purchase Price
	 	$	6.50	 	 	 	 	 	 	 	236,518	 	 	 	82,781	 
	Second Closing Purchase Price
	 	$	6.50	 	 	 	 	 	 	 	301,944	 	 	 	105,681	 

 40.

 

     IN WITNESS WHEREOF, the undersigned has executed this Purchase Agreement or caused its duly
authorized officers to execute this Purchase Agreement as of the date first above written.

	 	 	 	 	 	 	 
	IF AN INDIVIDUAL:	 	IF A CORPORATION, PARTNERSHIP,
	 	 	  TRUST, ESTATE OR OTHER ENTITY:
	 
 

	 	 	 	 	 	 
	(Signature)	 	Nanocap Fund, L.P.
	 	 	 
	 	 	Print name of entity
	 
 

	 	 	 	 	 	 
	(Printed Name)	 	By:	 	/s/ W. Bradford Stephens
	 	 	 	 	 
	 

	 	 	 	Name:
	 	W. Bradford Stephens
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	Managing Partner
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	State of Delaware
	 	 	 
	 	 	Print jurisdiction of organization of entity

	 	 	 
	Address:

	 	Address:
	 
	 	 
	 

	 	c/o Stephens Investment Managment
	 

	 	 
	 

	 	One Sansome Street, Suite 2900
	 

	 	 
	 

	 	San Fransisco, CA 94104
	 

	 	 

Aggregate dollar amount of Common Shares and Warrants committed to be purchased pursuant to the
terms of the Agreement:

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	Common Shares	 	 	Warrant Shares	 
	First Closing Purchase Price
	 	$	6.50	 	 	 	 	 	 	 	84,470	 	 	 	29,565	 
	Second Closing Purchase Price
	 	$	6.50	 	 	 	 	 	 	 	107,838	 	 	 	37,743	 

 41.

 

     IN WITNESS WHEREOF, the undersigned has executed this Purchase Agreement or caused its duly
authorized officers to execute this Purchase Agreement as of the date first above written.

	 	 	 	 	 	 	 
	IF AN INDIVIDUAL:	 	IF A CORPORATION, PARTNERSHIP,
	 	 	  TRUST, ESTATE OR OTHER ENTITY:
	 
 

	 	 	 	 	 	 
	(Signature)	 	Nanocap Qualified Fund, L.P.
	 	 	 
	 	 	Print name of entity
	 
 

	 	 	 	 	 	 
	(Printed Name)	 	By:	 	/s/ W. Bradford Stephens
	 	 	 	 	 
	 

	 	 	 	Name:
	 	W. Bradford Stephens
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	Managing Partner
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	 
	 	 	Print jurisdiction of organization of entity

	 	 	 
	Address:

	 	Address:
	 
	 	 
	 

	 	Stephens Investment Managment
	 

	 	 
	 

	 	c/o One Sansome Street, Suite 2900
	 

	 	 
	 

	 	San Fransisco, CA 94104
	 

	 	 

Aggregate dollar amount of Common Shares and Warrants committed to be purchased pursuant to the
terms of the Agreement:

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	Common Shares	 	 	Warrant Shares	 
	First Closing Purchase Price
	 	$	6.50	 	 	 	 	 	 	 	152,047	 	 	 	53,216	 
	Second Closing Purchase Price
	 	$	6.50	 	 	 	 	 	 	 	194,107	 	 	 	67,937	 

 42.

 

     IN WITNESS WHEREOF, the undersigned has executed this Purchase Agreement or caused its duly
authorized officers to execute this Purchase Agreement as of the date first above written.

	 	 	 	 	 	 	 
	IF AN INDIVIDUAL:
	 	 	 	 	 	 
	 	 	Walker Smith Capital, L.P.
	 
 

	 	 	 	 	 	 
	(Signature)	 	Signed by
for and on behalf of 
WS Captal Management, L.P. General Partner
	 	 	 
	 	 	Print name of entity
	 
 

	 	 	 	 	 	 
	(Printed Name)	 	By:	 	/s/ Joseph I. Worsham
	 	 	 	 	 
	 

	 	 	 	Name:
	 	Joseph I. Worsham
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	COO
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	 
	 	 	Print jurisdiction of organization of entity

	 	 	 
	Address:

	 	Address:
	 
	 	 
	 

	 	Walker Smith Capital, L.P.
	 

	 	 
	 

	 	300 Crescent Court, Suite 1111
	 

	 	 
	 

	 	Dallas, TX 75201
	 

	 	 
	 

	 	214-756-6073 (telephone)
	 

	 	 
	 

	 	214-756-6079 (fax)
	 

	 	 
	 

	 	Attn: Joe Worsham (joe@walksmith.com)
	 

	 	 
	 

	 	Tax I.D.# 75-2681597
	 

	 	 

Aggregate dollar amount of Common Shares and Warrants committed to be purchased pursuant to the
terms of the Agreement:

Total Purchase Price: $79,098.50

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	Common Shares	 	 	Warrant Shares	 
	First Closing Purchase Price
	 	$	6.50	 	 	 	 	 	 	 	5,346	 	 	 	1,871	 
	Second Closing Purchase Price
	 	$	6.50	 	 	 	 	 	 	 	6,823	 	 	 	2,388	 

 43.

 

     IN WITNESS WHEREOF, the undersigned has executed this Purchase Agreement or caused its duly
authorized officers to execute this Purchase Agreement as of the date first above written.

	 	 	 	 	 	 	 
	IF AN INDIVIDUAL:
	 	 	 	 	 	 
	 	 	Walker Smith Capital QP, L.P.
	 
 

	 	 	 	 	 	 
	(Signature)	 	WS Capital Management, L.P., General Partner
	 	 	 
	 	 	Print name of entity
	 
 

	 	 	 	 	 	 
	(Printed Name)	 	By:	 	/s/ Joseph I. Worsham
	 	 	 	 	 
	 

	 	 	 	Name:
	 	Joseph I. Worsham
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	COO
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	 
	 	 	Print jurisdiction of organization of entity

	 	 	 
	Address:

	 	Address:
	 
	 	 
	 

	 	Walker Smith Capital, L.P.
	 

	 	 
	 

	 	300 Crescent Court, Suite 1111
	 

	 	 
	 

	 	Dallas, TX 75201
	 

	 	 
	 

	 	214-756-6073 (telephone)
	 

	 	 
	 

	 	214-756-6079 (fax)
	 

	 	 
	 

	 	Attn: Joe Worsham (joe@walksmith.com)
	 

	 	 
	 

	 	Tax I.D.# 75-2951420
	 

	 	 

Aggregate dollar amount of Common Shares and Warrants committed to be purchased pursuant to the
terms of the Agreement: $481,903.50

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	Common Shares	 	 	Warrant Shares	 
	First Closing Purchase Price
	 	$	6.50	 	 	 	 	 	 	 	32,566	 	 	 	11,398	 
	Second Closing Purchase Price
	 	$	6.50	 	 	 	 	 	 	 	41,573	 	 	 	14,551	 

 44.

 

     IN WITNESS WHEREOF, the undersigned has executed this Purchase Agreement or caused its duly
authorized officers to execute this Purchase Agreement as of the date first above written.

	 	 	 	 	 	 	 
	IF AN INDIVIDUAL:	 	Walker Smith International Fund, Limited
	 
 

	 	 	 	 	 	 
	(Signature)	 	WS Capital Management, L.P.,
	 	 	as agent and attorney-in-fact
	 	 	 
	 	 	Print name of entity
	 
 

	 	 	 	 	 	 
	(Printed Name)	 	By:	 	/s/ Joseph I. Worsham
	 	 	 	 	 
	 

	 	 	 	Name:
	 	Joseph I. Worsham
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	COO
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	 
	 	 	Print jurisdiction of organization of entity
	 
	 	 	 	 	 	 

	 	 	 
	Address:

	 	Address:
	 
	 	 
	 
	 	 
	 

	 	Walker Smith Capital, L.P.
	 

	 	 
	 

	 	300 Crescent Court, Suite 1111
	 

	 	 
	 

	 	Dallas, TX 75201
	 

	 	 
	 

	 	214-756-6073 (telephone)
	 

	 	 
	 

	 	214-756-6079 (fax)
	 

	 	 
	 

	 	Attn: Joe Worsham (joe@walksmith.com)
	 

	 	 

     Aggregate dollar amount of Common Shares and Warrants committed to be purchased pursuant to the
terms of the Agreement: $686,998

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Common Shares	 	 	Warrant Shares	 
	First Closing Purchase Price
	 	$	6.50	 	 	 	46,425	 	 	 	16,249	 
	Second Closing Purchase Price
	 	$	6.50	 	 	 	59,267	 	 	 	20,743	 

 45.

 

     IN WITNESS WHEREOF, the undersigned has executed this Purchase Agreement or caused its duly
authorized officers to execute this Purchase Agreement as of the date first above written.

	 	 	 	 	 	 	 
	 	 	SRB Greenway Capital, L.P.
	IF AN INDIVIDUAL:	 	By: SRB Management, L.P., General Partner
	 
 

	 	 	 	 	 	 
	(Signature)	 	By: BC Advisory, L.L.C., General Partner
	 	 	 
	 	 	Print name of entity
	 
 

	 	 	 	 	 	 
	(Printed Name)	 	By:	 	/s/ Steven R. Becker
	 	 	 	 	 
	 

	 	 	 	Name:
	 	Steven R. Becker
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	Member
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	 
	 	 	Print jurisdiction of organization of entity
	 
	 	 	 	 	 	 

	 	 	 
	Address:

	 	Address:
	 
	 	 
	 
	 	 
	 

	 	SRB Greenway Capital, L.P.
	 

	 	 
	 

	 	300 Crescent Court, Suite 1111
	 

	 	 
	 

	 	Dallas, TX 75201
	 

	 	 
	 

	 	214-756-6073 (telephone)
	 

	 	 
	 

	 	214-756-6079 (fax)
	 

	 	 
	 

	 	Attn: Joe Worsham (joe@walksmith.com)
	 

	 	 
	 

	 	Tax I.D. # 20-1718174
	 

	 	 

     Aggregate dollar amount of Common Shares and Warrants committed to be purchased pursuant to the
terms of the Agreement: $183,001.00

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Common Shares	 	 	Warrant Shares	 
	First Closing Purchase Price
	 	$	6.50	 	 	 	12,366	 	 	 	4,328	 
	Second Closing Purchase Price
	 	$	6.50	 	 	 	15,788	 	 	 	5,526	 

 46.

 

     IN WITNESS WHEREOF, the undersigned has executed this Purchase Agreement or caused its duly
authorized officers to execute this Purchase Agreement as of the date first above written.

	 	 	 	 	 	 	 
	 	 	SRB Greenway Capital (QP), L.P.
	IF AN INDIVIDUAL:	 	By: SRB Management, L.P., General Partner
	 
 

	 	 	 	 	 	 
	(Signature)	 	By: BC Advisors, L.L.C., General Partner
	 	 	 
	 	 	Print name of entity
	 
	 	 	 	 	 	 
	 

	 	 	 	 	 	 
	(Printed Name)	 	By:	 	/s/ Steven R. Becker
	 	 	 	 	 
	 

	 	 	 	Name:
	 	Steven R. Becker
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	Member
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	 
	 	 	Print jurisdiction of organization of entity

	 	 	 
	Address:

	 	Address:
	 
	 	 
	 
	 	 
	 

	 	SRB Greenway Capital, L.P.
	 

	 	 
	 

	 	300 Crescent Court, Suite 1111
	 

	 	 
	 

	 	Dallas, TX 75201
	 

	 	 
	 

	 	214-756-6073 (telephone)
	 

	 	 
	 

	 	214-756-6079 (fax)
	 

	 	 
	 

	 	Attn: Joe Worsham (joe@walksmith.com)
	 

	 	 
	 

	 	Tax I.D. # 20-1939469
	 

	 	 

     Aggregate dollar amount of Common Shares and Warrants committed to be purchased pursuant to the
terms of the Agreement:

Total Purchase Price: $1,219,400

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Common Shares	 	 	Warrant Shares	 
	First Closing Purchase Price
	 	$	6.50	 	 	 	82,402	 	 	 	28,841	 
	Second Closing Purchase Price

	 	$	6.50	 	 	 	105,198	 	 	 	36,819	 

 47.

 

     IN WITNESS WHEREOF, the undersigned has executed this Purchase Agreement or caused its duly
authorized officers to execute this Purchase Agreement as of the date first above written.

	 	 	 	 	 	 	 
	 	 	SRB Greenway Offshore Operating Fund, L.P.
	IF AN INDIVIDUAL:	 	By: SRB Management, L.P., General Partner
	 
 

	 	 	 	 	 	 
	(Signature)	 	By: BC Advisors, L.L.C., General Partner
	 	 	 
	  	 	Print name of entity
	 
	 	 	 	 	 	 
	 
 

	 	 	 	 	 	 
	(Printed Name)	 	By:	 	/s/
	 	 	 	 	 
	 

	 	 	 	Name:
	 	Steve Becker
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	Member
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	 
	 	 	Print jurisdiction of organization of entity

	 	 	 
	Address:

	 	Address:
	 
	 	 
	 
	 	 
	 

	 	SRB Greenway Capital, L.P.
	 

	 	 
	 

	 	300 Crescent Court, Suite 1111
	 

	 	 
	 

	 	Dallas, TX 75201
	 

	 	 
	 

	 	214-756-6073 (telephone)
	 

	 	 
	 

	 	214-756-6079 (fax)
	 

	 	 
	 

	 	Attn: Joe Worsham (joe@walksmith.com)
	 

	 	 
	 

	 	Tax I.D. # n/a — offshore entity
	 

	 	 

     Aggregate dollar amount of Common Shares and Warrants committed to be purchased pursuant to the
terms of the Agreement: $97,597.50

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	Common Shares	 	 	 	 	 	 	Warrant Shares	 
	First Closing Purchase Price
	 	$	6.50	 	 	 	 	 	 	 	 	6,595	 	 	 	 	 	 	 	2,308	 
	Second Closing Purchase Price
	 	$	6.50	 	 	 	 	 	 	 	 	8,420	 	 	 	 	 	 	 	2,947	 

 48.

 

     IN WITNESS WHEREOF, the undersigned has executed this Purchase Agreement or caused its duly
authorized officers to execute this Purchase Agreement as of the date first above written.

	 	 	 	 	 	 	 
	 	 	HHMI Investments, L.P.
	IF AN INDIVIDUAL:
	 	 	 	 	 	 
	 
 

	 	 	 	 	 	 
	(Signature)	 	By: WS Capital Management, L.P., Investment Manager
	 	 	 
	 	 	Print name of entity
	 
 

	 	 	 	 	 	 
	(Printed Name)	 	By:	 	/s/ Joseph I. Worsham
	 	 	 	 	 
	 

	 	 	 	Name:
	 	Joseph I. Worsham
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	COO
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	 
	 	 	Print jurisdiction of organization of entity

	 	 	 
	Address:

	 	Address:
	 
	 	 
	 
	 	 
	 

	 	SRB Greenway Capital, L.P.
	 

	 	 
	 

	 	300 Crescent Court, Suite 1111
	 

	 	 
	 

	 	Dallas, TX 75201
	 

	 	 
	 

	 	214-756-6073 (telephone)
	 

	 	 
	 

	 	214-756-6079 (fax)
	 

	 	 
	 

	 	Attn: Joe Worsham (joe@walksmith.com)
	 

	 	 
	 

	 	Tax I.D. # 20-3752378
	 

	 	 

     Aggregate dollar amount of Common Shares and Warrants committed to be purchased pursuant to the
terms of the Agreement: $252,000

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Common Shares	 	 	Warrant Shares	 
	First Closing Purchase Price 
	 	$	6.50	 	 	 	17,029	 	 	 	5,960	 
	Second Closing Purchase Price

	 	$	6.50	 	 	 	21,740	 	 	 	7,609	 

 49.

 

     IN WITNESS WHEREOF, the undersigned has executed this Purchase Agreement or caused its duly
authorized officers to execute this Purchase Agreement as of the date first above written.

	 	 	 	 	 	 	 
	IF AN INDIVIDUAL:	 	IF A CORPORATION, PARTNERSHIP,
	 	 	  TRUST, ESTATE OR OTHER ENTITY:
	 
 

	 	 	 	 	 	 
	(Signature)	 	By: Abingworth Bioequities Master Fund Limited
	 	 	 
	 	 	Print name of entity
	 
 

	 	 	 	 	 	 
	(Printed Name)	 	By:	 	/s/ James Abell
	 	 	 	 	 
	 

	 	 	 	Name:
	 	James Abell
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	Director
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	Cayman Islands
	 	 	 
	 	 	Print jurisdiction of organization of entity

	 	 	 
	Address:

	 	Address:
	 
	 	 
	 

	 	c/o 38 Jermyn Street
	 

	 	 
	 

	 	London
	 

	 	 
	 

	 	SWIY 6DN
	 

	 	 

     Aggregate dollar amount of Common Shares and Warrants committed to be purchased pursuant to the
terms of the Agreement:

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Common Shares	 	 	Warrant Shares	 
	First Closing Purchase Price
	 	$	6.50	 	 	 	0	 	 	 	0	 
	Second Closing Purchase Price
	 	$	6.50	 	 	 	307,700	 	 	 	107,695	 

 50.

 

     IN WITNESS WHEREOF, the undersigned has executed this Purchase Agreement or caused its duly
authorized officers to execute this Purchase Agreement as of the date first above written.

	 	 	 	 	 	 	 
	IF AN INDIVIDUAL:	 	IF A CORPORATION, PARTNERSHIP,
	 	 	  TRUST, ESTATE OR OTHER ENTITY:
	 
 

	 	 	 	 	 	 
	(Signature)	 	Bristol Investment Fund, Ltd.
	 	 	 
	 	 	Print name of entity
	 
 

	 	 	 	 	 	 
	(Printed Name)	 	By:	 	/s/ Paul Kessler
 
	 

	 	 	 	 
	 

	 	 	 	Name:
	 	Paul Kessler
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	Director
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	Cayman Islands
	 	 	 
	 	 	Print jurisdiction of organization of entity

	 	 	 
	Address:

	 	Address:
	 
	 	 
	 
	 	 
	 

	 	c/o Bristol Capital Advisors, LLC
	 

	 	 
	 

	 	Attn: Amy Wang
	 

	 	 
	 

	 	10990 Wilshire Blvd., Suite 1410
	 

	 	 
	 

	 	Los Angeles, CA 90027
	 

	 	 
	 
	 	 
	 
	 	 
	 

	 	P: (310) 696-0333 ext. 115
	 

	 	 
	 

	 	F: (310) 696-0334
	 

	 	 

     Aggregate dollar amount of Common Shares and Warrants committed to be purchased pursuant to the
terms of the Agreement: $500,006

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Common Shares	 	 	Warrant Shares	 
	First Closing Purchase Price
	 	$	6.50	 	 	 	33,788	 	 	 	11,826	 
	Second Closing Purchase Price
	 	$	6.50	 	 	 	43,136	 	 	 	15,097	 

 51.

 

     IN WITNESS WHEREOF, the undersigned has executed this Purchase Agreement or caused its duly
authorized officers to execute this Purchase Agreement as of the date first above written.

	 	 	 	 	 	 	 
	IF AN INDIVIDUAL:	 	IF A CORPORATION, PARTNERSHIP,
	 	 	  TRUST, ESTATE OR OTHER ENTITY:
	 
	 	 	 	 	 	 
	 	 	Capital Ventures International
	 	 	 
	(Signature)	 	 
	 	 	By: Heights Capital Management, Inc., its authorized agent
	 	 	 
	 	 	Print name of entity
	 
 

	 	 	 	 	 	 
	(Printed Name)	 	By:	 	/s/ Martin Kissinger
	 	 	 	 	 
	 

	 	 	 	Name:
	 	Martin Kissinger
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	Investment Manager
	 	 	
	 
	 	 	 	 	 	 
	 	 	 
	 	 	Print jurisdiction of organization of entity
	 
	 	 	 	 	 	 

	 	 	 
	Address:

	 	Address:
	 
	 	 
	 
	 	 
	 

	 	101 California Street, Suite 3250
	 

	 	 
	 

	 	San Francisco, CA 94111
	 

	 	 
	 
	 	 
	 

	 	 

     Aggregate dollar amount of Common Shares and Warrants committed to be purchased pursuant to the
terms of the Agreement: $2,249,994.50

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Common Shares	 	 	 	Warrant Shares	 
	First Closing Purchase Price 
	 	$	6.50	 	 	 	152,046	 	 	 	 	53,216	 
	Second Closing Purchase Price

	 	$	6.50	 	 	 	194,107	 	 	 	 	67,938	 

 52.

 

     IN WITNESS WHEREOF, the undersigned has executed this Purchase Agreement or caused its duly
authorized officers to execute this Purchase Agreement as of the date first above written.

	 	 	 	 	 	 	 
	IF AN INDIVIDUAL:	 	IF A CORPORATION, PARTNERSHIP,
	 	 	  TRUST, ESTATE OR OTHER ENTITY:
	 
 

	 	 	 	 	 	 
	(Signature)	 	Clarion Capital Corporation
	 	 	 
	 	 	Print name of entity
	 
 

	 	 	 	 	 	 
	(Printed Name)	 	By:	 	/s/ Morton Cohen
	 	 	 	 	 
	 

	 	 	 	Name:
	 	Morton Cohen
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	Chief Executive
	 

	 	 	 	 	 	 
	 
	 	 
	 	 	Delaware
	 	 	 
	 	 	Print jurisdiction of organization of entity

	 	 	 
	Address:

	 	Address:
	 
	 	 
	 
	 	 
	 

	 	1801 East 9th Street
	 

	 	 
	 

	 	Cleveland, Ohio 44114
	 

	 	 
	 
	 	 
	 

	 	 

     Aggregate dollar amount of Common Shares and Warrants committed to be purchased pursuant to the
terms of the Agreement: $500,006.00

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Common Shares	 	 	Warrant Shares	 
	First Closing Purchase Price
	 	$	6.50	 	 	 	33,788	 	 	 	11,826	 
	Second Closing Purchase Price

	 	$	6.50	 	 	 	43,136	 	 	 	15,097	 

 53.

 

     IN WITNESS WHEREOF, the undersigned has executed this Purchase Agreement or caused its duly
authorized officers to execute this Purchase Agreement as of the date first above written.

	 	 	 	 	 	 	 
	IF AN INDIVIDUAL:	 	IF A CORPORATION, PARTNERSHIP,
	 	 	  TRUST, ESTATE OR OTHER ENTITY:
	 
 

	 	 	 	 	 	 
	(Signature)	 	Crestview Capital Master, LLC
	 	 	 
	 	 	Print name of entity
	 
 

	 	 	 	 	 	 
	(Printed Name)	 	By:	 	/s/ Stewart R. Flink
 
	 

	 	 	 	Name:
	 	Stewart R. Flink
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	Managing Member
	 

	 	 	 	 	 	 
	 
	 	 	Delaware
	 	 	 
	 	 	Print jurisdiction of organization of entity
	 
	 	 	 	 	 	 

	 	 	 
	Address:

	 	Address:
	 
	 	 
	 
	 	 
	 

	 	95 Revere Drive, Suite A
	 

	 	 
	 

	 	Northbrook, Illinois 60062
	 

	 	 
	 
	 	 
	 

	 	 

     Aggregate dollar amount of Common Shares and Warrants committed to be purchased pursuant to the
terms of the Agreement: $3,000,003.50

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Common Shares	 	 	Warrant Shares	 
	First Closing Purchase Price
	 	$	6.50	 	 	 	202,729	 	 	 	70,955	 
	Second Closing Purchase Price
	 	$	6.50	 	 	 	258,810	 	 	 	90,584	 

 54.

 

     IN WITNESS WHEREOF, the undersigned has executed this Purchase Agreement or caused its duly
authorized officers to execute this Purchase Agreement as of the date first above written.

	 	 	 	 	 	 	 
	IF AN INDIVIDUAL:	 	IF A CORPORATION, PARTNERSHIP,
	 	 	  TRUST, ESTATE OR OTHER ENTITY:
	 
	 	 	 	 	 	 
	 

	 	 	 	 	 	 
	(Signature)	 	Fidelity Securities Fund: Fidelity OTC Portfolio
	 	 	 
	 	 	Print name of entity
	 
	 	 	 	 	 	 
	 

	 	 	 	 	 	 
	(Printed Name)	 	By:	 	/s/ Christine Reynolds
	 	 	 	 	 
	 

	 	 	 	Name:
	 	Christine Reynolds
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	Treasurer
	 

	 	 	 	 	 	 
	 
	 	 
	 	 	Massachusetts
	 	 	 
	 	 	Print jurisdiction of organization of entity

	 	 	 
	Address:

	 	Address:
	 
	 	 
	 
	 	 
	 

	 	82 Devonshire Street Mail Zone E31C
	 

	 	 
	 

	 	Boston, MA 02109
	 

	 	 
	 

	 	Attn: Andrew Boyd, Esq.
	 

	 	 

     Aggregate dollar amount of Common Shares and Warrants committed to be purchased pursuant to the
terms of the Agreement: $15,000,004.50

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Common Shares	 	 	Warrant Shares	 
	First Closing Purchase Price
	 	$	6.50	 	 	 	1,013,646	 	 	 	354,776	 
	Second Closing Purchase Price
	 	$	6.50	 	 	 	1,294,047	 	 	 	452,917	 

 55.

 

     IN WITNESS WHEREOF, the undersigned has executed this Purchase Agreement or caused its duly
authorized officers to execute this Purchase Agreement as of the date first above written.

	 	 	 	 	 	 	 
	IF AN INDIVIDUAL:	 	IF A CORPORATION, PARTNERSHIP,
	 	 	  TRUST, ESTATE OR OTHER ENTITY:
	 
 

	 	 	 	 	 	 
	(Signature)	 	Nite Capital L.P.
	 	 	 
	 	 	Print name of entity
	 
 

	 	 	 	 	 	 
	(Printed Name)	 	By:	 	/s/ Keith A. Goodman
 
	 	 	 	 	 
	 

	 	 	 	Name:
	 	Keith A. Goodman
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	Manager of the General Partner
	 

	 	 	 	 	 	 
	 
	 	 
	 	 	Illinois
	 	 	 
	 	 	Print jurisdiction of organization of entity

	 	 	 
	Address:

	 	Address:
	 
	 	 
	 
	 	 
	 

	 	Nite Capital LP
	 

	 	 
	 

	 	100 East Cook Avenue, Suite 201
	 

	 	 
	 

	 	Libertyville, IL 50048
	 

	 	 

     Aggregate dollar amount of Common Shares and Warrants committed to be purchased pursuant to the
terms of the Agreement: $750,002.50

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Common Shares	 	 	Warrant Shares	 
	First Closing Purchase Price
	 	$	6.50	 	 	 	50,682	 	 	 	17,739	 
	Second Closing Purchase Price
	 	$	6.50	 	 	 	64,703	 	 	 	22,646	 

 56.

 

     IN WITNESS WHEREOF, the undersigned has executed this Purchase Agreement or caused its duly
authorized officers to execute this Purchase Agreement as of the date first above written.

	 	 	 	 	 	 	 
	IF AN INDIVIDUAL:	 	IF A CORPORATION, PARTNERSHIP,
	 	 	  TRUST, ESTATE OR OTHER ENTITY:
	 
 

	 	 	 	 	 	 
	(Signature)	 	Omicron Master Trust
	 	 	 
	 	 	Print name of entity
	 
 

	 	 	 	 	 	 
	(Printed Name)	 	By:	 	/s/ Bruce Bernstein
	 	 	 	 	 
	 

	 	 	 	Name:
	 	Bruce Bernstein
	 

	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	Managing Partner
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	Bermuda
	 	 	 
	 	 	Print jurisdiction of organization of entity
	 
	 	 	 	 	 	 

	 	 	 
	Address:

	 	Address:
	 
	 	 
	 
	 	 
	 

	 	650 5th Avenue, 24th Floor
	 

	 	 
	 

	 	New York, NY 10019
	 

	 	 
	 

	 	Attn: Brian Daly
	 

	 	 
	 

	 	Tel: 212 258-2302
	 

	 	 
	 

	 	Fax: 212 258-2315
	 

	 	 

     Aggregate dollar amount of Common Shares and Warrants committed to be purchased pursuant to the
terms of the Agreement: $999,999.00

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Common Shares	 	 	Warrant Shares	 
	First Closing Purchase Price
	 	$	6.50	 	 	 	67,576	 	 	 	23,652	 
	Second Closing Purchase Price
	 	$	6.50	 	 	 	86,270	 	 	 	30,194	 

 57.

 

Exhibit A

FORM OF WARRANT

The Form of Warrant is filed separately as Exhibit 10.70 of the Company’s Current Report on Form
8-K, filed on November 24, 2005

58.

 

Exhibit B

INSTRUCTION SHEET FOR PURCHASER

(to be read in conjunction with the entire

Securities Purchase Agreement)

	A.	 	Complete the following items in the Securities Purchase Agreement:

	 	1.	 	Provide the information regarding the Purchaser requested on the signature
page. The Agreement must be executed by an individual authorized to bind the Purchaser.
	 
	 	2.	 	Exhibit B-1 — Stock Certificate Questionnaire:
	 
	 	 	 	Provide the information requested by the Stock Certificate Questionnaire.
	 
	 	3.	 	Exhibit B-2 — Registration Statement Questionnaire:
	 
	 	 	 	Provide the information requested by the Registration Statement Questionnaire.
	 
	 	4.	 	Exhibit B-3 or B-4 — Purchaser Certificate:
	 
	 	 	 	Provide the information requested by the Certificate for Individual Purchasers or
the Certificate for Corporate, Partnership, Trust, Foundation and Joint Purchasers,
as applicable.
	 
	 	5.	 	Return the signed Securities Purchase Agreement to:

John L. Brottem, Esq.

Cooley Godward llp

Five Palo Alto Square

3000 El Camino Real

Palo Alto, California 94306-2155

Fax: 650-745-3924

	B.	 	Instructions regarding the transfer of funds for the purchase of Securities will be
telecopied to the Purchaser at a later date.
	 
	C.	 	Upon the resale of the Registrable Shares by the Purchaser after the Registration Statement
covering the Registrable Shares is effective, as described in the Securities Purchase
Agreement, the Purchaser:

	 	(i)	 	must deliver a current prospectus to the buyer (prospectuses may be obtained
from the Company at the Purchaser’s request), provided, however, that if Rule 172 is
then in effect, such Purchaser must confirm that a current prospectus is deemed to be
delivered to such buyer; and

59.

 

	 	(ii)	 	must send a letter in the form of Exhibit E to the Securities Purchase
Agreement to the Company so that the Registrable Shares may be properly transferred.

60.

 

Exhibit B-1

SOLEXA, INC.

STOCK CERTIFICATE QUESTIONNAIRE

Pursuant to Section 4.3 of the Agreement, please provide us with the following information:

	 	 	 	 	 
	1.

	 	The exact name that the Securities are to be registered in (this is
the name that will appear on the stock certificate(s)). You may use a
nominee name if appropriate:	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	2.

	 	The relationship between the Purchaser of the Securities and the
Registered Holder listed in response to item 1 above:	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	3.

	 	The mailing address of the Registered Holder listed in response to
item 1 above:	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	 
	 	 	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	 
	 	 	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	 
	 	 	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	 
	 	 	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	4.

	 	The Tax Identification Number of the Registered Holder listed in
response to item 1 above:	 	 
	 

	 	 	 	 

B-1

 

Exhibit B-2

SOLEXA, INC.

REGISTRATION STATEMENT QUESTIONNAIRE

     In connection with the preparation of the Registration Statement, please provide us with
the following information regarding the Purchaser.

A. General Information

     1. Please state your organization’s name exactly as it should appear in the Registration
Statement:                                                             

     2. Have you or your organization had any position, office or other material relationship
within the past three years with the Company or its affiliates other than as disclosed in the
Prospectus included in the Registration Statement?

 ̈ Yes  ̈ No

     If yes, please indicate the nature of any such relationships below:

      

      

B. Securities Holdings

     Please fill in all blanks in the following questions related to your beneficial ownership
of the Company’s capital stock. Generally, the term “beneficial ownership” refers to any
direct or indirect interest in the securities which entitles you to any of the rights or benefits
of ownership, even though you may not be the holder of record of the securities. For example,
securities held in “street name” over which you exercise voting or investment power would be
considered beneficially owned by you. Other examples of indirect ownership include ownership by a
partnership in which you are a partner or by an estate or trust of which you or any member of your
immediate family is a beneficiary. Ownership of securities held in the names of your spouse, minor
children or other relatives who live in the same household may be attributed to you.

     Please note: If you have any reason to believe that any interest in securities of the
Company which you may have, however remote, is a beneficial interest, please describe such
interest. For purposes of responding to this questionnaire, it is preferable to err on the side of
inclusion rather than exclusion. Where the SEC’s interpretation of beneficial ownership would
require disclosure of your interest or possible interest in certain securities of the Company, and
you believe that you do not actually possess the attributes of beneficial ownership, an appropriate
response is to disclose the interest and at the same time disclaim beneficial ownership of the
securities.

B-2.1

 

     1. As of [                    ], 2005, I owned outright (including shares registered in my name
individually or jointly with others, shares held in the name of a bank, broker, nominee, depository
or in “street name” for my account), the following number of shares of the Company’s capital stock:                                         .

     2. In addition to the number of shares I own outright as indicated by my answer to question
B(1), as of [                    ], 2005, I had or shared voting power or investment power, directly or
indirectly, through a contract, arrangement, understanding, relationship or otherwise, over the
following number of shares of the Company’s capital stock:                                         .

     If the answer to this question B(2) was not “zero,” please complete the following: with whom
shared; and the nature of the relationship and any underlying voting trust agreement, investment
arrangement or the like:

Shared Voting Power:

	 	 	 	 	 
	Number of Shares	 	With Whom Shared	 	Nature of Relationship
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 

Shared Investment Power:

	 	 	 	 	 
	Number of Shares	 	With Whom Shared	 	Nature of Relationship
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 

     3. As of [                    ], 2005, I will have the right to acquire                     shares of the
Company’s capital stock pursuant to outstanding stock options issued under the Company’s stock
option plans and                     shares pursuant to the exercise of outstanding warrants (none, indicated by
“0” above).

	 	 	 
	Options and Warrants
	Class	 	Number of Shares
	 	 	 
	 	 	 
	 	 	 

B-2.2

 

     (4) Please identify the natural person or persons who have voting and/or investment control
over
the Company’s securities that you own, and state whether such person(s) disclaims beneficial
ownership of the securities. For example, if you are a general partnership, please identify the
general partners in the partnership.

      

      

      

      

      

      

B-2.3

 

C. NASD Questions

     1. Are
you (i) a “member”1 of the National Association of Securities
Dealers, Inc. (the “NASD”), (ii) an
“affiliate”2 of a member of the NASD, (iii) a
“person associated with a member” or an “associated
person of a member”3 of the NASD or
(iv) an immediate family member4 of any of the foregoing persons? If yes, please
identify the member and describe such relationship (whether direct or indirect), and please respond
to Question Number 2 below; if no, please proceed directly to Question Number 3.

Yes _____ No _____

Description:

 

 

 

 

 

			
	1	 	NASD defines a “member” as
any broker or dealer admitted to membership in the NASD, or any officer or
partner or branch manager of such a member, or any person occupying a similar
status or performing a similar function for such a member.
	 
	2	 	The term “affiliate” means a
person that directly, or indirectly through one or more intermediaries,
controls, or is controlled by, or is in common control with, the person
specified. Persons who have acted or are acting on behalf of or for the
benefit of a person include, but are not necessarily limited to, directors,
officers, employees, agents, consultants and sales representatives. The
following should apply for purposes of the foregoing:

	 	(i)	 	a person should be presumed to control a Member if the person
beneficially owns 10 percent or more the outstanding voting securities of a
Member which is a corporation, or beneficially owns a partnership interest in
10 percent or more of the distributable profits or losses of a Member which is
a partnership;
	 
	 	(ii)	 	a Member should be presumed to control a person if the Member and
Persons Associated With a Member beneficially own 10 percent or more of the
outstanding voting securities of a person which is a corporation, or
beneficially own a partnership interest in 10 percent or more of the
distributable profits or losses of a person which is a partnership;
	 
	 	(iii)	 	a person should be presumed to be under common control with a Member
if:

	 	(1)	 	the same person controls both the Member and another person by
beneficially owning 10 percent or more of the outstanding voting
securities of a Member or person which is a corporation, or by
beneficially owning a partnership interest in 10 percent or more of the
distributable profits or losses of a Member or person which is a
partnership; or
	 
	 	(2)	 	a person having the power to direct or cause the direction of the
management or policies of the Member or such person also has the power to
direct or cause the direction of the management or policies of the other entity
in question.

	3	 	 The NASD defines a “person
associated with a member” or an “associated person of a
member” as being every sole proprietor, partner, equity owner, officer,
director or branch manager of any member, or any natural person occupying a
similar status or performing similar functions, or any natural person engaged
in the investment banking or securities business who directly or indirectly
controls or is controlled by such member (for example, any employee), whether
or not any such person is registered or exempt from registration with the NASD.
	 
	4	 	 Immediate family includes parents, mother-in-law, father-in-law, husband or wife, brother or sister,
brother-in-law or sister-in-law, son-in-law or daughter-in-law, and children,
or any other person who is supported, directly or indirectly, to a material
extent, by a person associated with a member of the NASD or any other
broker/dealer.

B-2.4

 

     2. If you answered “yes” to Question Number 1, please furnish any information as to whether
any such member intends to participate in any capacity in the private placement, including the
details of such participation:

Description:

 

 

 

 

     3. Are
you or have you been an “underwriter or related person”5 or a person
associated with an underwriter or related person, including, without limitation, with respect to
the proposed public offering? If yes, please identify the underwriter or related person and
describe such relationship (whether direct or indirect).

Yes _____ No _____

Description:

 

 

 

 

     4. If known, please describe in detail any underwriting compensations, arrangements or
dealings entered into during the previous twelve months, or proposed to be consummated in the next
twelve months, between (i) any underwriter or related person, member of the NASD, affiliate of a
member of the NASD, person associated with a member or associated person of a member of the NASD or
any immediate family member thereof, on the one hand, and (ii) the Company, or any director,
officer or stockholder thereof, on the other hand, which provides for the receipt of any item of
value and/or the transfer of any warrants, options or other securities from the Company to any such
person (other than the information relating to the arrangements with any investment firm or
underwriting organization which may participate in the proposed public offering).

Description:

 

 

 

 

     5. Have you purchased the securities in the ordinary course of business ?

Yes _____ No _____

 

			
	5	 	The term “underwriter or related
person” includes underwriters, underwriters’ counsel, financial
consultants and advisors, finders, members of the selling or distribution
group, and any and all other persons associated with or related to any of such
persons, including members of the immediate family of such persons.

B-2.5

 

The answers to the foregoing questions are correctly stated to the best of my information and
belief. I shall advise John L. Brottem at (650) 843-5358, the Company’s outside counsel, promptly
of any changes in the foregoing information prior to the effectiveness of the registration
statement.

	 	 	 	 	 
	 
	 	 	 	 
	 	 	 
	 	 	(Print name of Selling Security Holder)
	 
	 	 	 	 
	 	 	 
	 	 	(Signature)
	 
	 	 	 	 
	 

	 	By:	 	 
	 

	 	 	 	 
	 	 	(Name and title of signatory, if stockholder is an entity)
	 
	 	 	 	 
	 	 	 
	 	 	(Date)

B-2.6

 

Exhibit B-3

SOLEXA, INC.

CERTIFICATE FOR INDIVIDUAL PURCHASERS

     If the investor is an individual Purchaser (or married couple) the Purchaser must
complete, date and sign this Certificate.

Certificate

     I certify that the representations and responses below are true and accurate:

     In order for the Company to offer and sell the Securities in conformance with state and
federal securities laws, the following information must be obtained regarding your investor status.
Please initial each category applicable to you as an investor in the Company.

     ___(1) A natural person whose net worth1, either individually or jointly with
such person’s spouse exceeds $1,000,000;

     ___(2) A natural person who had an income2 in excess of $200,000, or joint
income with the person’s spouse in excess of $300,000, in 2003 and 2004, and reasonably expects to
have individual income reaching the same level in 2005;

     ___(3) An executive officer or director of the Company.

	 	 	 	 	 
	Date:
	 	 	 	 
	 

	 	 
	 	 
	 

	 	 	 	Name(s) of Purchaser
	 
	 	 	 	 
	 

	 	 	 	 
	 

	 	 	 	Signature
	 
	 	 	 	 
	 

	 	 	 	 
	 

	 	 	 	Signature

 

			
	1	 	For purposes of this Certificate,
“net worth” means the excess of total assets at fair market value
over total liabilities, except that the principal residence owned by a natural
person shall be valued either (a) at cost, including the cost of improvements,
net of current encumbrances upon the property, or (b) at the appraised value of
the residence as determined upon a written appraisal used by an institutional
lender making a loan to the individual secured by the property, including the
cost of subsequent improvements, net of current encumbrances upon the property.
As used in the preceding sentence, “institutional lender” means a
bank, savings and loan company, industrial loan company, credit union or
personal property broker or a company whose principal business is as a lender
of loans secured by real property and which has such loans receivable in the
amount of $2,000,000 or more.
	 
	2	 	For purposes of this Certificate,
“income” means adjusted gross income, as reported for federal
income tax purposes, increased by the following amounts: (a) the amount of any
tax exempt interest income received, (b) the amount of losses claimed as a
limited partner in a limited partnership, (c) any deduction claimed for
depletion, (d) amounts contributed to an IRA or Keogh retirement plan, (e)
alimony paid, and (f) any amounts by which income from long-term capital gains
has been reduced in arriving at adjusted gross income pursuant to the
provisions of Section 1202 of the Internal Revenue Code.

B-3

 

Exhibit B-4

SOLEXA, INC.

CERTIFICATE FOR CORPORATE, PARTNERSHIP,

TRUST, FOUNDATION, AND JOINT PURCHASERS

     If the investor is a corporation, partnership, trust, pension plan, foundation, joint
purchaser (other than a married couple) or other entity, an authorized officer, partner, or trustee
must complete, date and sign this Certificate.

Certificate

     The undersigned certifies that the representations and responses below are true and accurate:

     (a) The investor has been duly formed and is validly existing and has full power and authority
to invest in the Company. The person signing on behalf of the undersigned has the authority to
execute and deliver the Securities Purchase Agreement on behalf of the Purchaser and to take other
actions with respect thereto.

     (b) Indicate the form of entity of the undersigned:

	 	o	 	Limited Partnership
	 
	 	o	 	General Partnership
	 
	 	o	 	Corporation
	 
	 	o	 	Revocable Trust (identify each grantor and indicate under what circumstances
the trust is revocable by the grantor:
	 
	 
	 	 	 	 

	 
	 	 	 	 

	 
	 	 	 	 

	 
	 	 	 	 

(Continue on a separate piece of paper, if necessary.)
	 
	 
	 	o	 	Other Type of Trust (indicate type of trust and, for trusts other than
pension trusts, name the grantors and beneficiaries:

	 
	 
	 
	 	 	 	 

	 
	 	 	 	 

	 
	 	 	 	 

	 
	 	 	 	 

(Continue on a separate piece of paper, if necessary.)
	 
	 	o	 	Other form of organization (indicate form of organization (                    ).

B-4.2

 

     (c) Indicate the approximate date the undersigned entity was formed:                     .

     (d) In order for the Company to offer and sell the Securities in conformance with state and
federal securities laws, the following information must be obtained regarding your investor status.
Please initial each category applicable to you as an investor in the Company.

     ___(1) A bank as defined in Section 3(a)(2) of the Securities Act, or any savings
and loan association or other institution as defined in Section 3(a)(5)(A) of the Securities
Act whether acting in its individual or fiduciary capacity;

     ___(2) A broker or dealer registered pursuant to Section 15 of the Securities
Exchange Act of 1934;

     ___(3) An insurance company as defined in Section 2(13) of the Securities Act;

     ___(4) An investment company registered under the Investment Company Act of 1940
or a business development company as defined in Section 2(a)(48) of that Act;

     ___(5) A Small Business Investment Company licensed by the U.S. Small Business
Administration under Section 301(c) or (d) of the Small Business Investment Act of 1958;

     ___(6) A plan established and maintained by a state, its political subdivisions,
or any agency or instrumentality of a state or its political subdivisions, for the benefit
of its employees, if such plan has total assets in excess of $5,000,000;

     ___(7) An employee benefit plan within the meaning of the Employee Retirement
Income Security Act of 1974, if the investment decision is made by a plan fiduciary, as
defined in Section 3(21) of such act, which is either a bank, savings and loan association,
insurance company, or registered investment adviser, or if the employee benefit plan has
total assets in excess of $5,000,000 or, if a self-directed plan, with investment decisions
made solely by persons that are accredited investors;

     ___(8) A private business development company as defined in Section 202(a)(22) of
the Investment Advisers Act of 1940;

     ___(9) An organization described in Section 501(c)(3) of the Internal Revenue
Code, a corporation, Massachusetts or similar business trust, or partnership, not formed for
the specific purpose of acquiring the Securities, with total assets in excess of $5,000,000;

     ___(10) A trust, with total assets in excess of $5,000,000, not formed for the
specific purpose of acquiring the Securities, whose purchase is directed by a sophisticated
person who has such knowledge and experience in financial and business matters that such
person is capable of evaluating the merits and risks of investing in the Company;

B-4.2

 

     ___(11) An entity in which all of the equity owners qualify under any of the above
subparagraphs. If the undersigned belongs to this investor category only, list the equity
owners of the undersigned, and the investor category which each such equity owner satisfies:

      

      

      

      

(Continue on a separate piece of paper, if necessary.)

	 	 	 	 	 
	Dated:

	 	 	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	 
	 	 	 	 
	 	 	 
	Name of investor	 	 
	 
	 	 	 	 
	 	 	 
	Signature and title of authorized	 	 
	officer, partner or trustee	 	 

B-4.2

 

Exhibit C

OPINION OF COMPANY COUNSEL

November [___], 2005

To the Purchasers listed on Exhibit A hereto

Re:     Solexa, Inc. Private Placement

Dear Ladies and Gentlemen:

     We have acted as counsel for Solexa, Inc., a Delaware corporation (the “Company”), in
connection with the issuance and sale of up to 3,750,445 shares of the Company’s common stock, par
value $0.01 per share (the “Common Stock”) (the “Shares”) and warrants (the “Warrants”) to purchase
an aggregate of up to 1,312,657 shares of Common Stock (the “Warrant Shares” and collectively with
the Shares and Warrants, the “Securities”), to the Purchasers at the First Closing under that
certain Securities Purchase Agreement dated as of November 18, 2005 (the “Purchase Agreement”). We
are rendering this opinion pursuant to Section 5.4 of the Purchase Agreement. Except as otherwise
defined herein, capitalized terms used but not defined herein have the respective meanings given to
them in the Purchase Agreement.

     In connection with this opinion, we have examined and relied upon the representations and
warranties as to factual matters contained in and made pursuant to the Purchase Agreement by the
various parties and originals or copies certified to our satisfaction, of such records, documents,
certificates, opinions, memoranda and other instruments as in our judgment are necessary or
appropriate to enable us to render the opinion expressed below.

     As to certain factual matters, we have relied upon certificates of officers of the Company and
have not sought to independently verify such matters. Where we render an opinion “to our
knowledge” or concerning an item “known to us” or our opinion otherwise refers to our knowledge, it
is based solely upon (i) an inquiry of attorneys within this firm who have represented the Company
in this transaction, (ii) receipt of a certificate executed by an officer of the Company covering
such matters, and (iii) such other investigation, if any, that we specifically set forth herein.

     In rendering this opinion, we have assumed: the authenticity of all documents submitted to us
as originals; the conformity to originals of all documents submitted to us as copies; the accuracy,
completeness and authenticity of certificates of public officials; the due authorization, execution
and delivery of all documents (except the due authorization, execution and delivery by the Company
of the Purchase Agreement and the Warrants (together, the “Financing Agreements”)), where
authorization, execution and delivery are prerequisites to the effectiveness of such documents; and
the genuineness and authenticity of all signatures on original documents (except the signatures on
behalf of the Company on the Financing Agreements). We have also assumed: that all individuals
executing and delivering documents had the legal capacity to so execute and deliver; that the
Financing Agreements are obligations binding upon the parties thereto other than the Company; that
the parties to the Financing Agreements other than the Company have filed any required California
franchise or income tax returns and have paid any

D-1

 

required California franchise or income taxes; and that there are no extrinsic agreements or
understandings among the parties to the Financing Agreements that would modify or interpret the
terms of the Financing Agreements or the respective rights or obligations of the parties
thereunder.

     Our opinion is expressed only with respect to the federal laws of the United States of America
and the laws of the State of California and the General Corporation Law of the State of Delaware.
We express no opinion as to whether the laws of any particular jurisdiction apply, and no opinion
to the extent that the laws of any jurisdiction other than those identified above are applicable to
the subject matter hereof.

     We are not rendering any opinion as to any statute, rule, regulation, ordinance, decree or
decisional law relating to antitrust, banking, land use, environmental, pension, employee benefit,
tax, fraudulent conveyance, usury, laws governing the legality of investments for regulated
entities, regulations T, U or X of the Board of Governors of the Federal Reserve System or local
law. Furthermore, we express no opinion with respect to compliance with antifraud laws, rules or
regulations relating to securities or the offer and sale thereof; compliance with fiduciary duties
by the Company’s Board of Directors or stockholders; compliance with safe harbors for disinterested
Board of Director or stockholder approvals; compliance with state securities or blue sky laws
except as specifically set forth below; compliance with the Investment Company Act of 1940;
compliance with laws that place limitations on corporate distributions; the enforceability of
provisions in the Financing Agreements concerning the voting of the Company’s capital stock (other
than solely administrative obligations of the Company).

     With regard to our opinion in paragraphs 1 and 3 below with respect to the good standing of the
Company, we have relied solely upon certificates of the Secretaries of State of the indicated
jurisdictions as of a recent date.

     With regard to our opinion in paragraph 6 below, we have examined and relied upon a certificate
executed by an officer of the Company, to the effect that the consideration for all outstanding
shares of capital stock of the Company was received by the Company in accordance with the
provisions of the applicable Board of Directors resolutions and any plan or agreement relating to
the issuance of such shares, and we have undertaken no independent verification with respect
thereto.

     With regard to our opinion in paragraph 6 below with respect to securities of the Company to
be issued after the date hereof, we express no opinion to the extent that, notwithstanding its
current reservation of shares of Common Stock, future issuance of securities of the Company or
anti-dilution adjustments to outstanding securities of the Company cause the Warrants to be
convertible for more shares of Common Stock than the number that then remain authorized but
unissued.

     With regard to our opinion in paragraph 8 below with respect to pending or overtly threatened
litigation, we have made an inquiry of the attorneys within this firm who have represented the
Company in this transaction, examined and relied upon a certificate executed by an officer of the
Company covering such matters, and checked the records of this firm to

B-4.2

 

ascertain that we are not acting as counsel of record for the Company in any such matter. We
have made no further investigation.

     With regard to our opinion in paragraph 10 concerning exemption from registration, our opinion
is expressed only with respect to the offer and sale of the Shares without regard to any offers or
sales of other securities occurring prior to or subsequent to the date hereof.

     On the basis of the foregoing, in reliance thereon and with the foregoing qualifications, we
are of the opinion that:

	1.	 	The Company has been duly incorporated and is a validly existing corporation in good standing
under the laws of the State of Delaware.

	2.	 	The Company has the requisite corporate power to own its property and assets and to conduct
its business as it is currently being conducted.

	3.	 	The Company is duly qualified to do business as a foreign corporation and is in good standing
under the laws of California.

	4.	 	The Company has the corporate power to execute, deliver and perform its obligations under the
Financing Agreements.

	5.	 	Each of the Financing Agreements has been duly and validly authorized, executed and delivered
by the Company and each such agreement constitutes a valid and binding agreement of the
Company enforceable against the Company in accordance with its respective terms, except as
rights to indemnity and contribution under section 7.3 of the Purchase Agreement may be
limited by applicable laws and except as enforcement may be limited by applicable bankruptcy,
insolvency, reorganization, arrangement, moratorium or other similar laws affecting creditors’
rights, and subject to general equity principles and to limitations on availability of
equitable relief, including specific performance.

	6.	 	The Company’s authorized capital stock consists of (a) sixty million (60,000,000) shares of
Common Stock, and (b) two million (2,000,000) shares of Preferred Stock, par value $0.01 per
share. The Shares and Warrant Shares have been duly authorized and the Warrant Shares have
been reserved for issuance upon exercise of the Warrants. The Shares and Warrants, when
issued, sold and delivered against payment therefor in accordance with the terms of the
Purchase Agreement and the Warrant Shares, if issued on the date hereof upon exercise of the
Warrants and payment therefor in accordance with the terms of the Warrants, will be validly
issued, outstanding, fully paid and nonassessable. To our knowledge, except as provided in
the SEC Documents, the Financing Agreements or the Disclosure Schedule, there are no options,
warrants, conversion privileges, preemptive rights or other rights presently outstanding to
purchase any of the authorized but unissued capital stock of the Company.

	7.	 	The execution and delivery of the Financing Agreements by the Company and the issuance of the
Shares and Warrants pursuant thereto do not violate any provision of the Company’s Amended and
Restated Certificate of Incorporation, as amended, or Bylaws,

B-4.2

 

	   	    	as amended, and do not violate (a) any governmental statute, rule or regulation which in our
experience is typically applicable to transactions of the nature contemplated by the
Financing Agreements or (b) any order, writ, judgment, injunction, decree, determination or
award which has been entered against the Company and of which we are aware, in each case to
the extent the violation of which would materially and adversely affect the Company and its
subsidiaries, taken as a whole.

	  8.	 	To our knowledge, there is no action, proceeding or investigation pending or overtly
threatened against the Company before any court or administrative agency that questions the
validity of the Purchase Agreement or that could reasonably be expected to result, either
individually or in the aggregate, in a material adverse effect on the Company and its
subsidiaries, taken as a whole that has not been disclosed in writing to the Investors.

	  9.	 	All consents, approvals, authorizations, or orders of, and filings, registrations, and
qualifications with any U.S. Federal or California regulatory authority or governmental body
required for the issuance of the Shares and Warrants, have been made or obtained, except (a)
for the filing of a Form D pursuant to Securities and Exchange Commission Regulation D and (b)
for the filing of the notice to be filed under California Corporations Code Section
25102.1(d).

	10.	 	The offer and sale of the Shares and Warrants are exempt from the registration requirements
of the Securities Act of 1933, as amended, subject to the timely filing of a Form D pursuant
to Securities and Exchange Commission Regulation D.

        This opinion is intended solely for your benefit and is not to be made available to or be
relied upon by any other person, firm, or entity without our prior written consent.

	 	 	 	 	 
	Very Truly Yours,	 	 
	 
	 	 	 	 
	Cooley Godward llp	 	 
	 
	 	 	 	 
	By:
	 	 	 	 
	 

	 	 	 	 
	 

	 	James C. Kitch	 	 

B-4.2

 

Exhibit D

SOLEXA, INC.

IMPORTANT — DO NOT REMOVE THIS INSTRUCTION SHEET FROM THE ATTACHED SHARE CERTIFICATE UNLESS
AND UNTIL THE SHARES ARE SOLD AS FOLLOWS:

(1) THE SHARES ARE RESOLD PURSUANT TO THE REGISTRATION STATEMENT ON FORM S-3 (NO.
[                    ]), AND, IN CONNECTION WITH SUCH RESALE, THE HOLDER HAS PROVIDED TO THE COMPANY OR
THE TRANSFER AGENT FOR THE COMPANY’S STOCK A PURCHASER’S CERTIFICATE OF SUBSEQUENT SALE AND THE
HOLDER HAS DELIVERED A CURRENT PROSPECTUS OR, IF RULE 172 UNDER THE SECURITIES ACT OF 1933 AS
AMENDED IS THEN IN EFFECT, THE HOLDER HAS CONFIRMED THAT A CURRENT PROSPECTUS IS DEEMED TO BE
DELIVERED IN CONNECTION WITH SUCH RESALE; OR

(2) THE SHARES ARE RESOLD IN A TRANSACTION EXEMPT FROM THE REGISTRATION REQUIREMENTS OF THE
SECURITIES ACT OF 1933, AS AMENDED, PROVIDED THAT, PRIOR TO SUCH RESALE, THE HOLDER HAS NOTIFIED
THE COMPANY OF SUCH DISPOSITION AND PROVIDED THE COMPANY WITH WRITTEN ASSURANCES, IN FORM AND
SUBSTANCE REASONABLY SATISFACTORY TO THE COMPANY OF COMPLIANCE WITH THE REQUIREMENTS OF SUCH
EXEMPTION.

DO NOT REMOVE THIS INSTRUCTION SHEET FROM

THE ATTACHED SHARE CERTIFICATE

EXCEPT IN ACCORDANCE WITH

THE INSTRUCTIONS SET FORTH ABOVE.

B-4.2

 

Exhibit E

PURCHASER’S CERTIFICATE OF SUBSEQUENT SALE

To:     Cooley Godward llp

			
	
Attention:	 	Trevor Dutcher, Esq.

Five Palo Alto Square

3000 El Camino Real

Palo Alto, CA 94306-2155

The undersigned, the selling securityholder or an officer of, or other duly authorized person,
hereby certifies that                                                                                  represents that it has sold
shares of the Common Stock of Solexa, Inc. and that such

        [fill in name of selling
securityholder]
shares were sold on
                    
either (i) in accordance with the registration statement on Form S-3 with file number [                            ],

                                       [date]

 in which case the selling securityholder certifies that such
selling securityholder has delivered a current prospectus in connection with such sale, provided,
however, that if Rule 172 under the Securities Act of 1933, as amended, is then in effect, such
selling securityholder has confirmed that a current prospectus is deemed to be delivered in
connection with such sale, or (ii) in accordance with Rule 144 under the Securities Act of 1933
(“Rule 144”), in which case the selling securityholder certifies that it has complied with the
requirements of Rule 144.

Print or type:

	 	 	 	 	 
	 

	 	Number of shares sold (if sold on
multiple dates, please provide a
breakdown by date):	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	 

	 	Name of selling securityholder:	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	 

	 	Name of individual representing
selling securityholder (if an
institution):	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	 

	 	Title of individual representing
selling securityholder (if an
institution):	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	Signature by:	 	 
	 
	 	 	 	 
	 

	 	Selling securityholder or

individual representative:	 	 
	 

	 	 	 	 

E-1

 

Exhibit F

Form of Voting Agreement

     The Form of Voting Agreement is filed separately as Exhibit 99.1 of the Company’s Current
Report on Form 8-K, filed on November 23, 2005

E-1

 

Table of Contents

	 	 	 	 	 	 	 
	 	 	 	 	Page	 
	ARTICLE 1           AUTHORIZATION AND SALE OF COMMON SHARES AND WARRANTS	 	 	1	 
	1.1
	 	Authorization	 	 	1	 
	ARTICLE 2           CLOSING DATES; DELIVERY	 	 	2	 
	2.1
	 	Closing Dates. Delivery	 	 	2	 
	ARTICLE 3           REPRESENTATIONS AND WARRANTIES OF THE COMPANY	 	 	3	 
	3.1
	 	Organization and Standing	 	 	3	 
	3.2
	 	Corporate Power; Authorization	 	 	3	 
	3.3
	 	Issuance and Delivery of the Shares	 	 	4	 
	3.4
	 	SEC Documents; Financial Statements	 	 	4	 
	3.5
	 	Governmental Consents	 	 	4	 
	3.6
	 	No Material Adverse Change	 	 	4	 
	3.7
	 	Authorized Capital Stock	 	 	5	 
	3.8
	 	Litigation	 	 	5	 
	3.9
	 	Eligibility to Use Form S-3	 	 	5	 
	3.10
	 	Company not an “Investment
Company.”	 	 	5	 
	3.11
	 	NASDAQ Compliance	 	 	5	 
	3.12
	 	Use of Proceeds	 	 	5	 
	3.13
	 	Brokers and Finders	 	 	5	 
	3.14
	 	No Directed Selling Efforts or General Solicitation	 	 	6	 
	3.15
	 	No Integrated Offering	 	 	6	 
	3.16
	 	Private Placement	 	 	6	 
	3.17
	 	Internal Accounting Controls	 	 	6	 
	3.18
	 	Intellectual Property	 	 	6	 
	3.19
	 	Questionable Payments	 	 	7	 
	3.20
	 	Transactions with Affiliates	 	 	7	 
	3.21
	 	Disclosure	 	 	7	 
	3.22
	 	Dilution; Sales By Purchasers	 	 	7	 
	ARTICLE 4           REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE PURCHASERS
	 	 	8	 
	4.1
	 	Authorization	 	 	8	 

i.

 

Table of Contents

(continued)

	 	 	 	 	 	 	 
	 	 	 	 	Page	 
	4.2
	 	Investment Experience	 	 	8	 
	4.3
	 	Investment Intent	 	 	8	 
	4.4
	 	Registration or Exemption Requirements	 	 	9	 
	4.5
	 	Dispositions	 	 	9	 
	4.6
	 	No Legal, Tax or Investment Advice	 	 	10	 
	4.7
	 	Confidentiality	 	 	10	 
	4.8
	 	Residency	 	 	10	 
	4.9
	 	Governmental Review	 	 	10	 
	4.10
	 	Legend	 	 	10	 
	4.11
	 	Foreign Investors	 	 	11	 
	ARTICLE 5           CONDITIONS TO CLOSING OBLIGATIONS OF PURCHASERS	 	 	11	 
	5.1
	 	Representations and Warranties	 	 	11	 
	5.2
	 	Covenants	 	 	12	 
	5.3
	 	Certificates	 	 	12	 
	5.4
	 	Legal Opinion	 	 	12	 
	5.5
	 	Amended and Restated Company Support Agreement	 	 	12	 
	5.6
	 	Listing	 	 	12	 
	5.7
	 	Officer’s Certificate	 	 	12	 
	5.8
	 	Judgments	 	 	12	 
	5.9
	 	Secretary’s Certificate	 	 	12	 
	5.10
	 	Stop Orders	 	 	12	 
	5.11
	 	Stockholder Approval	 	 	12	 
	ARTICLE 6           CONDITIONS TO CLOSING OBLIGATIONS OF COMPANY	 	 	13	 
	6.1
	 	Receipt of Payment	 	 	13	 
	6.2
	 	Representations and Warranties	 	 	13	 
	6.3
	 	Covenants	 	 	13	 
	6.4
	 	Delivery of Purchaser Questionnaire	 	 	13	 
	ARTICLE 7           COVENANTS	 	 	13	 
	7.1
	 	Definitions	 	 	13	 
	7.2
	 	Registration Procedures and Expenses	 	 	14	 
	7.3
	 	Indemnification	 	 	16	 

ii.

 

Table of Contents

(continued)

	 	 	 	 	 	 	 
	 	 	 	 	Page	 
	7.4
	 	Prospectus Delivery	 	 	18	 
	7.5
	 	Termination of Obligations	 	 	19	 
	7.6
	 	Reporting Requirements	 	 	19	 
	7.7
	 	Blue Sky	 	 	19	 
	7.8
	 	Stockholder Approval	 	 	19	 
	7.9
	 	Publicity	 	 	20	 
	ARTICLE 8           RESTRICTIONS ON TRANSFERABILITY OF SECURITIES;
COMPLIANCE WITH SECURITIES ACT	 	 	20	 
	8.1
	 	Restrictions on Transferability	 	 	20	 
	8.2
	 	Instruction Sheet	 	 	20	 
	8.3
	 	Transfer of Securities	 	 	20	 
	8.4
	 	Purchaser Information	 	 	21	 
	8.5
	 	Material Non-Public Information	 	 	21	 
	ARTICLE 9           MISCELLANEOUS	 	 	21	 
	9.1
	 	Termination	 	 	21	 
	9.2
	 	Waivers and Amendments	 	 	22	 
	9.3
	 	Broker’s Fee	 	 	22	 
	9.4
	 	Governing Law	 	 	22	 
	9.5
	 	Survival	 	 	22	 
	9.6
	 	Successors and Assigns	 	 	22	 
	9.7
	 	Entire Agreement	 	 	22	 
	9.8
	 	Notices, etc	 	 	23	 
	9.9
	 	Severability of this Agreement	 	 	23	 
	9.10
	 	Counterparts	 	 	23	 
	9.11
	 	Further Assurances	 	 	23	 
	9.12
	 	Currency	 	 	23	 
	9.13
	 	Waiver of Conflicts	 	 	23	 
	A.
	 	     GENERAL INFORMATION	 	 	1	 
	B.
	 	     SECURITIES HOLDINGS	 	 	1	 
	C.
	 	     NASD QUESTIONS	 	 	5	 
	Exhibit A — Form of Warrant	 	 	 	 
	Exhibit B — Instruction Sheet For Purchaser	 	 	B	 

iii.

 

Table of Contents

(continued)

	 	 	 	 	 	 	 
	Exhibit B — Instruction Sheet For Purchaser	 	 	B	 
	Exhibit B-1 — Solexa, Inc. Stock Certificate Questionnaire	 	 	B-1	 
	Exhibit B-2 — Solexa, Inc. Registration Statement Questionnaire	 	 	B-2.1	 
	Exhibit B-3 — Solexa, Inc. Certificate for Individual Purchasers	 	 	B-3	 
	Exhibit B-4 — Solexa, Inc. Certificate for Corporate, Partnership,
Trust, Foundation and Joint Purchasers	 	 	B-4.1	 
	Exhibit C —Opinion of Company Counsel	 	 	C-1	 
	Exhibit D — Instruction Sheet	 	 	D-1	 
	Exhibit E — Form of Purchaser’s Certificate of Subsequent Sale	 	 	E-1	 
	Exhibit F — Form of Voting Agreement	 	 	F-1	 

iv.exv10w70

 

Exhibit 10.70

THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED (THE “ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR
HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO SUCH SECURITIES UNDER THE
ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT
REQUIRED.

SOLEXA, INC.

WARRANT TO PURCHASE COMMON STOCK

________ __, 2005

Void After ________ __, 2010

     This Certifies That, for value received, [___], or assigns (the “Holder”),
is entitled to subscribe for and purchase at the Exercise Price (defined below) from Solexa, Inc.,
a Delaware corporation, with its principal office at 25861 Industrial Boulevard, Hayward, CA 94545
(the “Company”) up to [___] shares of the common stock of the Company, par value $0.01
per share (the “Common Stock”).

     1. Definitions. As used herein, the following terms shall have the
following respective meanings:

          (a) “Exercise Period” shall mean the period commencing with the date that is one hundred and
eighty (180) days after the date hereof and ending five (5) years from the date hereof, unless
sooner terminated as provided below.

          (b) “Exercise Price” shall mean seven dollars and fifty cents ($7.50) per share, subject to
adjustment pursuant to Section 5 below.

          (c) “Exercise Shares” shall mean the shares of the Common Stock issuable upon exercise of this
Warrant.

     2. Exercise of Warrant. The rights represented by this Warrant may be
exercised in whole or in part at any time during the Exercise Period (subject to Section 7), by
delivery of the following to the Company at its address set forth above (or at such other address
as it may designate by notice in writing to the Holder):

          (a) An executed Notice of Exercise in the form attached hereto;

          (b) Payment of the Exercise Price in cash or by check; and

          (c) This Warrant.

     Certificates for shares purchased hereunder shall be transmitted by the transfer agent of the
Company to the Holder by crediting the account of the Holder’s prime broker with the Depository
Trust Company through its Deposit Withdrawal Agent Commission (“DWAC”)

 1.

 

system if the Company is a participant in such system (and so long as the legend may be
removed in accordance with Section 4.10 of the Purchase Agreement), and otherwise by physical
delivery to the address specified by the Holder in the Notice of Exercise within 5 Trading Days
from the delivery to the Company of the Notice of Exercise Form, surrender of this Warrant and
payment of the aggregate Exercise Price as set forth above
(“Warrant Share Delivery Date”). This
Warrant shall be deemed to have been exercised on the date the Exercise Price is received by the
Company. The Warrant Shares shall be deemed to have been issued, and Holder or any other person so
designated to be named therein shall be deemed to have become a holder of record of such shares for
all purposes, as of the date the Warrant has been exercised by payment to the Company of the
Exercise Price.

     The person in whose name any certificate or certificates for Exercise Shares are to be issued
upon exercise of this Warrant shall be deemed to have become the holder of record of such shares on
the date on which this Warrant was surrendered and payment of the Exercise Price was made,
irrespective of the date of delivery of such certificate or certificates, except that, if the date
of such surrender and payment is a date when the stock transfer books of the Company are closed,
such person shall be deemed to have become the holder of such shares at the close of business on
the next succeeding date on which the stock transfer books are open.

     2.1 Net Exercise. During any period during which this Warrant would otherwise be exercisable
and the Registration Statement (as defined in Section 7.2 of the Securities Purchase Agreement
dated November 18, 2005, by and among the Company and the individuals and entities identified on
the signature pages hereto (the “Purchase
Agreement”)) is not effective, in lieu of exercising this
Warrant by payment of cash, the Holder may elect to receive shares equal to the value (as
determined below) of this Warrant (or the portion thereof being canceled) by surrender of this
Warrant at the principal office of the Company together with the properly endorsed Notice of
Exercise in which event the Company shall issue to the Holder a number of shares of Common Stock
computed using the following formula:

	 	 	 
	X =

	 	Y (A-B)
	 

	 	     A

	 	 	 
	Where X =

	 	the number of shares of Common Stock to be issued to the Holder
	 
	 	 
	Y =

	 	the number of shares of Common Stock purchasable under the
Warrant or, if only a portion of the Warrant is being exercised, the portion of
the Warrant being canceled (at the date of such calculation)
	 
	 	 
	A =

	 	the fair market value of one share of the Company’s Common
Stock (at the date of such calculation)
	 
	 	 
	B =

	 	Exercise Price (as adjusted to the date of such calculation)

          For purposes of the above calculation, the “fair market value” of one share of Common Stock
shall mean (i) the average of the closing sales prices for the shares of Common Stock on the Nasdaq
SmallCap Market or other trading market where such security is listed or traded as reported by
Bloomberg Financial Markets (or a comparable reporting service of

 2.

 

national reputation selected by the Company and reasonably acceptable to the holders if
Bloomberg Financial Markets is not then reporting sales prices of such security) (collectively,
“Bloomberg”) for the ten (10) consecutive trading days immediately preceding such date, or (ii) if
the Nasdaq SmallCap Market is not the principal trading market for the shares of Common Stock, the
average of the reported sales prices reported by Bloomberg on the principal trading market for the
Common Stock during the same period, or, if there is no sales price for such period, the last sales
price reported by Bloomberg for such period, or (iii) if neither of the foregoing applies, the last
sales price of such security in the over-the-counter market on the pink sheets or bulletin board
for such security as reported by Bloomberg, or if no sales price is so reported for such security,
the last bid price of such security as reported by Bloomberg or (iv) if fair market value cannot be
calculated as of such date on any of the foregoing bases, the fair market value shall be as
determined by the Board of Directors of the Company in the exercise of its good faith judgment.

     2.2 Issuance of New Warrants. Upon any partial exercise of this Warrant, the Company, at its
expense, will forthwith and, in any event within five (5) business days, issue and deliver to the
Holder a new warrant or warrants of like tenor, registered in the name of the Holder, exercisable,
in the aggregate, for the balance of the Warrant Shares.

     2.3 Payment of Taxes and Expenses. The Company shall pay any recording, filing, stamp or
similar tax which may be payable in respect of any transfer involved in the issuance of, and the
preparation and delivery of certificates (if applicable) representing, (i) any Warrant Shares
purchased upon exercise of this Warrant and/or (ii) new or replacement warrants in the Holder’s
name or the name of any transferee of all or any portion of this Warrant.

     3. Covenants of the Company.

     3.1 Covenants as to Exercise Shares. The Company covenants and agrees that all Exercise
Shares that may be issued upon the exercise of the rights represented by this Warrant will, upon
issuance, be validly issued and outstanding, fully paid and nonassessable, and free from all taxes,
liens and charges with respect to the issuance thereof. The Company further covenants and agrees
that the Company will at all times during the Exercise Period, have authorized and reserved, free
from preemptive rights, a sufficient number of shares of its Common Stock to provide for the
exercise of the rights represented by this Warrant. If at any time during the Exercise Period the
number of authorized but unissued shares of Common Stock shall not be sufficient to permit exercise
of this Warrant, the Company will take such corporate action as may, in the opinion of its counsel,
be necessary to increase its authorized but unissued shares of Common Stock to such number of
shares as shall be sufficient for such purposes.

     3.3 Notices of Record Date. In the event of any taking by the Company of a record of the
holders of any class of securities for the purpose of determining the holders thereof who are
entitled to receive any dividend (other than a cash dividend which is the same as cash dividends
paid in previous quarters) or other distribution, the Company shall mail to the Holder, at least
ten (10) days prior to the date specified herein, a notice specifying the date on which any such
record is to be taken for the purpose of such dividend or distribution.

 3.

 

     4. Disposition of Warrant and Exercise Shares.

          (a) The Holder further agrees not to make any disposition of all or any part of the Warrant or
Exercise Shares in any event unless and until:

               (i) The Company shall have received a letter secured by the Holder from the Securities and
Exchange Commission stating that no action will be recommended to the Commission with respect to
the proposed disposition; or

               (ii) There is then in effect a registration statement under the Act covering such proposed
disposition and such disposition is made in accordance with said registration statement; or

               (iii) The Holder shall have notified the Company of the proposed disposition and shall have
furnished the Company with a reasonably detailed statement of the circumstances surrounding the
proposed disposition, and if reasonably requested by the Company, the Holder shall have furnished
the Company with an opinion of counsel, reasonably satisfactory to the Company, for the Holder to
the effect that such disposition will not require registration of such Warrant or Exercise Shares
under the Act or any applicable state securities laws; provided, however, that no such opinion of
counsel shall be required for sales (i) under Rule 144, (ii) to one of its nominees, affiliates or
a nominee thereof, (iii) to a pension or profit-sharing fund established and maintained for its
employees or for the employees of any affiliate, (iv) from a nominee to any of the aforementioned
persons as beneficial owner of this Warrant or such Warrant Shares, or (v) to a qualified
institutional buyer, so long as such transfer is effected in compliance with Rule 144A under the
Securities Act.

          (b) The Holder understands and agrees that subject to Section 4.10 of the Purchase Agreement,
all certificates evidencing the shares to be issued to the Holder may bear the following legend:

“THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED (THE “ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR
HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THE
SECURITIES UNDER THE ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT
SUCH REGISTRATION IS NOT REQUIRED.”

     5. Adjustment of Exercise Price and Shares. 

          (a) In the event of changes in the outstanding Common Stock of the Company by reason of stock
dividends, split-ups, recapitalizations, reclassifications, combinations or exchanges of shares,
separations, reorganizations, liquidations, consolidation, acquisition of the Company (whether
through merger or acquisition of substantially all the assets or stock of the Company), or the
like, the number and class of shares available under the Warrant in the aggregate and the Exercise
Price shall be correspondingly adjusted to give the Holder of the Warrant, on exercise for the same
aggregate Exercise Price, the total number, class, and kind of shares or other property as the
Holder would have owned had the Warrant been exercised prior to

 4.

 

the event and had the Holder continued to hold such shares until the event requiring
adjustment. The form of this Warrant need not be changed because of any adjustment in the number
of Exercise Shares subject to this Warrant.

          (b) If at any time or from time to time the holders of Common Stock of the Company (or any
shares of stock or other securities at the time receivable upon the exercise of this Warrant) shall
have received or become entitled to receive, without payment therefor,

               (i) Common Stock or any shares of stock or other securities which are at any time directly or
indirectly convertible into or exchangeable for Common Stock, or any rights or options to subscribe
for, purchase or otherwise acquire any of the foregoing by way of dividend or other distribution
(other than a dividend or distribution covered in Section 5(a) above),

               (ii) any cash paid or payable otherwise than as a cash dividend or

               (iii) Common Stock or additional stock or other securities or property (including cash) by way
of spinoff, split-up, reclassification, combination of shares or similar corporate rearrangement
(other than shares of Common Stock pursuant to Section 5(a) above),

then and in each such case, the Holder hereof will, upon the exercise of this Warrant, be entitled
to receive, in addition to the number of shares of Common Stock receivable thereupon, and without
payment of any additional consideration therefor, the amount of stock and other securities and
property (including cash in the cases referred to in clauses (ii) and (iii) above) which such
Holder would hold on the date of such exercise had he been the holder of record of such Common
Stock as of the date on which holders of Common Stock received or became entitled to receive such
shares or all other additional stock and other securities and property.

     6. Subsequent Equity Sales. 

               (i) If, at any time prior to the one and one half (1 1/2) year anniversary of the date
hereof, the Company issues additional shares of Common Stock or rights, warrants, options or other
securities or debt convertible, exercisable or exchangeable for shares of Common Stock or otherwise
entitling any individual or entity to acquire shares of Common Stock (collectively, “Common Stock
Equivalents”) at an effective net price to the Company per share of Common Stock (the “Effective
Price”) less than six dollars and fifty cents ($6.50) (as adjusted for any stock dividends,
combinations, splits, recapitalizations and the like after the date hereof), then the Exercise
Price shall be reduced to equal the product of (A) the Exercise Price in effect immediately prior
to such issuance of Common Stock or Common Stock Equivalents times (B) a fraction, the numerator of
which is the sum of (1) the number of shares of Common Stock outstanding immediately prior to such
issuance, plus (2) the number of shares of Common Stock which the aggregate Effective Price of the
Common Stock issued (or deemed to be issued) would purchase at the Exercise Price, and the
denominator of which is the aggregate number of shares of Common Stock outstanding or deemed to be
outstanding immediately after such issuance. For purposes of this paragraph, in connection with
any issuance of any Common Stock Equivalents, (A) the maximum number of shares of Common Stock
potentially issuable at any time upon conversion, exercise or exchange of such Common Stock
Equivalents (the “Deemed

 5.

 

Number”) shall be deemed to be outstanding upon issuance of such Common Stock Equivalents, (B) the
Effective Price applicable to such Common Stock shall equal the minimum dollar value of
consideration payable to the Company to purchase such Common Stock Equivalents and to convert,
exercise or exchange them into Common Stock (net of any discounts, fees, commissions and other
expenses), divided by the Deemed Number, and (C) no further adjustment shall be made to the
Exercise Price upon the actual issuance of Common Stock upon conversion, exercise or exchange of
such Common Stock Equivalents.

               (ii) If, at any time while this Warrant is outstanding, the Company issues Common Stock
Equivalents with an Effective Price or a number of underlying shares that floats or resets or
otherwise varies or is subject to adjustment based (directly or indirectly) on market prices of the
Common Stock (a “Floating Price Security”) in a transaction the primary purpose of which is to
raise capital, then for purposes of applying the preceding paragraph in connection with any
subsequent exercise, the Effective Price will be determined separately on each Exercise Date and
will be deemed to equal the lowest Effective Price at which any holder of such Floating Price
Security is entitled to acquire Common Stock on such Exercise Date (regardless of whether any such
holder actually acquires any shares on such date).

               (iii) Notwithstanding the foregoing, no adjustment will be made under this Section 6 in
respect to any issuance of Common Stock (A) upon exercise or conversion of any options or other
securities described in the SEC Documents (as defined in the Purchase Agreement) or Disclosure
Schedule to the Purchase Agreement or otherwise pursuant to any employee benefit plan of the
Company or its subsidiaries or hereafter adopted by the Company, or (B) in connection with any
grant of options to employees, officers, directors or consultants of the Company pursuant to a
stock option plan duly adopted by the Company’s board of directors or in respect of the issuance of
Common Stock upon exercise of any such options.

     7. Fractional Shares. No fractional shares shall be issued upon the
exercise of this Warrant as a consequence of any adjustment pursuant hereto. All Exercise Shares
(including fractions) issuable upon exercise of this Warrant may be aggregated for purposes of
determining whether the exercise would result in the issuance of any fractional share. If, after
aggregation, the exercise would result in the issuance of a fractional share, the Company shall, in
lieu of issuance of any fractional share, pay the Holder otherwise entitled to such fraction a sum
in cash equal to the product resulting from multiplying the then current fair market value of an
Exercise Share by such fraction.

     8. Fundamental Transactions. If, at any time while this Warrant is outstanding,
any capital reorganization, reclassification of the capital stock of the Company, consolidation or
merger of the Company with another corporation in which the Company is not the survivor, or sale,
transfer or other disposition of all or substantially all of the Company’s assets to another
corporation shall be effected, then the Company shall use its best efforts to ensure that lawful
and adequate provision shall be made whereby each Holder shall thereafter continue to have the
right to purchase and receive upon the basis and upon the terms and conditions herein specified and
in lieu of the Exercise Shares issuable upon exercise of the Warrant, shares of stock in the
surviving or acquiring corporation (“Acquirer”), as the case may be, such that the value of the
option to purchase such number of shares, as determined in accordance with the Black-Scholes Option
Pricing formula set forth in Appendix (A) hereto, is equivalent to the lesser of (i) the

 6.

 

value of this Warrant to purchase the Exercise Shares, as determined in accordance with the
Black-Scholes Option Pricing formula in Appendix (B) hereto or (ii) 125% of the Built-in Gain, as
long as the Built-in-Gain is at least 50% of the strike price, as determined in accordance with
Appendix (C) hereto. Moreover, appropriate provision shall be made with respect to the rights and
interests of each Holder to the end that the provisions hereof (including, without limitation,
provisions for adjustment of the Exercise Price) shall thereafter be applicable, as nearly
equivalent as may be practicable in relation to any shares of stock thereafter deliverable upon the
exercise thereof. The Company shall not effect any such consolidation, merger, sale, transfer or
other disposition unless prior to or simultaneously with the consummation thereof the successor
corporation (if other than the Company) resulting from such consolidation or merger, or the
corporation purchasing or otherwise acquiring such assets or other appropriate corporation or
entity shall assume by written instrument, the obligation to deliver to the holder of the Warrant,
at the last address of such holder appearing on the books of the Company, such shares of stock, as,
in accordance with the foregoing provisions, such holder may be entitled to purchase, and the other
obligations under this Warrant. The provisions of this section shall similarly apply to successive
reorganizations, reclassifications, consolidations, mergers, sales, transfers or other
dispositions. If the Company, in spite of using its best efforts, is unable to cause this Warrant
to continue in full force and effect until the expiration date of the Warrant in connection with
any capital reorganization, reclassification of the capital stock of the Company, consolidation or
merger of the Company with another corporation in which the Company is not the survivor, or sale,
transfer or other disposition of all or substantially all of the Company’s assets to another
corporation, then the Company shall pay the Holder in cash the lesser of (i) an amount calculated
in accordance with the Black-Scholes Option Pricing formula set forth in Appendix (B) hereto or
(ii) 125% of the Built-in Gain, as long as the Built-in-Gain is at least 50% of the strike price,
as determined in accordance with Appendix (C) hereto.

     9. No Stockholder Rights. This Warrant in and of itself shall not entitle
the Holder to any voting rights or other rights as a shareholder of the Company.

     10. Registration Rights. The Holder of the Warrant Shares shall be entitled
to the registration rights to such Warrant Shares provided by the Purchase Agreement.

     11. Transfer of Warrant. Subject to applicable laws and the restriction on
transfer set forth on the first page of this Warrant, this Warrant and all rights hereunder are
transferable, by the Holder in person or by duly authorized attorney, upon delivery of this Warrant
and the form of assignment attached hereto to any transferee designated by Holder. The transferee
shall sign an investment letter in form and substance reasonably satisfactory to the Company and
its counsel.

     12. Lost, Stolen, Mutilated or Destroyed Warrant. If this Warrant is lost,
stolen, mutilated or destroyed, the Company may, on such terms as to indemnity or otherwise as it
may reasonably impose (which shall, in the case of a mutilated Warrant, include the surrender
thereof), issue a new Warrant of like denomination and tenor as the Warrant so lost, stolen,
mutilated or destroyed. Any such new Warrant shall constitute an original contractual obligation
of the Company, whether or not the allegedly lost, stolen, mutilated or destroyed Warrant shall be
at any time enforceable by anyone.

 7.

 

     13. Notices, etc. All notices required or permitted hereunder shall be in
writing and shall be deemed effectively given: (a) upon personal delivery to the party to be
notified, (b) when sent by confirmed telex or facsimile if sent during normal business hours of the
recipient, if not, then on the next business day, (c) five (5) days after having been sent by
registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) day after
deposit with a nationally recognized overnight courier, specifying next day delivery, with written
verification of receipt. All communications shall be sent to the Company at the address listed on
the signature page and to Holder at:

[_____]

or at such other address as the Company or Holder may designate by ten (10) days advance written
notice to the other parties hereto.

     14. Acceptance. Receipt of this Warrant by the Holder shall constitute
acceptance of and agreement to all of the terms and conditions contained herein.

     15. Governing Law. This Warrant and all rights, obligations and liabilities
hereunder shall be governed by the laws of the State of California.

 8.

 

     In Witness Whereof, the Company has caused this Warrant to be executed by its duly
authorized officer as of November ___, 2005.

	 	 	 	 	 
	 	SOLEXA, INC. 	 
	 
	 	 	 	 
	 	By:
	 	 	 
	 	 	 
	 	 
	 	 	 
	 	Name:
	 	 	 
	 	 
	 	 	 
	 	Title:
	 	 	 
	 	 
	 	 	 
	 	Address:

	 	25861 Industrial Boulevard
	 	 
	 	Hayward, CA 94545

 

 

APPENDIX

(A)

Black Scholes Option Pricing formula to be used when calculating the amount per share
shall be: C = StN(d1) — Ke-r(T-t)N(d2), where

C = warrant value

S = price of Acquirer’s stock as determined by reference to the closing price on the
securities exchange or Nasdaq National Market over the 20-day period ending three trading
days prior to the closing of the capital reorganization, reclassification of the capital
stock of the Company, consolidation or merger of the Company with another corporation in
which the Company is not the survivor, or sale, transfer or other disposition of all or
substantially all of the Company’s assets to another corporation described in Section 8 if
the Acquirer’s stock is then traded on such exchange or system, or the average of the
closing bid or sale prices (whichever is applicable) in the over-the-counter market over the
20-day period ending three trading days prior to the closing of the transaction if the
Acquirer’s stock is then actively traded in the over-the-counter market, or the then most
recently completed financing if the Acquirer’s stock is not then traded on a securities
exchange or system or in the over-the-counter market.

T = __/__/20__

t = date of issue of warrant

T-t = time until warrant expiration = __ days or __ months

N = volatility = average of the daily price changes of the Acquirer’s stock on the
securities exchange or Nasdaq National Market over the period beginning on the issue date of
this Warrant and ending three trading days prior to the public announcement of the capital
reorganization, reclassification of the capital stock of the Company, consolidation or
merger of the Company with another corporation in which the Company is not the survivor, or
sale, transfer or other disposition of all or substantially all of the Company’s assets to
another corporation described in Section 8 if the Acquirer’s stock is then traded on such
exchange or system, or the average of the daily change in the closing bid or sale prices
(whichever is applicable) in the over-the-counter market over the period beginning on the
issue date of this Warrant and ending three trading days prior to the public announcement of
the transaction if the Acquirer’s stock is then actively traded in the over-the-counter
market, or 0.6 if the Acquirer’s stock is not then traded on a securities exchange or system
or in the over-the-counter market.

d1 = (ln(S/K) + (r-l+ N^2/2)(T-t)) ÷ (N√(T-t))

ln = natural logarithm

l = dividend rate of the Acquirer for the most recent 12-month period at the time of closing
of the capital reorganization, reclassification of the capital stock of the Company,

 

 

consolidation or merger of the Company with another corporation in which the Company is not
the survivor, or sale, transfer or other disposition of all or substantially all of the
Company’s assets to another corporation.

K = $ 7.50

r = the 90-day Treasury Bill rate from the most recent auction reported on the website: www.publicdebt.treas.gov

d2 = d1- N√(T-t)/365

(B)

Black Scholes Option Pricing formula to be used when calculating the amount per Warrant
Share shall be: C = StN(d1) — Ke-r(T-t)N(d2),
where

C = warrant value

S = price of Company stock as determined by reference to the closing price on the securities
exchange or Nasdaq National Market over the 20-day period ending three trading days prior to
the closing of the capital reorganization, reclassification of the capital stock of the
Company, consolidation or merger of the Company with another corporation in which the
Company is not the survivor, or sale, transfer or other disposition of all or substantially
all of the Company’s assets to another corporation described in Section 8 if the Company’s
stock is then traded on such exchange or system, or the average of the closing bid or sale
prices (whichever is applicable) in the over-the-counter market over the 20-day period
ending three trading days prior to the closing of the transaction if the Company’s stock is
then actively traded in the over-the-counter market, or the then most recently completed
financing if the Company’s stock is not then traded on a securities exchange or system or in
the over-the-counter market.

T = __/__/20__

t = date of issue of warrant

T-t = time until warrant expiration = __ days or __ months

N = volatility = average of the daily price changes of the Company’s stock on the securities
exchange or Nasdaq National Market over the period beginning on the issue date of this
Warrant and ending three trading days prior to the public announcement of the capital
reorganization, reclassification of the capital stock of the Company, consolidation or
merger of the Company with another corporation in which the Company is not the survivor, or
sale, transfer or other disposition of all or substantially all of the Company’s assets to
another corporation described in Section 8 if the Company’s stock is then traded on such
exchange or system, or the average of the daily change in the closing bid or sale prices
(whichever is applicable) in the over-the-counter market over the period beginning on the
issue date of this Warrant and ending three trading days prior to the public announcement of
the transaction if the Company’s stock is then actively traded in

2.

 

the over-the-counter market, or 0.6 if the Company’s stock is not then traded on a
securities exchange or system or in the over-the-counter market.

d1 = (ln(S/K) + (r-l+N^2/2)(T-t)) ÷ (N√(T-t))

ln = natural logarithm

l = dividend rate of the Company for the most recent 12-month period at the time of closing
of the capital reorganization, reclassification of the capital stock of the Company,
consolidation or merger of the Company with another corporation in which the Company is not
the survivor, or sale, transfer or other disposition of all or substantially all of the
Company’s assets to another corporation.

K = $ 7.50

r = the 90-day Treasury Bill rate from the most recent auction reported on the website: www.publicdebt.treas.gov

d2 = d1- N√(T-t)/365

3.

 

(C)

Built-In-Gain shall be determined as follows: B = S-K

B = Built-in-Gain

S = price of Company stock as determined by reference to the closing price on the securities
exchange or Nasdaq National Market over the 20-day period ending three trading days prior to
the closing of the capital reorganization, reclassification of the capital stock of the
Company, consolidation or merger of the Company with another corporation in which the
Company is not the survivor, or sale, transfer or other disposition of all or substantially
all of the Company’s assets to another corporation described in Section 8 if the Company’s
stock is then traded on such exchange or system, or the average of the closing bid or sale
prices (whichever is applicable) in the over-the-counter market over the 20-day period
ending three trading days prior to the closing of the transaction if the Company’s stock is
then actively traded in the over-the-counter market, or the then most recently completed
financing if the Company’s stock is not then traded on a securities exchange or system or in
the over-the-counter market.

K = $ 7.50

4.

 

NOTICE OF EXERCISE

TO: Solexa, Inc. 

     (1) o The undersigned hereby elects to purchase ___shares of the
Common Stock of Solexa,
Inc.  (the “Company”) pursuant to the terms of the attached
Warrant, and tenders herewith payment of the exercise price in full, together with all applicable
transfer taxes, if any.

          o The undersigned hereby elects to purchase ___shares of Common Stock of the
Company pursuant to the terms of the net exercise provisions set forth in Section 2.1 of the
attached Warrant, and shall tender payment of all applicable transfer taxes, if any.

     (2) Please issue a certificate or certificates representing said shares of Common Stock of the
Company in the name of the undersigned or in such other name as is specified below:

                                                                                

(Name)

                                                                                

                                                                                

(Address)

     (3) The undersigned represents that (i) the aforesaid shares of Common Stock are being
acquired for the account of the undersigned for investment and not with a view to, or for resale in
connection with, the distribution thereof and that the undersigned has no present intention of
distributing or reselling such shares, other than as contemplated by Article 7 of the Securities
Purchase Agreement dated as of November 18, 2005 by and among the Company and the purchasers named
therein (the “Purchase Agreement”); (ii) the undersigned is aware of the Company’s business affairs
and financial condition and has acquired sufficient information about the Company to reach an
informed and knowledgeable decision regarding its investment in the Company; (iii) the undersigned
is experienced in making investments of this type and has such knowledge and background in
financial and business matters that the undersigned is capable of evaluating the merits and risks
of this investment and protecting the undersigned’s own interests; (iv) the undersigned understands
that the shares of Common Stock issuable upon exercise of this Warrant have not been registered
(except to the extent a registration statement pursuant to and as contemplated by Article 7 of the
Purchase Agreement is effective) under the Securities Act of 1933, as amended (the “Securities
Act”), by reason of a specific exemption from the registration provisions of the Securities Act,
which exemption depends upon, among other things, the bona fide nature of the investment intent as
expressed herein, and, because such securities have not been registered under the Securities Act,
they must be held indefinitely unless subsequently registered under the Securities Act or an
exemption from such registration is available; (v) the undersigned is aware that the aforesaid
shares of Common Stock may not be sold pursuant to Rule 144 adopted under the Securities Act unless
certain conditions are met and until the undersigned has held the shares for the number of years
prescribed by Rule 144, that among the

 

 

conditions for use of the Rule is the availability of current information to the public about
the Company; and (vi) the undersigned agrees not to make any disposition of all or any part of the
aforesaid shares of Common Stock unless and until there is then in effect a registration statement
under the Securities Act covering such proposed disposition and such disposition is made in
accordance with said registration statement, or the undersigned has provided upon the Company’s
reasonable request, an opinion of counsel satisfactory to the Company, stating that such
registration is not required.

	 	 	 
	 
	 	 
	 

	 	 
	 
	 	 
	(Date)

	 	(Signature)
	 
	 	 
	 
	 	 
	 

	 	 
	 
	 	 
	 

	 	(Print name)

 

 

ASSIGNMENT FORM

(To assign the foregoing Warrant, execute this form

and supply required information. Do not use this

form to purchase shares.)

     For Value Received, the foregoing Warrant and all rights evidenced thereby are hereby
assigned to

			
	Name:	 	

 

(Please Print)

			
	Address:	 	

 

(Please Print)

Dated:                     , 20__

Holder’s

Signature:                                                                                                                        

Holder’s

Address:                                                                                                                        

NOTE: The signature to this Assignment Form must correspond with the name as it appears on the
face of the Warrant, without alteration or enlargement or any change whatever. Officers of
corporations and those acting in a fiduciary or other representative capacity should file proper
evidence of authority to assign the foregoing Warrant.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00094-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00094-of-00352.parquet"}]]